Switch based on AND gate protein
By constructing an integrated AND gate protein switch and multiple heterologous amino acid sensor domains, the trade-off between dynamic range and reversibility in the prior art is solved, and high sensitivity and rapid response under physiological conditions are achieved. It is suitable for Multi-target molecular detection.
Patent Information
- Application Number
- CN202380024124.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-05
- Filing Date
- 2023-01-04
- Publication Date
- 2024-11-26
AI Technical Summary
Existing protein biosensors are difficult to achieve the challenge of having both large dynamic range and maintaining reversibility and rapid response when constructed, especially under the requirements of detecting low-concentration target molecules and detecting multiple target molecules simultaneously. There are often trade-offs between them.
By constructing an integrated AND gate protein switch, multiple heterologous amino acid sensor domains are employed, combining regulatory moieties to achieve full reversibility and enhanced dynamic range of reporter proteins, allowing rapid response and detection of multiple target molecules under physiological conditions.
The ability to detect low-concentration target molecules under physiological conditions is achieved, while expanding the dynamic range, ensuring rapid response and high sensitivity of reporter proteins, suitable for clinical and industrial analyses.
Smart Images

Figure CN119032275A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to improved biosensors. In particular, the present invention relates to improved protein-based biosensors suitable for detecting one or more target molecules in a sample. The biosensors of the present invention may also be related to the field of synthetic biology, for example for the construction of artificial cells or extracellular signaling networks. The biosensors are fully reversible and have a dynamic range suitable for analytical and diagnostic applications. Background Art
[0002] The construction of artificial protein switches with selectable input and output parameters is a key goal of synthetic biology and biotechnology. Protein biosensors have applications in clinical and industrial analytics, particularly in diagnostics where needed. There is an unmet need in the art to convert analyte binding directly into a quantitative signal in a simple, wash-free, homogeneous assay format. In addition, artificial protein-based switches that interconvert different biochemical signals also enable the construction of biochemical pathways with non-natural proteins for metabolic, cellular and organismal engineering.
[0003] There are several competing approaches to construct protein biosensors, all of which aim to produce an off-state of the desired reporter domain that can be reversed by the selected analyte. Previously described approaches to construct protein-based biosensors include domain splitting, generation of reversible autoinhibition, and insertion of regulatory domains. Regulatory domain insertion provides direct reversible coupling between ligand binding and reporter activity, but relies on a small ligand-binding domain with an overall conformational change that is large enough to modulate reporter activity. Previously described biosensors address this problem by using peptide-receptor domains with large conformational changes and then applying protein engineering to couple the local concentration of the peptide ligand to the local concentration of the analyte. Such protein-based biosensors are described, for example, in WO2016 / 191812, WO2018 / 073588, and WO2019 / 207356.
[0004] The key parameters that determine the effectiveness of biosensors are selectivity, sensitivity, dynamic range and response rate. Dynamic range is particularly important because it determines the signal-to-noise ratio and the accuracy with which target analyte measurements can be performed. The construction of a protein switch with a practically relevant dynamic range is important, and generally requires extensive optimization of the construct produced by screening. Considering the overall properties of allostericity and the equilibrium properties of ligand binding, it is generally expected that there is a compromise between the dynamic range and reversibility of the system. Therefore, it is not desirable that a system (such as split protein) in a state be expected to show a large dynamic range but poor reversibility / slow. For example, in an exemplary system, a cysteine bond is introduced into the joint between the calmodulin regulatory domain insert and the glucose dehydrogenase reporter domain. The formation of a disulfate bond after the rearrangement of the receptor domain structure increases the dynamic range from 4 times to nearly 100 times, but at the expense of reversibility.
[0005] The present application solves these problems. This paper describes a method to construct a fully reversible protein switch with an unusually large dynamic range and fast activation time. This is achieved by building an integrated AND gate. Summary of the invention
[0006] The present invention relates to improved reporter proteins, such as enzymes, that can be used in biosensors. In particular, the improved enzymes are particularly suitable for detecting target molecules under physiological conditions, such as in biological samples. The improved enzymes include multiple heterologous amino acid sensor domains, are fully reversible, and have improved sensitivity, enhanced dynamic range and fast response time, making them particularly suitable for detecting target molecules that are usually at low concentrations under physiological conditions, and allow for the simultaneous detection of multiple target molecules.
[0007] Thus, the present invention provides a reporter protein comprising a first heterologous amino acid sequence responsive to binding to a first regulatory moiety and a second heterologous amino acid sequence responsive to binding to a second regulatory moiety, wherein binding of the first regulatory moiety to the first heterologous amino acid sequence and binding of the second regulatory moiety to the second heterologous amino acid sequence reversibly regulates the activity of the reporter protein.
[0008] Also provided is a biosensor comprising a reporter protein as described herein and one or more (e.g., at least one) regulatory moieties as described herein (e.g., a first regulatory moiety as described herein and a second regulatory moiety as described herein). Also provided is as described herein. Also provided herein is a method of detecting one or more target molecules, comprising contacting a reporter protein, or a biosensor, or a composition, or a kit as described herein; contacting the sample with the reporter protein, or a biosensor, or a composition, or a kit under conditions suitable for detecting the presence or absence of one or more target molecules in the sample.
[0009] The present invention also provides: (i) a method for diagnosing a disease or condition in an organism, comprising contacting a reporter protein, biosensor, composition, or kit as described herein with a sample obtained from the organism under conditions suitable for detecting the presence or absence of one or more target molecules in the sample, wherein the presence or absence of one or more target molecules in the sample indicates whether the organism suffers from the disease or condition or is at risk of suffering from the disease or condition; (ii) a method for monitoring one or more target molecules in an organism, the method comprising contacting a reporter protein, biosensor, composition, or kit as described herein with a sample obtained from the organism under conditions suitable for detecting and / or quantifying the presence or absence of one or more target molecules in the sample; (iii) a method for monitoring the expression of a target molecule in an organism (iv) a method for determining protein-protein or protein-small molecule interactions, comprising contacting a reporter protein, biosensor, composition, or kit as described herein with a sample under conditions suitable for detecting the presence or absence of an interaction between binding moieties B1′ and B1″ and / or an interaction between binding moieties B2′ and B2″; or an interaction between binding moieties B1′ and B1″ and target molecule TM1 and / or an interaction between binding moieties B2′ and B2″ and target molecule TM2.
[0010] A detection device is also provided, comprising a cell or chamber containing a reporter protein or biosensor as described herein. One or more nucleic acids encoding a reporter protein or biosensor as described herein are also provided. One or more expression vectors are also provided, comprising the one or more nucleic acids operably linked to one or more promoters. A host cell is also provided, comprising a reporter protein, a biosensor, or one or more nucleic acids or one or more expression vectors as described herein. A method of expressing a reporter protein or a biosensor as described herein in a host cell is also provided, the method comprising culturing a host cell as described herein under conditions suitable for expressing the reporter protein or biosensor.
[0011] Also provided is a method for converting a constitutively active enzyme into a reversibly regulated enzyme, the catalytic activity of which is dependent on the presence of one or more target molecules, the method comprising: (a) generating a library of single insertional enzyme mutants by inserting a heterologous amino acid sequence responsive to binding to a regulatory moiety at a number of different positions in the enzyme sequence, and selecting those single insertional enzyme mutants that exhibit a change in catalytic activity in response to binding to the regulatory moiety; and (b) generating a library of double insertional enzyme mutants by inserting an additional heterologous amino acid sequence responsive to binding to the regulatory moiety at a second site within the enzyme sequence, and selecting those double insertional enzyme mutants that exhibit a change in catalytic activity in the presence of the regulatory moiety and have an increased dynamic range compared to the corresponding single insertional enzyme mutant; optionally, wherein the change in catalytic activity occurs in less than 10 minutes, optionally in less than 5 minutes. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 : Design of artificial allosteric enzymes by domain insertion. (A) Schematic diagram of the domain of a constitutively active reporter protein. (B) Construction of chimeric proteins by inserting a receptor domain (e.g., calmodulin) into a reporter protein. (C) Activation of reporter protein activity by interaction of the chimera with a ligand, thereby inducing conformational changes in the receptor domain (using a calmodulin-binding peptide as an example). (D) Schematic diagram of the enzyme cascade for the conversion of trehalose to gluconolactone by trehalase (Tre) and PQQ-glucose dehydrogenase (PQQ-GDH).
[0013] Figure 2 : Construction and activity analysis of trehalase-CaM chimeras. (A) Schematic diagram of the chimeric Tre construct. (B) Schematic diagram of activation of Tre-CaM by calmodulin binding peptide (CaM-BP). (C) The structure of trehalase (PDB:2jg0) is represented as a ribbon, with insertion sites shown as spheres. (D) Activity analysis of solutions of 50 nM Tre-CaM mutants mixed with 50 nM GDH in the presence (dashed line) or absence (solid line) of 0.5 μM M13 CaM-BP in the presence of 50 mM trehalose, 0.6 mM PMS as an electron mediator, and 60 μM DCPIP reporter dye. The identity of the mutant is indicated by its insertion site.
[0014] Figure 3 : Construction of Tre chimeras with two CaM regulatory domains. (A) Based on the use of Figure 2 Schematic diagram of the design process for the combination of single insertion variants identified by the screening method outlined in D. (B) Activity analysis of 50 nM Tre G104_S440 CaM chimera solutions in the presence or absence of 0.5 μM M13CaM-BP. Figure 2D. (C) As in (B) but using Tre G104_P321 CaM chimera. (D) Activity of 50 nM solution of TreG104_P321 chimera in the presence of different concentrations of M13 CaM-BP peptide. (E) The titration data shown in (D) were fitted to obtain the apparent K d The value is 65 nM. (F) Ribbon representation model of Tre G104_P321 CaM chimera. Calcium ions are shown as spheres and M13 peptide is shown as a ribbon.
[0015] Figure 4 : Construction of a small molecule AND-gate biosensor with a large dynamic range using the 2CaM-Tre switch module. (A) Schematic diagram of the rapamycin biosensor based on the AND-gate switch, in which the 2CaM-Tre switch module is tagged with FKBP domains at the C-terminus and N-terminus. The activation domain consists of FRB fused to a low-affinity CaM-BP peptide. The addition of rapamycin promotes the binding of the components and activates trehalase activity. (B) Titration of 100 nM 2FKBP-Tre-2CaM and 200 nM FRB-CaM-BP with increasing concentrations of rapamycin. (C) The titration data shown in (B) were fitted to obtain the apparent K dThe value is 89 nM. (D) Biosensor based on an AND-gate Tre switch modulated by two inputs. Here the Tre-2CaM switch module is tagged with FKBP at the N-terminus and a cyclophilin domain at the C-terminus. FRB-CaM-BP and fusions of calcineurin A and B (CalA / B) with CaM-BP are used as activators. (E) Activity of the two-input system shown in (D) in the presence of rapamycin, cyclosporin A, or a mixture thereof. In the experiment, a 100 nM solution of FKBP-Tre-2CaM-cyclophilin was mixed with 100 nM FRB-CaM-BP and 100 nM CalA / B-CaM-BP and 50 nM wt GDH in the presence or absence of 350 nM rapamycin, cyclosporin, or a mixture thereof, and the change in DCIP dye absorbance over time was recorded. (F) To confer an additional level of regulation to the system shown in D, the AND-gate biosensor shown in (A) was combined with a two-component GDH biosensor for cyclosporin A. (G) Cyclophilin (CyP) domain-fused CaM-GDH chimeras are activated by CalA / B fused to CaM-BP in the presence of cyclosporin A. (H) Time traces of GDH activity for the systems shown in (F) and (G), where 100 nM FKBP-tre-2CaM-FKBP was mixed with 200 nM FRB-CaM-BP, 5 nM CaM-GDH-cyclophilin domain, and 30 nM CalA / B-CaM-BP in the presence or absence of 250 nM rapamycin, cyclosporin A, or a mixture thereof.
[0016] Figure 5 : Construction of β-lactamase single insertion CaM chimera (BLA-CaM). (A) Schematic diagram of the β-lactamase (BLA) assay. BLA degrades the β-lactam nitrocefin, which can be detected by a color change from yellow to red, for example using a wavelength λ=482 nm (wavelengths λ=486 nm and λ=480 nm can also be used). (B) The structure of β-lactamase is represented as a ribbon (PDB:3gmw), with the calmodulin insertion position shown as a sphere. (C) Activity of purified BLA-CaM chimeras in the presence (dashed line) or absence (solid line) of saturating concentrations of the M13 peptide. The insertion position is indicated by a number and a letter representing the missing amino acid.
[0017] Figure 6: Construction of β-lactamase double insertion CaM chimeras (2CaM-BLA). (A) Activity assay of 250 nM BLA-CaM41G solutions in the presence of 50 μM nitrocefin and in the presence (dashed line) or absence (solid line) of 1 μM M13 CaM-BP. (B) Activity of the reaction mixture from (A), but pre-incubated with 25 nM BLA-CaM 41G for the indicated time periods before adding nitrocefin. (C) Activity assay of 250 nM BLA-CaM 197E solutions in the presence of 50 μM nitrocefin and in the presence (dashed line) or absence (solid line) of 1 μM M13 CaM-BP. (D) Activity of the reaction mixture from (C), but pre-incubated with 25 nM BLA-CaM 197E for the indicated time periods before adding nitrocefin. (E) Schematic diagram of a chimeric BLA biosensor containing two CaM modules. (F) Activity of 250 nM BLA-CaM 41G_197E in the presence of 50 μM nitrocefin in the presence (dashed line) or absence (solid line) of 1 μM M13 CaM-BP. (G) Activity of the reaction mixture from (F) but pre-incubated with 10 nM BLA-CaM 41G_197E for the indicated time periods prior to the addition of nitrocefin. (H) Activity graph of 10 nM wild-type β-lactamase, mono-CaM-inserting β-lactamase, and CaM 41G and CaM 197E dual-CaM-inserting β-lactamase in the presence of saturating concentrations of M13 CaM-BP. (I) Maximum activity plots of 10 nM wild-type β-lactamase, CaM 41G and CaM 197E double CaM insertion β-lactamases, and the single insertion CaM-BLA 253G chimera, with a dynamic range of 207-fold.
[0018] Figure 7 : Rapamycin biosensor based on 2CaM-BLA switch. (A) Schematic diagram of the rapamycin two-component biosensor based on the BLA-CaM 41G_197E switch unit. (B) Activity analysis of 25 nM BLA-2CaM-2FKBP fusion protein and 100 nM FRB-CaM-BP (low affinity calmodulin binding peptide) solutions in the presence of 50 μM nitrocefin and increasing concentrations of rapamycin. (C) The data shown in (B) were fitted to a quadratic equation to obtain the apparent K d Value is 11 nM. (D) Activity assays were performed on solutions of 25 nM BLA-2CaM-2FKBP fusion protein, 100 nM FRB-CaM-BP, and 250 nM rapamycin incubated for the indicated time periods prior to the addition of 50 μM nitrocefin.
[0019] Figure 8 : Tacrolimus biosensor based on 2CaM-BLA switch. (A) Schematic diagram of the tacrolimus two-component biosensor based on the BLA-CaM 41G_197E switch unit. (B) Activity analysis of 25 nM BLA-2CaM-2FKBP fusion protein and 100 nM calcineurin A / B fusion CaM-BP (low affinity calmodulin binding peptide) solutions in the presence of 50 μM nitrocefin and increasing concentrations of tacrolimus. (C) The data shown in (B) were fitted to a quadratic equation to obtain the apparent K d The value is 14 nM. (D) Activity assays were performed on 25 nM BLA-2CaM-2FKBP fusion protein, 100 nM FRB-CaM-BP, and 250 nM tacrolimus solutions incubated for the indicated time periods prior to the addition of 50 μM nitrocefin.
[0020] Fig. 9 : Methotrexate biosensor based on 2CaM-BLA switch. (A) Schematic diagram of the methotrexate (MTX) two-component biosensor based on the BLA-CaM 41G_197E switch unit. (B) Time traces of the absorption changes of the following solutions, as indicated by arrows: 10nM BLA-2CaM 41G197, 10nM BLA-2CaM41G197 and 1μM M13CaM-BP added at 10 minutes, 10nM VHH-BLA-2CaM 41G197-VHH mixed with 100nM nanoCLAMP-BP, 10nM VHH-BLA-2CaM 41G197-VHH mixed with 100nM nanoCLAMP-BP and 250nM methotrexate added at 10 minutes. (C) Activity of 10 nM VHH-BLA-2CaM 41G197-VHH and 100 nM nanoCLAMP-BP solutions supplemented with the indicated concentrations of methotrexate. (D) The data shown in (C) were fitted to a quadratic equation to obtain the apparent K d The value is 7.3 nM. (E) Activity analysis of 10 nM VHH-BLA-2CaM41G197-VHH and 100 nM nanoCLAMP-BP solutions, 250 nM MTX incubated for the indicated time periods before adding 50 μM nitrocefin. (F) The data shown in (E) were plotted as a single exponential graph.
[0021] Fig.10: Construction of a clinically useful MTX assay using the developed 2CaM-BLA biosensor. (A) Photograph of a Beckman AU-480 clinical chemistry analyzer used to test a dual-component MTX biosensor based on the dual CaM switch modules of β-lactamases CaM 41G and CaM 197E. (B) Time traces of 20 mM Tris pH 7.4, 100 mM NaCl buffer (Abbot Architect MTX calibration kit) containing 10 nM VHH-BLA-2CaM41G197-VHH and 100 nM nanoCLAMP-BP and 50 μM nitrocefin supplemented with methotrexate standards in human serum at the indicated concentrations. (C) Curve fits of the data shown in (B) to a linear function. (D) Serum samples from 21 patients undergoing MTX therapy were analyzed using the 2CaM-BLA MTX biosensor (X-axis) or the Abbot Architect immunochemistry workstation (Y-axis).
[0022] Fig.11 : Construction of Glucose Dehydrogenase (GDH) AND-Gated Biosensor. (A) GDH-CaM 48N was activated by CaM-BP, and the activity of 10 nM GDH-CaM 48N solution was analyzed in the presence of 0.6 mM PMS as electron mediator and 60 μM DCPIP reporter dye with or without 1 μM 13 CaM-BP. (B) GDH-CaM 212N was activated by CaM-BP, and the activity of 10 nM GDH-CaM 212N solution was analyzed in the presence of 0.6 mM PMS as electron mediator and 60 μM DCPIP reporter dye with or without 1 μM 13 CaM-BP. (C) GDH-CaM 48N_212N is activated by CaM-BP, activity analysis of 10 nM GDH-CaM 48N_212N solution in the presence of 0.6 mM PMS as electron mediator and 60 μM DCPIP reporter dye in the presence or absence of 1 μM M13 CaM-BP.
[0023] Fig.12: Schematic representation of a biosensor design that requires only one ligand binding domain. (A) A biosensor in which binder 2 is operably linked to two CaM-BPs, each with a low affinity for calmodulin. (B) A biosensor design in which ligand binder 2 is operably linked between two fusion proteins, each of which includes a wild-type CaM-BP and a calmodulin domain with a low affinity for the CaM-BP. Addition of the ligand (asterisk) results in interaction between ligand binder 1 and ligand binder 2 and the ligand. Colocalization of the ligand binder 2 fusion protein with the reporter domain (black square) results in relocalization of the CaM-BP to the high affinity calmodulin module on the reporter domain, resulting in activation of the biosensor.
[0024] Fig.13 :2 Use of CaM-reporter units in monitoring protease activity. (A) Schematic showing a fusion protein in which CaM-BP is caged in a calmodulin mutant with low affinity for CaM-BP. The dotted line indicates the protease cleavage site. (B) As (A) but with unit repeats resulting in higher component affinity and reduced background activity. (C) A cage unit with repeated cages designed to reduce the background activity of the cage peptide. (D) As (C) but with a protease binding domain designed to increase the local concentration of the protease, thereby increasing the specificity of the system for a particular protease and increasing the rate of proteolysis.
[0025] Fig.14 : Electrochemical detection of β-lactamase activity. Cyclic voltammograms of 0.5 mM nitrocefin (dashed line) and its enzymatic hydrolysis product (solid line). Conditions: carbon paper-based electrode (0.5 × 0.5 cm immersion); scan rate 50 mV / s vs. Ag / AgCI (3 M KCI); 100 mM PBS, pH 7.2; β-lactosamidase (150–300 U / mL); enzyme reaction time 10 min; all experiments were performed in the dark at room temperature.
[0026] Fig.15: Expression of BLA-CaM fusion protein in E. coli and analysis of the ability of transgenic bacteria to survive on ampicillin. (A) Plasmid map of the modified pACYDuet vector, designed to essentially express the protein of interest in E. coli cells. (B) Optical density of DH5α E. coli strain transformed with pACYDuet-BLA-CaM253G, grown overnight in LB medium containing chloramphenicol at a concentration of 34 μg / ml and ampicillin at a concentration of 100 μg / ml, in the presence of the indicated concentrations of CaM-BP. (C) Agar plates containing 100 μg / ml ampicillin and 34 μg / ml chloramphenicol, inoculated with cells transformed with the pACYDuet-BLA-CaM253G vector. After plating, the indicated concentrations of CaM-BP were spotted onto the indicated positions of the plates, and the plates were incubated overnight at 37°C. Bacterial growth appears as dark spots.
[0027] Fig.16 : Use of CaM-BP to control ampicillin resistance of bacteria transformed with BLA-CaM fusions. Agar plates containing 34 μg / ml chloramphenicol (left) or 100 μg / ml ampicillin and 34 μg / ml chloramphenicol (right) were inoculated with DH5α cells transformed with the indicated constructs and grown overnight at 37°C.
[0028] Fig.17 : Constitutive expression of BLA-2CaM fusion protein in E. coli and analysis of the ability of transgenic bacteria to survive on ampicillin. (A) Plasmid map of the modified pACYDuet-modified BLA-2CaM 41G 197E vector, designed to express the protein of interest in the DH5α E. coli strain. (B, C) Agar plates containing 34 μg / ml chloramphenicol (B) or 34 μg / ml chloramphenicol and 100 μg / ml ampicillin (C) and inoculated with cells transformed with the pACYDuet-modified BLA-2CaM 41G197E vector. (D) Optical density of DH5α cells transformed with the pACYDuet-modified-BLA-2CaM 41G 197E vector, grown overnight in LB medium containing chloramphenicol at a concentration of 34 μg / ml and ampicillin at a concentration of 100 μg / ml in the presence of the indicated concentrations of CaM-BP. (E) Agar plates containing 100 μg / ml ampicillin and 34 μg / ml chloramphenicol were inoculated with cells transformed with the pACYDuet-modified BLA-2CaM 41G 197E vector. After plating, the indicated concentrations of CaM-BP were spotted at the indicated positions on the plates, and the plates were incubated overnight at 37°C. Bacterial growth appeared as dark spots.
[0029] Fig.18: Inducible expression of BLA-2CaM fusion proteins in E. coli and analysis of the ability of transgenic bacteria to survive on ampicillin. (A) Plasmid map of the modified PET28A-BLA-2CaM 41G 197E vector, designed to inducibly express the protein of interest in BL21(DE3) E. coli cells. (B) Optical density of BL21(DE3) E. coli cells transformed with PET28a-BLA-2CaM41G 197E, grown overnight in LB medium containing kanamycin at a concentration of 50 μg / ml and ampicillin at a concentration of 100 μg / ml in the presence of the indicated concentrations of CaM-BP and without and with 1 mM IPTG. (C) SDS-PAGE gel loaded with cells from the experiment shown in (B), with lane 1 loaded with purified BLA-2CaM 41G 197E protein. Agar plates containing 100 μg / ml ampicillin and 50 μg / ml kanamycin were inoculated with cells transformed with the PET28a-BLA-2CaM 41G197E vector. After plating, the indicated concentrations of CaM-BP and 1 mM IPTG were spotted on the indicated positions of the plates, and the plates were incubated overnight at 37°C. Bacterial growth appeared as dark spots.
[0030] Fig.19 : Emission scans of mNeon chimera fluorescent proteins with one or two calmodulin domains. Emission scans of 1 μM solutions of mNeon-CaM chimeras (small grey diamonds) and mNeon-2CaM (black spheres) were performed, keeping the excitation wavelength constant at 500 nm ± 5 nm. The scans were repeated after the addition of 5 μM 13 calmodulin binding peptide mNeon-CaM chimeras (grey triangles) and mNeon-2CaM (black diamonds).
[0031] Fig. 20 : Activity analysis of GDH affinity clamp single and double insertion chimeras. (A) Activity analysis of 10 nM solution of GDH affinity clamp chimera in which the affinity clamp is inserted at position 46. The assay was performed in the absence (solid line) and presence (dashed line) of 1 μM RGS ligand peptide. Fig.11 (B) As in (A) but using a GDH affinity clamp chimera solution in which the affinity clamp is inserted at position 54. (C) As in (A) and (B) but using a GDH affinity clamp chimera solution in which two affinity clamps are inserted at positions 46 and 54.
[0032] Fig.21: Biosensors based on 2CaM-Tre and 2CaM-GDH switch modules are used to construct a biosensor system with a large dynamic range regulated by two different inputs. (A) Schematic diagram of an allosteric enzyme cascade regulated at two different nodes. Here, a biosensor based on a rapamycin-controlled AND-gate Tre A is combined with an AND-gate GDH biosensor for methotrexate. (B) Activity graph of the enzyme cascade shown in A, where 100 nM of FKBP-2CaM-Tre-FKBP is mixed with 200 nM of FRB-CaM-BP, 20 nM of 2CaM-GDH-2VHH domain, and 100 nM of nanoCLAMP-CaM-BP in the presence or absence of 250 nM rapamycin, methotrexate, or a mixture thereof.
[0033] Fig. 22 : Thermostable methotrexate biosensor based on 2CaM-BLA switch. (A) Activity of 10 nM 2CaM-BLA-41G 197E solution in the presence of saturating concentration of M13 CaM-BP after incubation at the indicated temperatures for the following time periods: 4°C - 3 hours, 25°C - 3 hours, 37°C - 1 hour, 50°C - 30 minutes, 60°C - 10 minutes and 80°C - 10 minutes. (B) As described in A, but using K55Q, S82A, G92D, T140K, H153R, V184A mutants of 2CaM-BLA-41G 197E. (C) Absorbance changes of 10 nM 2CaM-BLA-41G / 197E and its K55Q, S82A, G92D, T140K, H153R, V184A mutants in the absence and presence of 1 M CaM-BP. (D) Relative activities of 10 nM 2CaM-BLA-41G 197E and its K55Q, S82A, G92D, T140K, H153R, V184A mutants in the presence of saturating concentrations of M13 peptide. (E) Activity of 10 nM methotrexate biosensor solution based on 2VHH 2CaM-BLA-41G 197EK55Q, S82A, G92D, T140K, H153R, V184A mutants mixed with 100 nM nanoCLAMP-CaM-BP was titrated with increasing concentrations of methotrexate. (F) K from C obs The rate plot was fitted to a quadratic equation, giving K d The value is 8.6±1.8nM. DETAILED DESCRIPTION
[0034] The present invention relates to improved reporter proteins, which can be used in biosensors, which are preferably capable of detecting target molecules. Typically, the reporter protein includes two or more (i.e., more than one, multiple) heterologous amino acid sequences, which act as sensor domains and undergo conformational changes after binding to a regulatory portion. The two or more heterologous amino acid sequences may be identical or different sequences. The binding of the regulatory portion to the two or more heterologous amino acid sequences induces conformational changes in the two or more heterologous amino acid sequences, which interact with each other (i.e., have an additive effect) and impart a large-scale conformational change to the reporter protein to convert it from an "off" state to an "on" state, or from an "on" state to an "off" state. The reporter protein then produces a detectable signal that can be detected and / or quantified. By coupling the binding of each heterologous amino acid sequence to their corresponding regulatory portion to depend on the presence of one or more target molecules, for example, by connecting the heterologous amino acid sequence and the regulatory portion to a binding portion pair configured to bind to a target molecule, the activation of the reporter protein can depend on the presence of one or more target molecules. The reporter proteins and biosensors described herein have the advantage of a large dynamic range with a clinically useful response time and also allow for the input of a variety of different target molecules.
[0035] Thus, the present invention provides a reporter protein (e.g., an enzyme, a fluorescent protein, or a binding domain, preferably an enzyme or a fluorescent protein, most preferably an enzyme) comprising a first heterologous amino acid sequence responsive to binding to a first regulatory moiety and a second heterologous amino acid sequence responsive to binding to a second regulatory moiety, wherein binding of the first regulatory moiety to the first heterologous amino acid sequence and binding of the second regulatory moiety to the second heterologous amino acid sequence reversibly regulates (preferably reversibly activates) the activity of the reporter protein (e.g., the catalytic activity of the enzyme, or the fluorescence of the fluorescent protein). Typically, each heterologous amino acid sequence (i.e., the first and second heterologous amino acid sequences) is provided as an inserted fragment within the amino acid sequence of the reporter protein (i.e., the enzyme or fluorescent protein).
[0036] An advantage of the claimed reporter proteins and biosensors comprising them is the significantly improved dynamic range while still maintaining the reversible regulation of the reporter protein activity. The dynamic range of the reporter protein (preferably an enzyme) can be at least 5 times, 10 times, 20 times, 30 times, 40 times, 50 times, 75 times, 100 times or 150 times. The dynamic range of the reporter protein is optionally at least 10 times, preferably at least 20 times. The dynamic range of the biosensor comprising the reporter protein described herein can be at least 5 times, 10 times, 20 times, 30 times, 40 times, 50 times, 75 times, 100 times or 150 times. The dynamic range of the biosensor comprising the reporter protein described herein is optionally at least 10 times, preferably at least 20 times. The dynamic range provides a measure of the ratio between the maximum achievable signal and background activity of the biosensor / reporter protein under the optimal conditions of detection. The larger the dynamic range, the better the signal-to-noise ratio of the biosensor / reporter protein, i.e., the better the sensitivity of the biosensor / reporter protein, and the smaller the change in the concentration of the target molecule that can be detected by the biosensor / reporter protein. The dynamic range of the biosensor / reporter protein of the present invention can be calculated by comparing the activity of the biosensor / reporter protein in the absence of the target molecule with the activity of the biosensor / reporter protein in the presence of the target molecule at a saturating concentration, i.e., a further increase in the concentration of the target molecule will not further increase the activity of the biosensor / reporter protein.
[0037] Therefore, the dynamic range (X) can be defined as the maximum possible signal level of the biosensor / reporter protein (i.e., in the presence of a saturating concentration of the target molecule and under optimal reaction and detection conditions) (B), divided by the background activity level, which is the signal level of the biosensor / reporter protein when the target molecule is not present in the assay (A). Therefore, the dynamic range X=B / A. For example, if the maximum possible signal level B is 60 and the background activity level A is 30, the dynamic range X=B / A=60 / 30=2, i.e., the dynamic range is 2 times. For example, a 10-fold dynamic range can be provided by a biosensor with a background activity level of 1 and a maximum signal level of 10 (X=B / A=10 / 1=10 times). The signal level can be defined as the observed reaction rate (i.e., the initial reaction speed) obtained by fitting the linear phase of the reaction curve.
[0038] definition
[0039] The term "variant" as used herein (e.g., in conjunction with a reporter protein, heterologous amino acid sequence, or regulatory moiety as described herein) may describe a functional fragment of an amino acid sequence, protein, or peptide of the invention, appropriately retaining its relevant activity or function, catalytic activity, or binding activity, as applicable. A variant may comprise an amino acid sequence comprising a deletion or insertion compared to any amino acid sequence disclosed herein. Such deletions or insertions may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids in length, or 1-5, 1-10, 1-20, 1-30, 1-40, or 1-50 amino acids in length, preferably 1-10 amino acids in length. Optionally, such deletions or insertions occur in a loop or at the N-terminus or C-terminus. A variant may preferably comprise an amino acid sequence comprising a mutation (i.e., a substitution, a point mutation) relative to the corresponding wild-type amino acid sequence or relative to the corresponding amino acid sequence disclosed herein. Variants may include up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90 or 100 mutations, or 1-5, 1-10, 1-15, 1-20, 1-30, 1-40 or 1-50 mutations, alternatively 1-20 mutations, preferably 1-10 mutations, most preferably 1-5 mutations relative to the corresponding wild-type amino acid sequence or relative to the corresponding reference amino acid sequence disclosed herein. For example, generally, conservative amino acid variations can be made without appreciable or substantial changes in function. For example, conservative amino acid substitutions can be tolerated, wherein charge, hydrophilicity, hydrophobicity, side chain "bulk", secondary and / or tertiary structure (e.g., helicity), regulatory moiety binding, target molecule binding, fluorescence, enzyme activity and / or inhibitory activity are substantially unchanged or changed to an extent that does not significantly or substantially impair the function of the biosensor. The variant may comprise an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, preferably 80%, more preferably 90%, and most preferably 95% sequence identity to any of the amino acid sequences disclosed herein.
[0040] The term "fragment" as used herein (e.g., in conjunction with a reporter protein, heterologous amino acid sequence, or regulatory moiety as described herein) generally describes a functional fragment of an amino acid sequence, protein, or peptide of the invention, appropriately retaining its relevant activity or function, catalytic activity, or applicable binding activity. Fragments are typically N-terminal and / or C-terminal truncations. Protein fragments may include up to 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, preferably up to 80%, 85%, more preferably up to 90% or most preferably 95% to 99% of the amino acid sequence disclosed herein. In some embodiments, a protein fragment may include up to 5, 10, 20, 40, 50, 70, 80, 90, 100, 120, 150, 180, 200, 220, 230. 250, 280, 300, 330, 350, 400, or 450 amino acids of an amino acid sequence disclosed herein. In some embodiments, a protein fragment may include a deletion of 1-10, 1-20, 1-30, 1-40, 1-50, 1-75, 1-100, preferably 1-50, and most preferably 1-100 amino acids relative to the wild-type sequence of the protein, typically at the N-terminus and / or C-terminus. The fragment is typically a functional fragment because it retains the desired activity of the corresponding wild-type protein (i.e., an activity associated with the biosensor described herein). A fragment may include a domain included in the full-length protein, typically the protein domain included in the fragment is the protein domain responsible for the activity of interest in the wild-type protein. The fragments may include up to 5, 10, 20, 40, 50, 70, 80, 90, 100, 120, 150, 180, 200, 220, 230, 250, 280, 300, 330, 350, 400 or 450 amino acids of the amino acid sequences disclosed herein.
[0041] As used herein, "sequence identity" can be determined by sequence comparison and alignment algorithms known in the art. In order to determine the percent identity of two proteins / polypeptides / peptides or two nucleic acid / polynucleotide sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the first sequence or the second sequence for optimal alignment). The amino acid residues or nucleotide residues at corresponding positions are then compared. When a position in the first sequence is occupied by the same residue as the corresponding position in the second sequence, the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = # identical positions / total # positions × 100), and a penalty is optionally imposed on the score for the number of gaps introduced and / or the length of the gaps introduced. Sequence identity is typically measured over the length of a shorter sequence.
[0042] Comparison of sequences and determination of percent identity between two sequences can be accomplished using algorithms. Alignment can be generated on specific portions of the aligned sequences with sufficient identity, but not on portions with low degrees of identity (i.e., local alignment). A non-limiting example of a local alignment algorithm for sequence comparison is Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264–68, modified to Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873–77. Such an algorithm is incorporated into the BLAST program (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403–10.
[0043] Alignment can be optimized by introducing appropriate gaps, and the identity percentage can be determined over the length of the aligned sequences (i.e., gap alignment). In order to obtain gap alignments for comparison purposes, gap BLAST described in Altschul et al., (1997) Nucleic Acids Res. 25 (17): 3389–3402 can be used. Alignment can be optimized by introducing appropriate gaps, and the identity percentage can be determined over the full length of the aligned sequences (i.e., global alignment). A non-limiting example of an algorithm for global comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). This algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package.
[0044] Preferably, the sequence identity between two sequences is determined using a pairwise global sequence alignment, wherein the alignment is calculated over the length of the sequences described herein (preferably over the length of the shorter sequence). Sequence identity can preferably be implemented using the Needleman-Wunsch alignment algorithm (e.g., by the online server EMBOSS Needle (EMBOSS: the European Molecular Biology Open Software Suite. (2000) Trends in genetics. 16 (6): 276–7) and applying the following parameters: matrix: DNAfull; gap opening penalty: 10.00; gap extension penalty: 0.5; terminal gap penalty: false; terminal gap opening penalty: 10.00; terminal gap extension penalty: 0.5.
[0045] The term "linker" as used herein (e.g., in conjunction with a reporter protein, heterologous amino acid sequence, binding moiety, or regulatory moiety as described herein) can be understood as any means of linking (i.e., connecting or conjugating) two proteins, peptides, or amino acid sequences together. The linker preferably comprises or consists of an amino acid sequence and can generally be between 1-20, 1-15, 1-10, or 1-5 amino acids in length, preferably between 1-10 amino acids. Typically, such a linker comprises glycine and serine residues, preferably at least 50%, 60%, 70%, 80%, 90% glycine and serine.
[0046] The term "kind of ...", e.g., the kind of heterologous amino acid sequence, protein, regulatory part, binding part or target molecule, can be understood to refer to the type or kind of protein / part. For example, proteins of the same kind typically have the same or closely related amino acid sequences, or include the same protein domains. Thus, proteins of the same kind can have at least 95% sequence identity, preferably at least 98% sequence identity, to each other, as measured over the length of the shorter sequence. Small molecules or ions of the same kind can have the same chemical identity or the same structure or closely related structures, so that they are recognized as variants of the same molecular structure. For example, molecules of the same kind can share a common molecular structure, such as at least 90%, preferably 95%, and most preferably at least 98% of the same molecular structure. According to these definitions, different kinds are any two proteins / molecules that would not be recognized as the same kind. Each kind can include multiple instances of a particular protein / molecule.
[0047] Reporter Protein
[0048] The reporter protein can be any protein that can produce or produce a detectable and / or measurable signal. The reporter protein can be any protein that can produce or produce a detectable and / or measurable signal, which can be reversibly inactivated so that the conformational changes in the reporter protein structure reduce or eliminate the generation or generation of a detectable and / or measurable signal. The reporter protein can be an enzyme, a fluorescent protein, or a binding domain. The reporter protein is preferably an enzyme or a fluorescent protein, most preferably an enzyme. The detectable and / or measurable signal can be, for example, an electron, a change in redox state, a proton (e.g., a change in pH), a color change, antibiotic resistance, luminescence, fluorescence, and / or radioactivity. The detectable signal can be measured using an electrochemical method (see, e.g., Fig.14 ), so that the formation of products by hydrolysis of the enzyme substrate can be measured electrochemically. As is well known to those skilled in the art, suitable electrochemical detection methods may be, for example, Fig.14The cyclic voltammogram is measured under the conditions described in the description of . The electrochemical method is capable of distinguishing between substrate and product and optionally capable of detecting electrons generated during such reaction. The electrochemical method is capable of detecting electrons generated during the conversion of substrate to product. The electrochemical method can be performed in biological fluids such as serum. For example, the electrochemical method can be used to monitor the hydrolysis of the substrate nitrocefin to detect β-lactamase activity.
[0049] Typically, when catalytically active, an enzyme is capable of reacting with or acting on an enzyme substrate, thereby causing a detectable signal. Non-limiting examples of suitable enzymes include trehalase, β-lactamase (ampicillin resistance protein), glucose dehydrogenase, oxidoreductase or dehydrogenase (e.g., flavin adenine dinucleotide-dependent glucose dehydrogenase (FADGDH), NAD-dependent glucose dehydrogenase (NAD-GDH), or pyranose dehydrogenase (PDH), aminoglycoside phosphotransferase (kanamycin resistance protein), α-amylase, carbonic anhydrase, β-galactosidase, glucose oxidase, lysozyme, malate dehydrogenase, peroxidase (e.g., horseradish peroxidase (HRP)), phosphatase (e.g., alkaline phosphatase), luciferase, transferase, Preferably, the enzyme is a trehalase, a β-lactamase, a glucose dehydrogenase, an oxidoreductase or a dehydrogenase (such as FADGDH or PDH), an aminoglycoside phosphotransferase, an α-amylase or a carbonic anhydrase. Most preferably, the enzyme is a trehalase, a β-lactamase or a glucose dehydrogenase. Non-limiting examples of suitable enzyme substrates include those that can produce color development, fluorescence, light (such as bioluminescence), electricity, pH, radioactivity and other detectable signals such as antibiotic resistance when the enzyme is expressed in a suitable host cell such as a microbial cell, a yeast cell, or preferably a bacterial cell.
[0050] Typically, when a fluorescent protein is active, it is capable of emitting light of a specific detectable wavelength when excited at a specific wavelength. Non-limiting examples of suitable fluorescent proteins include mNeon, green fluorescent protein (GFP), yellow fluorescent protein (YFP), red fluorescent protein (RFP), Cherry, mCherry, mCFP, mTurquoise2, mOrange, mKate, dsRed, eqFP611, Dronpa, TagRFP, KFP, EosFP / IrisFP, Dendra, fluorescent proteins based on bacterial phytochrome (BphP) (see, e.g., Matlashov, ME, et al., Nat Commun 2020; 11, 239), or fluorescent proteins derived from cyano cytochrome (CBCR) (e.g., miPRF670nano, see, e.g., Olinikyk OS, et al., Nat Commun. 2019; 10 (1): 279). Fluorescent proteins based on BphP and CBCR may include cofactors (e.g., biliverdin) for fluorescence. The fluorescent protein may be GFP or Cherry. The fluorescent protein may be mneon, a BphP-based fluorescent protein, or a CBCR-based fluorescent protein. The fluorescent protein may be mNeon. The reporter protein may be the fluorescent protein mNeon, in which case the detectable signal is the fluorescence emission of mNeon. The mNeon protein preferably includes a sequence having at least 90%, optionally 100%, identity to the sequence of SEQ ID NO: 73 or a variant or functional fragment thereof. Variants and functional fragments generally retain fluorescent activity.
[0051] Enzymes are generally proteins that can show catalytic activity to substrate molecules to produce detectable signals. The reporter protein may be trehalase, in which case the substrate may be trehalose, and the catalytic activity may be the conversion of trehalose to glucose. In the presence of an oxidoreductase or dehydrogenase, such as GDH, preferably pyrroloquinoline quinone-GDH (PQQ-GDH), glucose is converted to gluconolactone, thereby generating electrons, in which case the detectable signal is the generation of electrons. Trehalase preferably includes a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%, optionally 100% identity with the sequence of SEQ ID NO: 1 or its variant or functional fragment. The reporter protein may be β-lactamase, in which case the substrate may be nitrocefin, and the catalytic activity may be the degradation of the β-lactam ring of nitrocefin, thereby causing the color to change from yellow to red, so the detectable signal is the color change from yellow to red. The trehalase preferably comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%, optionally 100% identity to the sequence of SEQ ID NO: 3 or a variant or functional fragment thereof (e.g., SEQ ID NO: 4 or SEQ ID NO: 85). In some embodiments, the β-lactamase is a thermostable β-lactamase, for example, comprising a sequence having at least 98% or at least 99%, optionally 100% identity to the sequence of SEQ ID NO: 85. The reporter protein may be a GDH enzyme, preferably PQQ-GDH, in which case the substrate may be glucose, the catalytic activity may be the conversion of glucose into gluconolactone to generate electrons, and thus the detectable signal is the generation of electrons. PQQ-GDH preferably comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%, optionally 100% identity to the sequence of SEQ ID NO: 5 or a variant or functional fragment thereof. The eGFP-GDH fusion protein may comprise a sequence having at least 90%, optionally 100% identity to the sequence of SEQ ID NO: 78 or a variant or functional fragment thereof. The reporter protein may be a β-lactamase or an aminoglycoside phosphotransferase, in which case the substrate may be an antibiotic, such as ampicillin or kanamycin, respectively. The catalytic activity may be the degradation of the β-lactam ring of the antibiotic, and when the β-lactamase or aminoglycoside phosphotransferase is expressed in a host cell (e.g., a bacterial cell), the detectable signal may be conferring antibiotic resistance to the host cell (β-lactamase confers ampicillin resistance, and aminoglycoside phosphotransferase confers kanamycin resistance).The aminoglycoside phosphotransferase preferably comprises a sequence having at least 90%, optionally 100%, identity to the sequence of SEQ ID NO: 8 or a variant or functional fragment thereof. The reporter protein may be a carbonic anhydrase, in which case the catalytic activity is typically the interconversion of carbon dioxide and water with bicarbonate and hydrogen ions, so that the detectable signal is a change in pH. The carbonic anhydrase may comprise a sequence having at least 90%, optionally 100% identity to the sequence of SEQ ID NO: 10 or a variant or functional fragment thereof. The reporter protein may be an enzyme alpha-amylase, in which case the catalytic activity is typically the hydrolysis of polysaccharides (e.g., amylose, amylopectin, glycogen), most typically the hydrolysis of alpha-1,4 glycosidic bonds to form intermediate oligosaccharides (e.g., dextrins), maltose, and glucose. The alpha-amylase may comprise a sequence having at least 90%, optionally 100% identity to the sequence of SEQ ID NO: 83 or a variant or functional fragment thereof.
[0052] The reporter protein (preferably an enzyme) of the invention comprises a first heterologous amino acid sequence responsive to binding to a first regulatory moiety and a second heterologous amino acid sequence responsive to binding to a second regulatory moiety. The reporter protein of the invention may comprise more than one, optionally two or more, optionally a plurality of heterologous amino acid sequences, each of which is responsive to binding to a regulatory moiety. The reporter protein of the invention may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 heterologous amino acid sequences, optionally 1-5, preferably 1-3, most preferably 2 heterologous amino acid sequences, each of which is responsive to binding to a regulatory moiety.
[0053] The first heterologous amino acid sequence can be provided as an insert in the amino acid sequence of the reporter protein and the second heterologous amino acid sequence can be provided as an insert in the amino acid sequence of the reporter protein. Preferably, the heterologous amino acid sequences are inserted into different positions of the reporter protein amino acid sequence. Each and preferably all heterologous amino acid sequences can be provided as an insert (i.e., inserted therein) in the reporter protein amino acid sequence. Inserting two or more heterologous amino acid sequences in the amino acid sequence of the reporter protein usually reversibly inactivates the reporter protein, so that at least partial inactivation can be observed when inserting a heterologous amino acid sequence. Therefore, inserting two or more heterologous amino acid sequences in the amino acid sequence of the reporter protein can have additional or epistatic effects.
[0054] The combination of the regulating part and each (i.e. all) heterologous amino acid sequence reversibly regulates (preferably activates) the activity (preferably the catalytic activity of the enzyme) of the reporter protein. Typically, the combination of the first regulating part and the first heterologous amino acid sequence and the second regulating part and the second heterologous amino acid sequence reversibly activates the activity of the reporter protein. Typically, in order to fully activate the reporter protein, it is necessary to simultaneously combine the regulating part on all heterologous amino acid sequences inserted into the reporter protein. Therefore, it is preferred that the reporter protein / enzyme is engineered so that it can be switched to a more active state from a state of reduced activity according to the combination of the regulating part. Typically, the combination of the regulating part and each heterologous amino acid sequence is required to fully activate the reporter protein, and in the absence of the regulating part, the reporter protein does not usually show any detectable activity.
[0055] It should be understood that wild-type activity may not be conferred to the reporter protein by binding to a regulatory part. Generally, if a detectable signal is produced under appropriate reaction conditions, such as an electron, a proton, light, fluorescence, antibiotic resistance or a colored product, and it is possible to detect and / or measure, the reporter protein is active. When the reporter protein is an enzyme, if the enzyme can display specific enzymatic activity to produce a detectable signal (such as an electron, a proton, light, a color change, a colored product, antibiotic resistance or fluorescence) to a substrate molecule under appropriate reaction conditions, the enzyme may be catalytically active. When the reporter protein is a fluorescent protein, if detectable fluorescence is displayed when excited under an appropriate wavelength or luminescence, it may be active. As commonly used herein, the term "inactive" may refer to a reporter protein that can not substantially display a detectable and / or measurable signal under appropriate reaction conditions. As commonly used herein, the term "catalytically inactive" may refer to an enzyme that can not substantially display a specific enzymatic activity to a substrate molecule under appropriate reaction conditions. Typically, the detectable signal (e.g., electrons, protons, light, color change, colored product, antibiotic resistance, or fluorescence) produced will be significantly less than the signal produced by a corresponding active reporter protein, or, where the reporter protein is an enzyme, compared to the signal produced by a corresponding catalytically active enzyme (e.g., a corresponding wild-type enzyme). For an inactive reporter protein, such as a reporter protein comprising two or more heterologous amino acid sequences, the production of a detectable signal (e.g., electrons, protons, light, color change, colored product, antibiotic resistance, or fluorescence) may be completely absent.
[0056] The reporter proteins (preferably enzymes) described herein and biosensors including them react with substrate molecules or excitation wavelengths, in response to binding, interacting with, or otherwise detecting one or more target molecules, to produce a detectable signal (e.g., electrons, protons, light, color change, colored product, antibiotic resistance, or fluorescence). In this context, reacting, reacting, or reacting with a substrate molecule refers to enzymatic conversion of a substrate molecule into one or more product molecules, wherein the reaction produces a detectable signal, or the product molecule can be detected directly or indirectly (e.g., a glucose product produced by trehalase can be detected indirectly by using, for example, a PQQ-GDH enzyme to convert glucose into gluconolactone, thereby producing electrons, which can be detected). In this article, reacting, reacting, or reacting with an excitation wavelength refers to absorbing light of a specific excitation wavelength and emitting light of a different wavelength to produce a detectable fluorescent signal.
[0057] When the detectable signal is an electron, the biosensor can act as an electron donor, whereby the electrons generated by the reaction can flow directly or through an electron shuttle (i.e., an electron mediator), such as, but not limited to, phenazine methylsulfate or potassium ferrocyanide, thereby acting as an anode. The final change in the potential between the anode and the cathode can be detected by an electronic detector. When the reporter protein is an enzyme and the detectable signal is electronic generation, the reporter protein or biosensor can be attached to the electrode. The connection mode can allow electrons to be directly transferred from the oxidoreductase or biosensor to the electrode. Typically, the biosensor or enzyme acts as an electron donor, and the electrons generated by the reaction can flow directly to the electrode to form an anode. The electrode can be composed of gold, platinum, carbon nanotubes, or graphene. The enzyme or biosensor can be attached to the electrode surface using 1-pyrenebutyric acid succinimidyl ester (PBSE) as a heterobifunctional linker, wherein the active ester group of the PBSE linker can react with the amino group of the lysine residue in the oxidoreductase or biosensor. The electrode can be a screen-printed electrode laminated with a dry mixture containing the oxidoreductase and / or biosensor of the present invention, preferably also containing an electron mediator. The enzyme can be immobilized on the electrode via a modified cofactor (eg PQQ). The modified cofactor can be functionalized with a linker that is attached to the electrode surface covalently or non-covalently, for example via a linking group (eg via pyrene-carbon nanotube interactions).
[0058] The reporter protein, enzyme, fluorescent protein or biosensor described herein can be lyophilized (i.e., freeze-dried, lyophilized), for example, by using typical low-temperature dehydration methods well known in the art. The reporter protein, enzyme, fluorescent protein or biosensor described herein can be lyophilized and rehydrated (i.e., reconstituted) and maintain its activity, i.e., the activity is not significantly reduced after lyophilization and rehydration compared to the activity before lyophilization. The reporter protein, enzyme, fluorescent protein or biosensor described herein can be lyophilized, rehydrated and stored at room temperature for at least 7 days and maintain its activity.
[0059] Heterologous amino acid sequence
[0060] Described herein are reporter proteins (preferably enzymes) comprising two or more heterologous amino acid sequences. Described herein are reporter proteins (preferably enzymes) comprising a first heterologous amino acid sequence responsive to binding to a first regulatory moiety and a second heterologous amino acid sequence responsive to binding to a second regulatory moiety, wherein binding of the first regulatory moiety to the first heterologous amino acid sequence and binding of the second regulatory moiety to the second heterologous amino acid sequence reversibly regulate the activity of the reporter protein. The reporter protein may further comprise one or more additional heterologous amino acid sequences.
[0061] The heterologous amino acid sequence can be provided as an insert in the reporter protein amino acid sequence. Preferably, all heterologous amino acid sequences included in the reporter protein are provided as inserts in the amino acid sequence of the reporter protein. In some cases, the first heterologous amino acid sequence is provided as an insert in the amino acid sequence of the enzyme, and the second heterologous amino acid sequence is provided as an insert in the amino acid sequence of the reporter protein. However, the fusion of the heterologous amino acid sequence at the N-terminal and / or C-terminal of the reporter protein amino acid sequence is also possible. Preferably, the reporter protein amino acid sequence and two or more heterologous amino acid sequences (e.g., the first and second heterologous amino acid sequences) are present in a single continuous amino acid sequence, or form at least a portion of a single continuous amino acid sequence.
[0062] When provided as an insert, two or more (i.e., the first and second and any additional) heterologous amino acid sequences are adjacent to the corresponding portion, subsequence or fragment of the reporter protein. Two or more heterologous amino acid sequences can be inserted, for example, in series (i.e., as a continuous sequence, one after another) at the same position in the reporter protein amino acid sequence, wherein the C-terminus of one heterologous amino acid sequence is connected to the N-terminus of the next heterologous amino acid sequence in the series. However, preferably, each heterologous amino acid sequence is inserted into the amino acid sequence of the reporter protein at a different insertion position. Usually, in the amino acid sequence of the reporter protein, the insertion is tolerated without a position that prevents the reporter protein from stably folding. Preferably, the heterologous amino acid sequence is inserted into the amino acid sequence of the reporter protein at the solvent-exposed portion of the reporter protein. The heterologous amino acid sequence can be inserted into any of the α-helix, β-fold or loop of the reporter protein amino acid sequence, preferably near the active site; the preferred position order of the insertion site is usually the most preferred loop, followed by the β-fold, followed by the least preferred α-helix. Active site vicinity is understood to refer to any site at which structural perturbation results in a structural change in the conformation of the amino acid residues that constitute the active site of the reporter protein (i.e., the site responsible for the activity that produces a detectable or measurable signal). Thus, the insertion may be at a distance from the nearest active site residue. Within or The preferred range is The most preferred range is Each heterologous amino acid sequence can be provided as an insert within the reporter protein amino acid sequence, flanked by linkers. A linker can be added between each heterologous amino acid insert and the reporter protein sequence to aid in the tolerance of the insertion. Similarly, if two or more heterologous amino acid sequences are connected in series, they can be connected by a linker. The linker can be as described herein.
[0063] The reporter protein can include each heterologous amino acid sequence in the ring or corner region in the reporter protein structure, and it functionally tolerates the insertion of the heterologous amino acid sequence. The reporter protein can include two or more heterologous amino acid sequences at one or more positions (such as rings or corners) of the reporter protein, which include one or more amino acid residues that affect the activity of the reporter protein. When the reporter protein is an enzyme, the heterologous amino acid sequence insertion fragment can therefore replace one or more residues that affect the substrate binding and / or catalytic activity of the enzyme, so that the catalytic activity of the enzyme is regulated by two or more heterologous amino acid sequences (such as the first and second and optionally any other heterologous amino acid sequences). When the reporter protein is an enzyme, each heterologous amino acid sequence insertion fragment can replace one or more residues that affect substrate binding and / or one or more residues that affect catalytic activity. When the reporter protein is an enzyme, each heterologous amino acid sequence insertion fragment can prevent or reduce the combination of the substrate and the enzyme and / or can switch the enzyme to a state where the catalytic activity is reduced or a state where there is no catalytic activity. When the reporter protein is a fluorescent protein, the heterologous amino acid sequence insertion fragment can replace one or more residues that affect the structure of the fluorescent protein fluorophore, so that the fluorescence of the fluorescent protein is regulated by two or more heterologous amino acid sequences. When the reporter protein is a fluorescent protein, each heterologous amino acid sequence insertion fragment can prevent or reduce the level of fluorescence that the fluorescent protein can emit.
[0064] The heterologous amino acid sequence may be a protein. Preferably, all heterologous amino acid sequences are proteins. Typically, each heterologous amino acid sequence is a protein that can undergo conformational changes in response to binding to a regulatory portion. Each heterologous amino acid sequence may include one or more domains (e.g., one or two domains) that undergo structural rearrangement (i.e., conformational changes) after binding to the regulatory portion. Each heterologous amino acid sequence may include an unstructured or unfolded amino acid sequence that undergoes structural rearrangement or conformational changes after binding to the regulatory portion, which optionally produces one or more folded protein domains. Each heterologous amino acid sequence may be a protein that undergoes structural rearrangement or conformational changes after binding to the regulatory portion, which changes its interaction with the reporter protein. For example, the binding of the regulatory portion can induce structural rearrangement in the heterologous amino acid sequence, forming a binding site for the reporter protein, so that the reporter protein and the heterologous amino acid sequence bind, thereby regulating the activity of the reporter protein. Preferably, each heterologous amino acid sequence is a protein that undergoes structural rearrangement or conformational changes after binding to the regulatory portion, which increases or decreases the spatial distance between the N-terminus and the C-terminus of the heterologous amino acid sequence. Thus, the binding of the regulatory moiety to the heterologous amino acid sequence may cause a conformational change in the structure of the heterologous amino acid sequence. Each heterologous amino acid sequence may be a different protein, but preferably each heterologous amino acid sequence is the same protein, or a functional variant or fragment thereof. For example, the first and second heterologous amino acid sequences may be different proteins, or preferably may be the same protein, or a functional variant or fragment thereof. The first heterologous amino acid sequence may be a first type of protein or a functional fragment thereof, and the second heterologous amino acid sequence may be a second type of protein or a functional fragment thereof. In some cases, at least one (preferably all) heterologous amino acid sequence is calmodulin, or a variant or functional fragment thereof. In some cases, at least one (preferably all) heterologous amino acid sequence is an affinity clamp, as further described herein. In some cases, at least one (preferably all) heterologous amino acid sequence is a solute binding protein, as further described herein. The first heterologous amino acid sequence may be calmodulin and the second heterologous amino acid sequence may be an affinity clamp. Preferably, all heterologous amino acid sequences (e.g., the first and second, and optionally any additional heterologous amino acid sequences) are each calmodulin, or a functional fragment thereof. In preferred cases, at least one, preferably each, heterologous amino acid sequence is calmodulin, an engineered variant thereof, or a functional fragment thereof.
[0065] At least one, preferably all (e.g., the first and second) heterologous amino acid sequences may be a calcium binding protein, or a functional fragment thereof. At least one, preferably all (e.g., the first and second) heterologous amino acid sequences may be calmodulin, or a functional fragment thereof. At least one, preferably all (e.g., the first and second) heterologous amino acid sequences may be an affinity clamp (e.g., an ePDZ domain). At least one, preferably all (e.g., the first and second) heterologous amino acid sequences may be a solute binding protein (SBP) (also known as a periplasmic binding protein (PBP) or a flytrap protein, see, e.g., Edwards, KA, Talanta Open, 2021, 3: 100038). At least one, preferably all (e.g., the first and second) heterologous amino acid sequences may be an SH3 domain. At least one, preferably all (e.g., the first and second) heterologous amino acid sequences may be an antibody. At least one, preferably all (e.g., the first and second) heterologous amino acid sequences may be a leucine zipper peptide. The reporter protein comprises two or more heterologous amino acid sequences (e.g., the first and second heterologous amino acid sequences), and thus there may be a single species of heterologous amino acid sequences, wherein each heterologous amino acid sequence is identical. Alternatively, there may be multiple different kinds of heterologous amino acid sequences.
[0066] The reporter protein may include 2, 3, 4, 5, 6, 7, 8, 9, 10 or more heterologous amino acid sequences. The reporter protein may include 2 to 10 heterologous amino acid sequences. The reporter protein may include 2 to 5 heterologous amino acid sequences. Preferably, the reporter protein may include 2 or 3 heterologous amino acid sequences, which may be the same or different. Most preferably, the reporter protein includes two heterologous amino acid sequences, which may be the same or different. Therefore, the reporter protein may include a plurality of heterologous amino acid sequences of different species, such as 2, 3, 4, 5, 6, 7, 8, 9, 10 or more heterologous amino acid sequences. Preferably, the reporter protein includes one or two heterologous amino acid sequences of different species. Most preferably, the reporter protein includes a single heterologous amino acid sequence. Therefore, in some preferred cases, the reporter protein includes a first and a second heterologous amino acid sequence, which are heterologous amino acid sequences of the same species, i.e., they are the same. The heterologous amino acid sequence may be selected from calmodulin or a functional fragment thereof; an affinity clamp (eg, an ePDZ domain); an SBP; an SH3 domain; an antibody; a leucine zipper peptide; or a combination thereof.
[0067] Typically, at least one, preferably all (i.e., the first and second, and optionally any additional) heterologous amino acid sequences are amino acid sequences of a calcium binding protein, or a functional fragment thereof. When at least one heterologous amino acid sequence is a calcium binding protein or a functional fragment thereof, the regulation of reporter protein activity generally requires the presence of calcium ions. In a preferred case, at least one or preferably all (i.e., the first and second, and optionally any additional) heterologous amino acid sequences include, or preferably are, calmodulin or a functional fragment thereof. Calmodulin or a functional fragment thereof may be calcium insensitive. "Calmodulin" as described herein may be any previously described calmodulin or domain and variants thereof, and comprises derivatives and variants of specific calmodulin or domains described herein. At least one, or preferably all, heterologous amino acid sequences may comprise or consist of calmodulin, said calmodulin comprising a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity, alternatively at least 80%, preferably at least 90%, most preferably at least 95% sequence identity to any one of SEQ ID NO: 11, 12, 15 or 16, preferably SEQ ID NO: 11, or a variant or functional fragment thereof. At least one, or preferably each, heterologous amino acid sequence may comprise or consist of the sequence of any one of SEQ ID NO: 11, 12, 15 or 16, preferably SEQ ID NO: 11, or a variant or functional fragment thereof. An exemplary wild-type calmodulin is shown in SEQ ID NO: 15. Variants and functional fragments are described herein, and in such cases calmodulin activity is generally retained. For example, variants and functional fragments generally retain calcium binding activity and / or calmodulin binding peptide (CaM-BP) binding activity, preferably both activities are retained. Variants and functional fragments may not have calcium binding activity and / or be insensitive to calcium; such variants and functional fragments generally retain "calmodulin binding peptide" binding activity. When calmodulin or its functional fragment is insensitive to calcium, it can bind calcium, but such calcium binding may not significantly affect the conformation of calmodulin or its functional fragment. In some cases, at least one, preferably each, heterologous amino acid sequence may include calmodulin or its functional fragment or consist of it, and the calmodulin includes one or more modifications that result in a reduced binding affinity to calmodulin binding peptide (CaM-BP). Such calmodulin with reduced binding affinity for CaM-BP may comprise, or consist of, a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity, optionally at least 80%, preferably at least 90%, and most preferably at least 95% sequence identity to SEQ ID NO: 16, or a variant or functional fragment thereof.Such a calmodulin having reduced binding affinity for CaM-BP may comprise, or consist of, SEQ ID NO: 16, or a variant or functional fragment thereof.
[0068] When at least one, or preferably all, of the heterologous amino acid sequences are calmodulin or a functional fragment thereof, the activity of the reporter protein may be capable of being modulated in the presence of physiological calcium (i.e., by binding of the regulatory moiety to the respective heterologous amino acid sequence). Thus, typically, it is the binding of the regulatory moiety to calmodulin, rather than the binding of calcium thereto, that induces a conformational change in calmodulin. Thus, the regulatory moiety is typically not calcium. Physiological calcium concentrations are typically between 500 μM and 5 mM calcium (i.e., Ca 2+ ), preferably 1 mM to 2 mM calcium. In preferred cases, the binding of the regulatory moiety to each heterologous amino acid sequence reversibly modulates the activity of the reporter protein in the presence of at least 1 mM calcium, preferably 1 mM to 2 mM calcium. In some cases, changes in calcium concentration between 0.5–5 mM, preferably 1 mM to 2 mM, do not significantly affect the activity of the reporter protein. Thus, the activity of the reporter enzyme is generally independent of calcium concentration, wherein the calcium concentration is within physiological levels.
[0069] Typically, at least one, preferably all (i.e., the first and second, and optionally any additional) heterologous amino acid sequences are amino acid sequences of an affinity clamp, or functional fragments thereof. In preferred cases, at least one, or preferably all (i.e., the first and second, and optionally any additional) heterologous amino acid sequences include, or preferably are, an affinity clamp. As described herein, an "affinity clamp" may be any affinity clamp previously described and variants thereof. At least one, or preferably all, heterologous amino acid sequences may include or consist of an affinity clamp comprising a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity, optionally at least 80%, preferably at least 90%, most preferably at least 95% sequence identity to SEQ ID NO: 48 or 76, preferably SEQ ID NO: 76, or a variant or functional fragment thereof. At least one, or preferably each, heterologous amino acid sequence may include, or consist of, the sequence of SEQ ID NO: 76, or a variant or functional fragment thereof. Variants and functional fragments generally retain the ability to bind to an affinity clamp type ligand, which ligand may preferably be an RGS peptide ligand. An exemplary RGS peptide ligand may comprise or consist of the sequence of SEQ ID NO: 82. Thus, at least one, or preferably all (i.e., the first and second, and optionally any additional) heterologous amino acid sequences may comprise, or preferably consist of, an affinity clamp, which may optionally comprise the sequence SEQ ID NO: 76 capable of binding to a peptide ligand, wherein the peptide ligand optionally comprises the sequence SEQ ID NO: 82. Typically, binding of a peptide ligand to an affinity clamp induces a conformational change in the affinity clamp, and variants and functional fragments generally retain this activity.
[0070] Adjustment section
[0071] The regulating part is any part that can bind to the heterologous amino acid sequence defined herein. Generally, the binding of the regulating part to the heterologous amino acid sequence causes or induces a conformational change or structural rearrangement in the heterologous amino acid sequence. Therefore, the nature or identity of the regulating part generally depends on the nature or identity of the heterologous amino acid sequence. Therefore, when there are two different kinds of heterologous amino acid sequences (e.g., the first and second heterologous amino acid sequences are different), there may be two different kinds of regulating parts. When there are two or more heterologous amino acid sequences (which are heterologous amino acid sequences of the same kind) (e.g., the first and second heterologous amino acid sequences are the same), there is generally one kind of regulating part. The regulating part of the first heterologous amino acid sequence may be the same or different, preferably the same, as the regulating part of the second heterologous amino acid sequence. The regulating part of the first heterologous amino acid sequence may be connected to the regulating part of the second heterologous amino acid sequence.
[0072] The regulating part can be any ligand, analyte, small organic molecule, ion, epitope, domain, fragment, subunit, part or combination thereof. The regulating part can be a peptide or protein, including antibodies and antibody fragments, antigens, enzymes, phosphoproteins, glycoproteins, lipoproteins and glycoproteins. The regulating part can be a lipid, phospholipid, carbohydrate (including monosaccharides, disaccharides and polysaccharides), nucleic acids, nucleoproteins or any other molecule or analyte. The regulating part can be a small molecule, such as a drug or other drugs comprising an antibiotic. The regulating part can be any substance that induces conformational changes in a heterologous amino acid sequence, or any substance that promotes interaction between a heterologous amino acid sequence and a reporter protein to activate the reporter protein. Therefore, the regulating part can be a modification, such as a covalently added post-translational modification (such as phosphorylation, glycosylation, ubiquitination, lipidation, etc.), proteolytic cleavage (such as by a protease) or connection (such as forming a disulfide bond, such as to produce a redox sensor). The regulating part can be a peptide or a small molecule.
[0073] Preferably, the regulating part is a peptide. Preferably, the first and second regulating parts are peptides. The peptide can have any sequence, but can bind to a heterologous amino acid sequence. Therefore, the regulating part may include a peptide that can bind to a heterologous amino acid sequence as defined herein, or be composed of it. Generally, the binding of the peptide to the heterologous amino acid sequence causes a conformational change or structural rearrangement in the heterologous amino acid sequence. Therefore, when the regulating part is a peptide (i.e., a regulating peptide), the sequence of the peptide generally depends on the nature or identity of the heterologous amino acid sequence. Therefore, when there are two or more heterologous amino acid sequences of different species (e.g., the first and second heterologous amino acid sequences are different), there may be two or more heterologous regulating peptides of different species (e.g., the first and second regulating parts are different). When there are two or more heterologous amino acid sequences (which are heterologous amino acid sequences of the same species or type) (e.g., the first and second heterologous amino acid sequences are the same), there is generally one species or type of regulating peptide (e.g., the first and second regulating parts are the same).
[0074] When at least one of the heterologous amino acid sequences is calmodulin or a functional fragment thereof, at least one of the regulatory moieties may be a calmodulin binding peptide or a variant thereof. When all (i.e., the first and second, and optionally any additional) heterologous amino acid sequences are each calmodulin or a functional fragment thereof, the regulatory moiety (i.e., the first and second, and optionally any additional regulatory moieties) is typically a calmodulin binding peptide, or a variant thereof. Therefore, in preferred cases, the regulatory moiety is a calmodulin binding peptide or a variant thereof. In some cases, the first and second (and optionally any additional) heterologous amino acid sequences are each calmodulin protein or a variant or functional fragment thereof, and the first and second (and optionally any additional) regulatory moieties are each calmodulin binding peptide or a variant thereof, and wherein the binding of the calmodulin binding peptide to calmodulin activates the activity of the reporter protein.
[0075] Calmodulin binding peptides (CaM-BPs) preferably include any amino acid sequence (preferably a linear peptide epitope of 1-20 amino acids) that is capable of specifically binding to calmodulin (i.e. calmodulin, or a variant or functional fragment thereof, as defined herein), and preferably induces a structural rearrangement or conformational change in calmodulin, thereby bringing the N-terminus and C-terminus of calmodulin into proximity. Preferably, the CaM-BP is capable of binding to a heterologous amino acid sequence, which is calmodulin or a functional fragment thereof, provided as an insert within the amino acid sequence of a reporter protein. As further described herein, such binding typically reversibly regulates, preferably activates, the activity of the reporter protein. "CaM-BP" may be any previously described CaM-BP (see, e.g., Kursula, P., Amino Acids (2014), 46(10): 2295-304), or a variant thereof, and includes derivatives or variants of the specific CaM-BPs described herein. The CaM-BP may comprise a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity, alternatively at least 80% sequence identity, preferably at least 90% sequence identity, most preferably at least 95% sequence identity to any one of SEQ ID NOs: 17-35, preferably any one of SEQ ID NOs: 17, 18 or 19, most preferably SEQ ID NO: 17. The CaM-BP may comprise a contiguous sequence of at least 5, 6, 7, 8, 9 or 10, alternatively at least 5, preferably at least 10 amino acids of any one of SEQ ID NOs: 17-35, preferably any one of SEQ ID NOs: 17, 18 or 19, most preferably SEQ ID NO: 17, which is capable of binding calmodulin. The CaM-BP may comprise or consist of a sequence of any one of SEQ ID NOs: 17-35, preferably any one of SEQ ID NOs: 17, 18 or 19, most preferably SEQ ID NO: 17, or a variant thereof. Preferably, the CaM-BP may comprise or consist of a sequence of any one of SEQ ID NOs: 17, 18 or 19, most preferably SEQ ID NO: 17, or a variant thereof. Variants generally comprise sequences having 1-5 amino acid deletions or insertions relative to the sequence of any one of SEQ ID NOs: 17-35, preferably any one of SEQ ID NOs: 17, 18 or 19, most preferably SEQ ID NO: 17. Variants preferably comprise sequences comprising 1-10 mutations, preferably 1-5 mutations relative to the sequence of any one of SEQ ID NOs: 17-35, preferably any one of SEQ ID NOs: 17, 18 or 19, most preferably SEQ ID NO: 17. The variants retain binding to calmodulin.In some cases, the CaM-BP may have a reduced binding affinity for calmodulin, i.e., the CaM-BP may have a lower or reduced binding affinity for calmodulin than the binding affinity of the wild-type CaM-BP for the calmodulin. An exemplary wild-type CaM-BP is a peptide having the sequence of SEQ ID NO: 17. An exemplary CaM-BP having an increased binding affinity for calmodulin compared to the wild-type CaM-BP may have the sequence of SEQ ID NO: 18. A CaM-BP having a reduced binding affinity for calmodulin may preferably include the sequence of SEQ ID NO: 19 or a variant thereof, or consist essentially of it. An exemplary CaM-BP having a reduced binding affinity for calmodulin compared to the wild-type CaM-BP may have the sequence of SEQ ID NO: 19.
[0076] When at least one heterologous amino acid sequence is an affinity clamp or a functional fragment thereof, at least one regulatory moiety may be an affinity clamp binding peptide ligand (e.g., an RGS peptide ligand), or a variant thereof. When all (i.e., the first and second, and optionally any additional) heterologous amino acid sequences are each an affinity clamp or a functional fragment thereof, the regulatory moiety (i.e., the first and second, and optionally any other regulatory moiety) is typically an affinity clamp binding peptide ligand (e.g., an RGS peptide ligand), or a variant thereof. Thus, the regulatory moiety may be an affinity clamp binding peptide ligand (e.g., an RGS peptide ligand), or a variant thereof. In some cases, each of the first and second (and optionally any additional) heterologous amino acid sequences is an affinity clamp, or a variant or functional fragment thereof, and each of the first and second (and optionally any additional) regulatory moieties is an affinity clamp binding peptide ligand (e.g., an RGS peptide ligand), or a variant thereof, and wherein the binding of the affinity clamp binding peptide ligand (e.g., an RGS peptide ligand) to the affinity clamp activates the activity of the reporter protein.
[0077] Affinity clamp binding peptide ligands (e.g., RGS peptide ligands) preferably include any amino acid sequence (preferably a linear peptide epitope of 1-20 amino acids) that is capable of specifically binding to an affinity clamp as defined herein, and preferably inducing a structural rearrangement or conformational change in the affinity clamp. Preferably, the affinity clamp binding peptide ligand (e.g., RGS peptide ligand) is capable of binding to a heterologous amino acid sequence, which is an affinity clamp or a functional fragment thereof, which is provided as an insert in the amino acid sequence of the reporter protein. As further described herein, such binding typically reversibly modulates, preferably activates, the activity of the reporter protein. Affinity clamp binding peptide ligands (e.g., RGS peptide ligands) may include a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity to SEQ ID NO: 82, optionally at least 80% sequence identity, preferably at least 90% sequence identity, and most preferably at least 95% sequence identity. The affinity clamp binding peptide ligand (e.g., RGS peptide ligand) may include a contiguous sequence of at least 3, 4, 5, 6, 7, or 8, optionally at least 3, preferably at least 5 amino acids found in SEQ ID NO: 82, which is capable of binding to the affinity clamp. The affinity clamp binding peptide ligand (e.g., RGS peptide ligand) may include the sequence of SEQ ID NO: 82, or a variant thereof, or consist thereof. Variants typically include sequences with 1-5 amino acids, preferably 1 or 2 or 3, most preferably 1 or 2 amino acids deleted or inserted relative to the sequence of SEQ ID NO: 82. Variants preferably include sequences including 1-5 mutations, preferably 1-2 mutations relative to the sequence of SEQ ID NO: 82. The variant retains binding to the affinity clamp (e.g., SEQ ID NO: 76).
[0078] The regulatory moiety may be a peptide capable of binding to an affinity clamp (e.g., a PDZ domain binding peptide), in which case at least one of the heterologous amino acid sequences may be an affinity clamp (e.g., an ePDZ domain). The regulatory moiety may be an SH3 domain binding peptide, in which case at least one of the heterologous amino acid sequences may be an SH3 domain. The regulatory moiety may be an antibody binding peptide or an antigen, in which case at least one of the heterologous amino acid sequences may be an antibody. The regulatory moiety may be a leucine zipper peptide, in which case at least one of the heterologous amino acid sequences may be a second leucine zipper peptide. The regulatory moiety may be a small molecule, solute, or peptide capable of binding to a solute binding protein, as further described herein, in which case at least one of the heterologous amino acid sequences may be a solute binding protein. Depending on the number of different types of heterologous amino acid sequences contained in the reporter protein, there may be a variety of different types of regulatory moieties. Thus, the regulatory moiety may be selected from a calmodulin binding peptide or variant thereof; a peptide that binds to an affinity clamp; an SH3 domain binding peptide; an antibody binding peptide; a leucine zipper peptide; a small molecule, solute, or peptide that binds to a solute binding protein; or a combination thereof.
[0079] The length of the peptide may be 1-10, 1-15, 1-20, 1-30, 1-40, 1-50, 1-100, 1-200 amino acids, preferably 1-20 amino acids in length. The peptide may include or consist of a linear binding epitope that binds to a heterologous amino acid sequence. In some cases, the regulatory portion is a peptide that binds calmodulin or a functional fragment thereof. In preferred cases, the first regulatory portion is a CaM-BP and the second regulatory portion is a CaM-BP. Typically, the binding of the first CaM-BP to the first heterologous amino acid sequence (which is calmodulin or a fragment thereof), and the binding of the second CaM-BP to the second heterologous amino acid sequence (which is calmodulin or a fragment thereof), activates the activity of the reporter protein.
[0080] The first and second regulatory moieties may both be peptides, and the regulatory moiety of the first heterologous amino acid sequence may have the same sequence as the regulatory moiety of the second heterologous amino acid sequence or a different sequence (preferably, the same sequence as the regulatory moiety of the second heterologous amino acid sequence). The first and second regulatory moieties may both be peptides, and the first regulatory moiety of the first heterologous amino acid sequence may be linked to the second regulatory moiety of the second heterologous amino acid sequence, e.g., via a linker (e.g., a peptide linker, as further defined herein).
[0081] The regulatory moiety may be a "caged" regulatory moiety, for example the regulatory moiety may be linked to a protein that is capable of binding and thereby sequestering the regulatory moiety, such that the regulatory moiety is not free to bind to the heterologous amino acid sequence on the reporter protein. In this case, the regulatory moiety is preferably a peptide. The regulatory moiety may be linked to a protein that corresponds to a variant of the heterologous amino acid sequence on the reporter protein, but has a lower binding affinity for the regulatory moiety than the heterologous amino acid sequence on the reporter protein. The regulatory moiety may be linked to the protein via a linker, preferably a peptide linker. Thus, the caged regulatory moiety may be a fusion protein comprising a peptide regulatory moiety linked to a binding / sequestering protein via a peptide linker. The caged regulatory moiety may preferably include a calmodulin binding peptide (CaM-BP) (e.g., any one of SEQ ID NOs: 17-35, preferably any one of SEQ ID NOs: 17, 18, or 19, most preferably SEQ ID NO: 17), which is linked (optionally via a peptide linker) to a calmodulin protein with reduced binding affinity for CaM-BP, as described herein (e.g., SEQ ID NO: 16), as is typically the case when the first and second heterologous amino acid sequences on the reporter protein are calmodulin inserts. The first and second regulatory moieties may both be caged regulatory moieties, and optionally, the first regulatory moiety of the first heterologous amino acid sequence may be linked, for example, via a linker, to the second regulatory moiety of the second heterologous amino acid sequence.
[0082] In some cases, the peptide linker connecting the regulatory moiety and the binding / chelating protein may include a protease cleavage site. The caged regulatory moiety may preferably include a calmodulin binding peptide (CaM-BP) (e.g., any one of SEQ ID NOs: 17–35, preferably any one of SEQ ID NOs: 17, 18, or 19, most preferably SEQ ID NO: 17), which is linked to a calmodulin with reduced binding affinity for CaM-BP, as described herein (e.g., SEQ ID NO: 16) via a peptide linker that includes a protease cleavage site; this is typically the case when the first and second heterologous amino acid sequences on the reporter protein are calmodulin inserts. The caged regulatory moiety may include two CaM-BPs and two calmodulins with reduced binding affinity for CaM-BP, wherein the two calmodulins are linked by a peptide linker, and each calmodulin is linked to a corresponding CaM-BP via a peptide linker, wherein each linker includes a protease cleavage site. The caged regulatory portion may include a CaM-BP and two calmodulins with reduced binding affinity for CaM-BP, wherein the two calmodulins are connected by a peptide linker and one calmodulin is connected to CaM-BP by a peptide linker, wherein each linker includes a protease cleavage site. The caged regulatory portion may include a CaM-BP, two calmodulins with reduced binding affinity for CaM-BP, and a protease binding domain that specifically binds to a protease; wherein the two calmodulins are connected by a peptide linker that includes a target cleavage site for a protease, wherein one calmodulin is connected to CaM-BP by a peptide linker that includes a target cleavage site for a protease, and the other calmodulin is connected to the protease binding domain, optionally, wherein the protease binding domain binds to the protease. Such a caged regulatory portion reduces background activation of a reporter protein / biosensor. Such a caged regulatory portion that includes a protease cleavage site can be used in a biosensor for detecting a protease, wherein the protease cleavage site is a target cleavage site for a protease of interest.
[0083] Combination part
[0084] The reporter protein described herein is generally configured to be activated in the presence of one or more target molecules (i.e., one or more types of target molecules). Therefore, the reporter protein also includes at least one, preferably two binding moieties. The reporter protein may include a binding moiety (B1′). The reporter protein may include a first binding moiety (B1′) and a second binding moiety (B2′). The binding moiety on the reporter protein generally interacts and / or binds with the target molecule of the biosensor. Generally, each regulating moiety includes at least one, preferably one, binding moiety. The binding moiety on the regulating moiety may interact and / or bind with the target molecule of the biosensor. The corresponding binding moiety of the reporter protein generally forms an interaction pair with the corresponding binding moiety on the regulating moiety. Therefore, each regulating moiety may include a binding moiety capable of interacting with at least one binding moiety on the reporter protein. The regulatory part may include a binding part (B1″) capable of interacting with a binding part (B1′) on a reporter protein. The first regulatory part may include a binding part (B1″) capable of interacting with a first binding part (B1′) on a reporter protein, and the second regulatory part may include a binding part (B2″) capable of interacting with a second binding part (B2′) on a reporter protein. Preferably, the binding part (B1″) on the first regulatory part forms an interaction pair with the first binding part (B1′) on the reporter protein, and the binding part (B2″) on the second regulatory part forms an interaction pair with the second binding part (B2′) on the reporter protein. The first regulatory part and the second regulatory part may be connected (e.g., by a peptide linker, optionally as a fusion protein), and may also include a binding part (B1″) capable of interacting with a binding part (B1′) on a reporter protein.
[0085] Each binding moiety pair can interact directly, i.e. directly bind to each other. Preferably, each binding moiety pair interacts by binding to the target molecule. Therefore, the interaction between the binding moiety on the reporter protein and the binding moiety on the regulatory moiety may depend on the presence of the target molecule. Each binding moiety pair can bind to the same target molecule at the same time (i.e. simultaneously). The binding moiety (B1′) on the reporter protein and the binding moiety (B1″) on the regulatory moiety can bind to the target molecule (TM1) at the same time. Alternatively, the binding moiety (B1′) on the reporter protein can bind to the target molecule (TM1) and the binding moiety (B1″) on the regulatory moiety can bind to a complex of B1′ and TM1; or the binding moiety (B1″) on the regulatory moiety can bind to the target molecule (TM1) and the binding moiety (B1′) on the reporter protein can bind to a complex of B1″ and TM1. The first binding portion (B1′) on the reporter protein and the binding portion (B1″) of the first regulating portion can bind to the first target molecule (TM1) at the same time; and the second binding portion (B2′) on the reporter protein and the binding portion (B2″) on the second regulating portion can bind to the second target molecule (TM2) at the same time. The first binding portion (B1′) on the reporter protein can bind to the first target molecule (TM1), and the binding portion (B1″) of the first regulating portion can bind to the complex of B1′ and TM1, or the binding portion of the first regulating portion (B1″) can bind to the first target molecule (TM1) and the first binding portion (B1′) on the reporter protein can bind to the complex of B1′ and TM1; and the second binding portion (B2′) on the reporter protein can bind to the second target molecule (TM2), and the binding portion (B2″) on the second regulating portion can bind to the complex of B2′ and TM2, or the binding portion (B2″) on the second regulating portion can bind to the second target molecule (TM2) and the second binding portion (B2′) on the reporter protein can bind to the complex of B2′ and TM2. The interaction of binding moieties B1′ and B1″ may depend on the presence of a first target molecule TM1 and the interaction of binding moieties B2′ and B2″ may depend on the presence of a second target molecule TM2. The reporter protein may include other binding moieties (BX′; for example, B3′, B4′, etc.). The reporter protein may include the same number of binding moieties as the number of heterologous amino acid sequences included in the reporter protein. Such other binding moieties will form interaction pairs with their corresponding binding moieties (for example, BX′ will interact with BX″), wherein the corresponding binding moiety (BX″) will be included on the other regulatory moiety.
[0086] The binding moieties on the reporter protein may be the same or different types of binding moieties (i.e., the reporter protein may include only one type of binding moiety, or may include two different types of binding moieties). The binding moieties on the regulatory moieties may be the same or different types of binding moieties (i.e., each regulatory moiety may include the same (i.e., a single type) binding moiety, or there may be many different types of regulatory moieties, wherein each regulatory moiety includes different binding moieties, preferably there are two different types of regulatory moieties). Each binding moiety pair may interact with the same type of target molecule, so that one type (i.e., one class) of target molecules regulates the activity of the reporter protein. Alternatively, each binding moiety pair may interact with different types of target molecules, so that two or more (i.e., types) of target molecules regulate the activity of the reporter protein. A type of target molecule can be considered to refer to multiple target molecules, all of which are the same, i.e., the same molecule, compound or protein. Therefore, the binding moieties on the reporter proteins B1′ and B2′ may be the same type of binding moieties, in which case, typically, the corresponding binding moieties on the regulatory moieties B1″ and B2″ are the same type of binding moieties. In this case, TM1 and TM2 are typically the same type of target molecules. Alternatively, the binding moieties on reporter proteins B1' and B2' may be different kinds of binding moieties, in which case typically the corresponding binding moieties on regulatory moieties B1" and B2" are different kinds of binding moieties. In this case, TM1 and TM2 are typically different kinds of target molecules.
[0087] The reporter protein may include a first heterologous amino acid sequence responsive to binding to a first regulatory moiety and a second heterologous amino acid sequence responsive to binding to a second regulatory moiety, wherein binding of the first regulatory moiety to the first heterologous amino acid sequence and binding of the second regulatory moiety to the second heterologous amino acid sequence reversibly regulate the activity of the reporter protein; wherein the reporter protein may further include a first binding moiety B1′ and a second binding moiety B2′. The first regulatory moiety may further include a binding moiety B1″ and the second regulatory moiety may further include a binding moiety B2″. The binding moiety B1″ of the first regulatory moiety is capable of interacting with the first binding moiety B1′ of the reporter protein and the binding moiety B2″ of the second regulatory moiety is capable of interacting with the second binding moiety B2′ on the enzyme. Preferably, the interaction of the binding moieties B1′ and B1″ depends on the presence of the first target molecule TM1, while the interaction of the binding moieties B2′ and B2″ depends on the presence of the second target molecule TM2. Therefore, the binding moieties B1′ and B1″ may form a binding moiety pair that simultaneously binds to the target molecule TM1, while the binding moieties B2′ and B2″ may form a binding moiety pair that simultaneously binds to the target molecule TM2. The binding moieties B1' and B1" and the binding moieties B2' and B2" may be the same pair of binding moieties or different pairs of binding moieties. The target molecules TM1 and TM2 may be the same kind of target molecules or may be different kinds of target molecules.
[0088] In some cases, the reporter protein includes a binding portion B1′ that is capable of interacting with a corresponding binding portion B1″, typically through the target molecule TM1. The corresponding binding portion B1″ can be connected (optionally through a peptide linker) to a first regulatory portion and a second regulatory portion, which are configured to bind to a first and a second heterologous amino acid sequence on the reporter protein, respectively, thereby activating the reporter protein in the presence of TM1. In some preferred cases, the reporter protein comprises two calmodulin insert fragments and a binding portion B1′, wherein the corresponding binding portion B1″ is linked (preferably via a peptide linker, optionally as a fusion protein) to two CaM-BPs, preferably CaM-BPs having a reduced calmodulin binding affinity compared to the wild-type CaM-BP. The reporter protein may comprise two calmodulin insert fragments and a binding portion B1′, wherein the corresponding binding portion B1″ is linked (preferably via a peptide linker, optionally as a fusion protein) to two caged CaM-BPs, as further described herein, wherein each caged CaM-BP preferably comprises a CaM-BP linked to a calmodulin having a reduced binding affinity for the CaM-BP compared to the calmodulin insert fragment on the reporter protein.
[0089] As generally used herein, "binding moiety" or "binding portion" refers to one or more molecules or biological or chemical components or entities that are capable of recognizing, interacting and / or binding to each other, or preferably binding to one or more target molecules. The exact characteristics of the binding moieties used for the biosensors and reporter proteins described herein generally depend on the one or more target molecules to be detected by the reporter protein / biosensor. Therefore, the binding moieties of the reporter protein / biosensor can be selected as those that bind to the target molecules of interest. The binding moieties can be polypeptides, nucleic acids (e.g., single-stranded or double-stranded DNA or RNA), sugars, oligosaccharides, polysaccharides or other carbohydrates, lipids, or any combination of these substances, such as glycoproteins, PNA constructs, etc., or molecular components thereof. By way of example only, the binding moiety can be, or include: (i) an amino acid sequence of a ligand binding domain of a receptor that is responsive to the binding of a target molecule (e.g., a cognate growth factor, cytokine, hormone (e.g., insulin), neurotransmitter, etc.); (ii) an amino acid sequence of an ion or metabolite transporter (e.g., Ca 2+) that is capable of or responsive to the binding of a target molecule such as an ion or metabolite. 2+(iii) a zinc finger amino acid sequence responsive to zinc-dependent binding of a DNA target molecule; (iv) a helix-loop-helix amino acid sequence responsive to binding of a DNA target molecule; (v) a pleckstrin homology domain amino acid sequence responsive to binding of a phosphoinositide target molecule; (vi) an Src homology 2 or Src homology 3 domain amino acid sequence responsive to signaling protein; (vii) an antigen amino acid sequence responsive to binding of an antibody target molecule; or (vii) an antigen amino acid sequence responsive to binding of an antibody target molecule. i) an amino acid sequence of a protein kinase or phosphatase that responds to binding of a phosphorylatable or phosphorylated target molecule; (ix) a ubiquitin binding domain; (x) a protein or protein domain that binds to a small molecule, drug or antibiotic, such as the FKBP and FRB domains that rapamycin binds; (xi) a single-stranded or double-stranded DNA, RNA or PNA construct that binds to a nucleic acid target molecule, such as a DNA or RNA coupled or cross-linked to an amino acid sequence or other protein-nucleic acid interaction; and / or (xii) an affinity clamp, such as a PDZ-FH3 domain fusion; including modifications thereof or engineered versions thereof. In some cases, one of the binding moieties may be a small molecule binding protein, and the corresponding binding moiety may recognize (i.e., specifically bind to) a "small molecule: binding moiety" complex, but not a small molecule or binding moiety alone. For example, a binding moiety B1' or B2' on a reporter protein may bind to a small molecule X, while a binding moiety B1" or B2" may bind to a complex of X:B1' or X:B2', respectively, or vice versa. Preferably, the binding moiety is a protein. Preferably, the pair of binding moieties are proteins capable of interacting with each other either directly or, preferably, via binding to a target molecule.
[0090] Exemplary binding moieties, some of which are described in the Examples, are listed in the table below. Thus, binding moieties (e.g., B1′ and B1″ and / or B2′ and B2″) may be selected from the group consisting of: FKBP (SEQ ID NO: 36), FRB (SEQ ID NO: 37), calcineurin α and β subunits (including SEQ ID NOs: 38 and 39, or including SEQ ID NO: 40), human serum albumin (HAS) GA binder (SEQ ID NO: 41), cyclophilin (SEQ ID NO: 42), antibody fragments, particularly α-amylase binding antibody VHH fragments, VHH1 (SEQ ID NO: 43) and VHH2 (SEQ ID NO: 44), HAS antibody VHH binder (SEQ ID NO: 45), methotrexate binding antibody VHH fragment (SEQ ID NO: 46) or nanoCLAMP for methotrexate binding (SEQ ID NO: 47); and variants thereof. The skilled person can easily select compatible binding moiety pairs that can interact, preferably while binding to the target molecule at the same time. Variants are generally functional binding variants of the corresponding binding moieties of interest. The skilled person can generate antibodies and antibody (VHH) fragments targeting any number of known target molecules for use as binding moieties in the reporter protein / biosensor described herein. It should also be understood that the binding moiety can be modified or chemically derivatized, for example with a binding agent such as biotin, avidin, an epitope tag, a lectin, a carbohydrate or a lipid. As the skilled person will readily appreciate, a suitable binding moiety can be designed that binds to any target molecule of interest, for example by generating a VHH single domain antibody (VHH1) that binds to a target molecule (TMX), which may preferably be a peptide or a small molecule, and then generating a second VHH single domain antibody (VHH2) to recognize the "TMX: VHH1" complex. It is routine for the skilled person to generate such VHH single domain antibodies with the desired specificity for a known target.
[0091] The binding moiety may be or include an antibody or antibody fragment, including monoclonal and polyclonal antibodies, recombinant antibodies, Fab and Fab'2 fragments, DARPins, diabodies, single antibodies, nanoCLAMP (clostridial antibody mimetic protein, see, e.g., SEQ ID NO: 47), and single-chain antibody fragments (e.g., scFv). Suitably, the first and second binding moieties may be or include corresponding antibodies or antibody fragments (preferably scFv) that bind to the target molecule.
[0092] In some cases, the binding moiety (e.g., B1′ and B1″ and / or B2′ and B2″) is, or includes, the amino acid sequence of an affinity clamp. The affinity clamp preferably includes a recognition domain and, optionally, an enhancer domain. The recognition domain is typically capable of binding one or more target molecules, such as described in (i)-(ix) above. The recognition domain may include, but is not limited to, domains involved in phospho-tyrosine binding (e.g., SH2, PTB), phospho-serine binding (e.g., UIM, GAT, CUE, BTB / POZ, VHS, UBA, RING, HECT, WW, 14-3-3, Polo-BOX), phospho-threonine binding (e.g., FHA, WW, Polo-BOX), proline-rich region binding (e.g., EVH1, SH3, GYF), acetylated lysine binding (e.g., bromo), methylated lysine binding (e.g., Chroo, PHD), apoptosis (e.g., BIR, TRAF, DED, death, CARD, BH), cytoskeletal regulation (e.g., ADF, GEL, DH, CH FH2), ubiquitin binding or modified or engineered forms thereof, or other cellular functions (e.g., EH, CC, VHL, TUDOR, PUF Repeat, PAS, MH1, LRR1, IQ, HEAT, GRIP, TUBBY, SNARE, TPR, TIR, START, SOCSBox, SAM, RGS, PDZ, PB1, LIM, F-BOX, ENTH, EF-Hand, SHADOW, ARM, ANK). The enhancer domain typically increases or enhances the binding affinity to at least one target molecule. In some embodiments, the affinity can be increased by at least 10, 100 or 1000 times compared to the affinity of the recognition domain alone. The affinity clamp may also include a linker connecting the recognition domain and the enhancer domain.
[0093] In some cases, the affinity clamp includes a recognition domain and an enhancer domain, the recognition domain includes at least a portion of a PDZ domain or fragment, and the enhancer domain includes at least a portion of a fibronectin type III domain or fragment. The PDZ domain can be derived from human Erbin protein. Erbin-PDZ (ePDZ) binds to a target molecule, such as the C-terminus of p120-related catenin (e.g., δ-catenin and Armadillo repeat genes deleted in velocardiofacial syndrome (ARVCF)). Preferably, this case of the affinity clamp also includes the tenth (10th) type III (FN3) domain of human fibronectin as an enhancer domain. In some cases, the affinity clamp may include one or more linker amino acid sequences. For example, the linker amino acid sequence may connect a protease amino acid sequence (e.g., including a protease amino acid sequence) to an Erbin-PDZ domain, connect an Erbin-PDZ domain to a FN3 domain, and / or connect a FN3 domain to an inhibitor. Please also refer to WO2009 / 062170, Zhuang & Liu, 2011, Comput. Theoret. Chem. 963 448, Huang et al., 2009, J. Mol. Biol. 392 1221, Huang et al., 2008, PNAS (USA) 105 6578 and Koide and Huang Methods Enzymol. 2013; 523: 285–302 for a more detailed description of the structure and function of the affinity clamp and specific affinity clamps that can be used according to the present invention. Preferably, the affinity clamp may comprise or consist of the sequence of SEQ ID NO: 76, or a variant or functional fragment thereof (e.g., as a recognition domain), and may bind to an RGS peptide ligand comprising or consisting of the sequence of SEQ ID NO: 82, or a variant or functional fragment thereof. Thus, the binding part B1′ or B2′ may each comprise or consist of an affinity clamp, optionally comprising or consisting of the sequence of SEQ ID NO:76, and each binding part B1″ or B2″ may each comprise or consist of an RGS peptide ligand, optionally comprising or consisting of the sequence of SEQ ID NO:82, or vice versa.
[0094] The respective binding moieties in each binding moiety pair (i.e., the binding moiety on the reporter protein (e.g., B1′ or B2′) and the respective binding moiety on its regulatory part (e.g., B1″ or B2″)) are capable of directly interacting with each other. Preferably, the binding moieties in each binding moiety pair (i.e., the binding moiety of the reporter protein (e.g., B1′ or B2′) and its respective binding moiety on the regulatory part (e.g., B1″ or B2″)) are capable of binding, interacting or forming a complex with the target molecule (e.g., TM1 or TM2). The target molecule may include a plurality of different subunits, domains or epitopes, each of which may be bound by a corresponding binding moiety within a pair, thereby co-localizing the binding moiety pair and, therefore, co-localizing other components of the biosensor / reporter protein described herein. Therefore, the direct binding interaction between the target molecule and the binding moiety pair appropriately promotes the co-localization of the components of the biosensor described herein.
[0095] The binding moiety may be attached (i.e., conjugated, linked or fused) to the N or C terminus of the reporter protein, optionally via a linker. The reporter protein may include a binding moiety B1′, wherein the binding moiety B1′ may be optionally linked to the N or C terminus of the reporter protein via a linker. The reporter protein may include two binding moieties B1′ and B2′, wherein the first binding moiety (B1′) may be optionally linked to the N terminus of the reporter protein via a linker, and the second binding moiety (B2′) may be optionally linked to the C terminus of the reporter protein via a linker; or vice versa. The reporter protein and one or more binding moieties (e.g., the first and second binding moieties B1′ and B2′) may preferably be provided as a fusion protein. The reporter protein and one or more binding moieties may be provided as a single continuous amino acid sequence. A single continuous amino acid sequence may be provided, comprising the amino acid sequence of the binding moiety (B1′) from the N terminus to the C terminus, or from the C terminus to the N terminus, an optional linker, and the amino acid sequence of the reporter protein comprising the first and second heterologous amino acid sequences. A single continuous amino acid sequence can be provided, which includes the amino acid sequence of the first binding portion (B1′) from the N-terminus to the C-terminus, an optional linker, the amino acid sequence of the reporter protein including the first and second heterologous amino acid sequences, an optional linker, and the amino acid sequence of the second binding portion (B2′). The amino acid sequences of the first and second binding portions may be the same or different. The binding portion (e.g., B1′ and / or B2′) can be inserted into the amino acid sequence of the reporter protein, and the amino acid sequence of the optional binding portion is flanked by a linker. Typically, the binding portion (e.g., B1′ and / or B2′) can be inserted into the amino acid sequence of the reporter protein at a position that does not affect or affects the activity of the reporter protein, such as a loop region. Suitable linkers are described elsewhere herein.
[0096] The binding moiety (e.g., B1″ or B2″) can be connected (i.e., conjugated or fused) to the regulatory moiety. The first binding moiety (B1″) can be connected to the first regulatory moiety and the second binding moiety (B2″) can be connected to the second regulatory moiety. When the reporter protein includes the same first and second heterologous amino acid sequences, and includes the same first binding moiety (B1′) and second binding moiety (B2′) (B1′=B2′), a single type of regulatory moiety can be connected to a binding moiety that is capable of interacting with the first and second binding moieties. When the reporter protein comprises a binding moiety (B1′), the corresponding binding moiety B1″ may be connected to both the first and second regulatory moieties. When the regulatory moiety is a protein or peptide, the binding moiety (e.g., B1″ or B2″) may be optionally connected to the N-terminus or C-terminus of the regulatory moiety via a linker. Each regulatory moiety may comprise a binding moiety. The regulatory moiety and the binding moiety may be provided as a fusion protein. The regulatory moiety and the binding moiety may be provided as a single continuous amino acid sequence. A single continuous amino acid sequence may be provided, which comprises, from N-terminus to C-terminus: the amino acid sequence of the binding moiety, an optional linker, and the amino acid sequence of the regulatory moiety; or comprises, from N to C-terminus: the amino acid sequence of the regulatory moiety, an optional linker, and the amino acid sequence of the binding moiety (e.g., B1″–RM1, RM1–B1″ , B2″–RM2, RM2–B2″, wherein “–” may include a linker). The binding portion may be inserted into the amino acid sequence of the regulatory portion, optionally wherein the amino acid sequence of the binding portion may be flanked by a linker. Typically in this case, the binding portion may be inserted into the amino acid sequence of the regulatory portion at a position that does not affect or influences the binding of the regulatory portion to its corresponding heterologous amino acid sequence. A binding portion may include two regulatory portions. The binding portion and the two regulatory portions may be provided as a fusion protein. The binding portion and the two regulatory portions may be provided as a single continuous amino acid sequence. A single continuous amino acid sequence may be provided, which includes, from N-terminus to C-terminus: a first regulatory portion, an optional linker, a binding portion, an optional linker, and a second regulatory portion. Suitable linkers are described elsewhere herein.
[0097] Target molecule
[0098] The reporter protein / biosensor described herein is capable of detecting one or more target molecules. For each target molecule to be detected, the biosensor generally includes one or more binding moiety pairs capable of binding (usually simultaneously) to the target molecule, wherein for each binding moiety pair, the reporter protein includes one binding moiety and the regulatory moiety includes the corresponding second binding moiety in the pair. The reporter protein / biosensor may be capable of detecting one species or type of target molecule. The reporter protein / biosensor may be capable of detecting two species or types of target molecules. The reporter protein may include a first binding moiety B1′ and a second binding moiety B2′, and there may be two types of regulatory moieties, including a first regulatory moiety of a first binding moiety B1″ and a second regulatory moiety including a second binding moiety B2″, wherein the binding moieties B1′ and B1″ form a binding pair and are capable of interacting with the target molecule TM1 simultaneously, and the binding moieties B2′ and B2″ form a binding pair and are capable of interacting with the target molecule TM2 simultaneously. The target molecules TM1 and TM2 may be target molecules of the same species or target molecules of different species. The reporter protein may include the same first binding part B1′ and second binding part B2′ (B1′=B2′), and there may be one type of regulatory part, which includes a binding part that forms a binding pair with B1′ or B2′ in the presence of the target molecule TM1. The reporter protein may include a binding part B1′ and a binding part B1″, and the binding part B1″ forms a binding pair with B1′ in the presence of the target molecule TM1, connected to the first and second regulatory parts, wherein the first and second regulatory parts may be the same or different, depending on the heterologous amino acid sequence of the reporter protein.
[0099] The target molecule (e.g., TM1 and / or TM2) can be any ligand, analyte, ion (e.g., calcium, Ca 2+), small organic molecules, epitopes, domains, fragments, subunits, parts or combinations thereof. The target molecule (e.g., TM1 and / or TM2) may be a protein, for example, including antibodies and antibody fragments, antigens, enzymes such as α-amylase, human, serum albumin, phosphoproteins, glycoproteins, lipoproteins and glycoproteins. The target molecule (e.g., TM1 and / or TM2) may be a lipid, a phospholipid, a carbohydrate including monosaccharides, disaccharides and polysaccharides; a nucleic acid, a nucleoprotein. The target molecule (e.g., TM1 and / or TM2) can be a small molecule, a chemical entity, or any other analyte, including drugs, such as immunosuppressive drugs, including rapamycin (i.e., sirolimus), cyclosporin, and tacrolimus (i.e., FK506), and other drugs, including antibiotics, vitamins, prohibited substances, illicit drugs or addictive drugs, chemotherapeutic agents and lead compounds in drug design and screening, molecules and analytes commonly found in biological samples, such as biomarkers, tumor and other antigens, receptors, DNA binding proteins including transcription factors, hormones, neurotransmitters, growth factors, cytokines, receptors, metabolic enzymes, signaling molecules, nucleic acids such as DNA and RNA, membrane lipids and other cellular components, pathogen-derived molecules including viral, bacterial, protozoan, fungal and worm proteins, lipids, carbohydrates and nucleic acids. The target molecule can be a protease. This is particularly true when the biosensor includes a cage-modulating moiety as further described herein. Typically, in this case, in the presence of a target protease of the biosensor, the protease cleaves the target protease cleavage site in the cage regulatory portion, thereby releasing the regulatory portion, which then binds to the heterologous amino acid sequence of the reporter protein, thereby activating the reporter protein. In the case where the target molecule is a protease and the biosensor includes a cage regulatory portion, the reporter protein may not include a binding domain. In the case where the target molecule is a protease and the biosensor includes a cage regulatory portion, the cage regulatory portion may include a protease binding domain that can act to increase the local concentration of the target protease at the protease cleavage site of the cage regulatory portion.
[0100] Preferably, the target molecule (e.g., TM1 and / or TM2) may be selected from the group consisting of: (i) hormones, including: fertility hormones, such as progesterone, estradiol, luteinizing hormone (LH) and follicle stimulating hormone (FSH); stress hormones (e.g., hormones associated with psychological stress) such as cortisol and α-amylase; metabolic hormones (e.g., hormones associated with metabolic state or providing an indication of metabolic state) such as insulin and glucose; (ii) therapeutic drugs, such as methotrexate, rapamycin, tacrolimus and cyclosporin A; and (iii) environmental pollutants, such as phenolic glucosides. The reporter protein / biosensor may be configured to detect any one of the target molecules. The reporter protein / biosensor may be configured to detect any two of the target molecules. In particularly preferred cases, the target molecule (e.g., TM1 and / or TM2) may be methotrexate, phenolic glucosides, rapamycin, tacrolimus and / or cyclosporin A. The reporter protein / biosensor may be configured to detect any one of methotrexate, phenolic glucoside, rapamycin, tacrolimus, and / or cyclosporin A. For example, TM1 and TM2 are the same and are selected from the group consisting of: methotrexate, phenolic glucoside, rapamycin, tacrolimus, and / or cyclosporin A. The reporter protein / biosensor may be configured to detect any two of methotrexate, phenolic glucoside, rapamycin, tacrolimus, and / or cyclosporin A. For example, TM1 and TM2 are different and are each independently selected from the group consisting of: methotrexate, phenolic glucoside, rapamycin, tacrolimus, and / or cyclosporin A. The reporter protein / biosensor may be configured to detect rapamycin and cyclosporin A. For example, TM1 is rapamycin and TM2 is cyclosporin A. For example, TM1 is rapamycin and TM2 is rapamycin. For example, TM1 is cyclosporin A and TM2 is cyclosporin A. The skilled person will readily be able to select suitable pairs of binding moieties, typically proteins or antibodies, which are capable of binding to a chosen target molecule of interest, for example using conventional interaction screening and binding assays, such as surface plasmon resonance methods, eg ELISA or Biacore.
[0101] Exemplary binding moieties and target molecules are described in the Examples. In some cases, the target molecules (e.g., TM1 and TM2) are enzymes, such as alpha amylase. In this case, the first and second binding moieties may be antibodies thereof, such as the exemplified camelid antibodies VHH1 and VHH2 (SEQ ID NOs: 43 and 44) or variants thereof (e.g., B1′ and B2′ each include a VHH1 containing the sequence SEQ ID NO: 43; and B1″ and B2″ each include a VHH2 containing the sequence SEQ ID NO: 44). In some cases, the target molecules (e.g., TM1 and TM2) are small organic molecules, such as rapamycin. In this case, the first and second binding moieties may be FKBP and FRB (SEQ ID NOs: 36 and 37), respectively, or variants thereof (e.g., B1′ and B2′ each include a FKBP containing the sequence SEQ ID NO: 36; and B1″ and B2″ each include a FRB containing the sequence SEQ ID NO: 37). In some cases, the target molecule (e.g., TM1 and TM2) is a small organic molecule, such as FK506 (i.e., tacrolimus). In this case, the first and second binding moieties may be FKBP and calcineurin α / β complex (SEQ ID NO: 36 and 38 and 39 or 40), or variants thereof (e.g., B1′ and B2′ each include an FKBP containing the sequence SEQ ID NO: 36; and B1″ and B2″ each include a calcineurin α / β complex containing the sequence SEQID NO: 38 and 39, or 40). In some cases, the target molecule (e.g., TM1 and TM2) is human serum albumin (HAS). In this case, the first and second binding moieties may be HAS GA binders and HAS-specific VHHs (SEQ ID NO: 41 and 45), or variants thereof (e.g., B1′ and B2′ each include an HAS GA binder containing the sequence SEQ ID NO: 41; and B1″ and B2″ each include an HAS-specific VHH containing the sequence SEQ ID NO: 45). In some cases, the target molecule is cyclosporin (e.g., TM1 and TM2). In this case, the first and second binding moieties may be cyclophilin (SEQ ID NO: 42) and calcineurin α / β complex (SEQ ID NO: 38 and 39, or 40), respectively, or variants thereof (e.g., B1′ and B2′ each include cyclophilin, the cyclophilin including the sequence SEQ ID NO: 38; and B1″ and B2″ each include calcineurin α / β complex, the complex including the sequence SEQ ID NO: 38 and 39, or 40). In some cases, the target molecule (e.g., TM1 and TM2) is methotrexate (MTX).In this case, the first and second binding moieties may be MTX-specific VHH and MTX-specific nanoCLAMP (SEQ ID NOs: 46 and 47), respectively, or variants thereof (e.g., B1′ and B2′ each include an MTX-specific VHH including the sequence SEQ ID NO: 46; and B1″ and B2″ each include an MTX-specific nanoCLAMP including the sequence SEQ ID NO: 47). In some cases, the target molecules are rapamycin and cyclosporin (e.g., TM1 is rapamycin and TM2 is cyclosporin). In this case, the binding moiety B1′ may include FKBP (SEQ ID NO: 36) and the binding moiety B2′ may include cyclophilin (SEQ ID NO: 42), and the binding moiety B1″ may include FRB (SEQ ID NO: 37) and the binding moiety B2″ may include calcineurin α / β complex (SEQ ID NOs: 38 and 39, or 40).
[0102] Biosensors
[0103] The reporter proteins described herein are designed to be incorporated into biosensors, for example for detecting target molecules. Biosensors comprising reporter proteins as described herein are described herein. The biosensor typically comprises: (i) a reporter protein as described herein; and (ii) one or more regulatory moieties as described herein. The biosensor preferably comprises: (i) a reporter protein as described herein; (ii) a first regulatory moiety as described herein; and (iii) a second regulatory moiety as described herein. The biosensor may comprise: (i) a reporter protein as described herein; and (ii) one or more cage regulatory moieties as described herein. When the reporter protein is an enzyme, the biosensor may further comprise a substrate for the enzyme (i.e., an enzyme substrate or substrate molecule), as further described herein.
[0104] The function of the reporter protein / biosensor described herein is based on the principle that the reporter protein can have a series of inactive conformations. Although the conformation of the active reporter protein may be similar to that of the wild-type parent molecule, there may be many different inactive conformations of the reporter protein. Therefore, many conformation-induced inactivation changes in the reporter protein can be induced by inserting two or more heterologous amino acid sequences at different insertion positions. Then, the conformational changes at these insertion sites can undergo free body interactions or synergistic combinations to convert the reporter protein from an inactive state to an active state.
[0105] Thus, typically, the binding of the regulatory moiety to the heterologous amino acid sequence induces a conformational change in the heterologous amino acid sequence, which in turn induces a conformational change in the reporter protein. The binding of the regulatory moiety to each heterologous amino acid sequence included in the reporter protein (e.g., the binding of the first regulatory moiety to the first heterologous amino acid sequence and the binding of the second regulatory moiety to the second heterologous amino acid sequence) induces a number of conformational changes, the sum of which induces a conformational change in the reporter protein, causing it to change from an inactive state to an active state. Thus, typically, only the binding of the regulatory moiety at all heterologous amino acid sequences included in the reporter protein will activate the reporter protein. Thus, the reporter protein / biosensor of the present invention can be characterized as an "AND gate" biosensor, because two simultaneous inputs (e.g., the first and second regulatory moieties binding to the first and second heterologous amino acid sequences, respectively) are required to trigger the output, i.e., the activity of the reporter protein that produces a detectable and / or measurable signal.
[0106] The activity of the reporter protein ultimately depends on the presence of one or more target molecules (e.g., TM1, or TM1 and TM2). Typically, the reporter protein / biosensor of the present invention is designed to detect one or two target molecules (e.g., TM1=TM2, or TM1 and TM2). Typically, the reporter protein includes one half of a binding moiety pair (e.g., B1′ or B2′), and the other half of this binding moiety pair (e.g., B1″ or B2″) is included on the regulatory part, respectively. Typically, this binding moiety pair (e.g., B1′ and B1″, or B2′ and B2″) interacts through mutual recognition of target molecules (e.g., TM1 or TM2, respectively). Therefore, in the presence of a target molecule, this binding moiety pair simultaneously binds to the target molecule, thereby co-localizing the regulatory part with the reporter protein. This enhances or promotes the binding of the regulatory part to the heterologous amino acid sequence included in the reporter protein. There can be two binding moiety pairs in the biosensor, so that the reporter protein includes two binding moieties, each forming one half of two binding moiety pairs, wherein the corresponding other half of the pair is located on the regulatory part.
[0107] For the detection of a target molecule, two binding moieties can be identical, so that in the presence of the target molecule, two binding moieties are simultaneously combined with respective target molecules to co-locate the reporter protein with two regulating parts. Alternatively, for the detection of a target molecule, the reporter protein may include a binding moiety and a corresponding second binding moiety may be connected to two regulating parts, so that in the presence of the target molecule, a single binding moiety is combined with the target molecule to co-locate the reporter protein with two regulating parts. In either case, this enhances and promotes the combination of each heterologous amino acid sequence included in the regulating part and the reporter protein, thereby inducing two groups of conformational changes in the reporter protein, thereby converting it from an inactive state to an active state. The need for two separate inputs leads to low background noise (for example, because the random activation of the reporter protein is very unlikely) and a high dynamic range of the reporter protein. Compared with the single insertion variant, it also seems to be conducive to the higher maximum catalytic activity of the biosensor. Generally, there is a compromise between dynamic range and catalytic activity. It has been surprisingly found that the use of two high catalytic activity and low dynamic range modules allows to avoid this compromise, to produce modules with both high catalytic activity and high dynamic range. This is exemplified by the biosensors described herein, such as the BLA-2CaM MTX biosensor.More binding moiety pairs and more heterologous amino acid sequences can be included to require more input, which can further increase the dynamic range of the reporter protein.
[0108] For detecting two target molecules, the two binding moiety pairs can be different, so that when only one target molecule is present, only one binding moiety pair simultaneously binds to the target molecule to co-localize the reporter protein with only a single regulating portion. The presence of a second target molecule is necessary to activate the reporter protein, so that in the presence of the first and second target molecules, the two binding moiety pairs simultaneously bind to their respective target molecules to co-localize the reporter protein with the two regulating portions. The regulating portion binds to each heterologous amino acid sequence included in the reporter protein, thereby inducing two sets of conformational changes in the reporter protein, and thereby converting it from an inactive state to an active state. Therefore, the requirement for two separate inputs can be used to detect the simultaneous presence of two target molecules.
[0109] Thus, in some cases, in the presence of a first target molecule (TM1), the first binding moiety (B1′) on the reporter protein interacts with its respective binding moiety (B1″) on the first regulatory moiety; and in the presence of a second target molecule (TM2), the second binding moiety (B2′) on the reporter protein interacts with its respective binding moiety (B2″) on the second regulatory moiety, co-localizing the reporter protein with the first and second regulatory moieties and promoting the binding of the first regulatory moiety to the first heterologous amino acid sequence included in the reporter protein and the binding of the second regulatory moiety to the second heterologous amino acid sequence included in the reporter protein. The binding of the first regulatory moiety to the first heterologous amino acid sequence and the binding of the second regulatory moiety to the second heterologous amino acid sequence (usually in parallel and simultaneously) typically induce a conformational change in the reporter protein, thereby reversibly regulating the activity of the reporter protein. Thus, ultimately, the presence of the first target molecule TM1 and the second target molecule TM2 reversibly regulates the activity of the reporter protein.
[0110] The activity of the reporter protein is then detected by an appropriate method, depending on the properties of the reporter protein, to read out the presence of one or more target molecules.
[0111] Composition, kit and detection device
[0112] As described above, provided herein are biosensors comprising (i) a reporter protein as described herein; (ii) a first regulating moiety as described herein; and (iii) a second regulating moiety as described herein. Also described herein are compositions or kits comprising: (a) a reporter protein as described herein; or (b) a biosensor as described herein. When the reporter protein is an enzyme, the composition or kit may also include a substrate for the enzyme, as further described herein.
[0113] The composition or kit may further include one or more target molecules. For example, the composition or kit may further include a first target molecule (TM1) and / or a second target molecule (TM2). Suitable target molecules are further described herein, but are preferably selected from methotrexate, phenolic glucosides, rapamycin, tacrolimus, cyclosporin A. The composition or kit may also include a first type of target molecule (e.g., TM1=TM2, which are the same), for example, as a positive control. The composition or kit may also include two types of target molecules (i.e., TM1 and TM2, which are different), for example, for a positive control.
[0114] The composition or kit may also include a sample, which is usually provided by the user and added to the composition or kit as provided. The sample may be suspected of containing one or more target molecules, or may be testing for the presence of one or more target molecules. Therefore, the sample may or may not include the target molecule TM1 and / or the target molecule TM2, or it may not be known whether the sample includes TM1 and / or TM2. The sample may be a biological or environmental sample, preferably a biological sample. A biological sample may be understood to refer to a sample derived from organic matter, preferably a sample obtained from a living organism. The biological sample may be obtained from an animal (preferably a mammal, most preferably a human), a plant or a fungus. The sample may be obtained from an agriculturally important animal or plant, such as livestock (e.g., cattle, sheep, pigs, chickens, etc.) or crops (e.g., vegetables, grains or other foods). The sample may be a biological sample, wherein the biological sample is selected from: tissue, blood, plasma, serum, saliva, interstitial fluid, milk, juice, juice, or homogenate. An environmental sample may be understood to mean a sample derived from an inorganic substance, such as a water sample, a rock sample or an air sample. A skilled artisan will be able to readily use the compositions and kits and / or prepare specific samples for analysis according to the methods described herein.
[0115] The composition or kit comprising the reporter protein or biosensor of the present invention may also include a second enzyme, also referred to herein as an adapter enzyme. The terms "second enzyme" and "adaptase" can be used interchangeably. In the case where the reporter protein is an enzyme, the composition or kit may also include an adapter enzyme (i.e., a second enzyme). The effect of an adapter enzyme is generally to convert the enzyme product of the biosensor into a reading that is easier or simpler to detect. Therefore, the product of the enzyme of the biosensor is generally a substrate for the adapter enzyme. For example, the enzyme of the biosensor may be a trehalase, which catalyzes the conversion of trehalose into glucose. The adapter enzyme may be, for example, a GDH enzyme, which converts glucose into gluconolactone and electrons. The electrons produced by the GDH enzyme can then be easily measured.
[0116] In some cases, the adapter enzyme may include a heterologous amino acid sequence responsive to a peptide, wherein the binding of the peptide to the heterologous amino acid sequence reversibly regulates the catalytic activity of a second enzyme, wherein the substrate of the adapter enzyme is a catalytic product of a reporter protein as described herein, wherein the reporter protein is an enzyme. The adapter enzyme is typically a fast enzyme, preferably a diffusion-limited enzyme. The adapter enzyme may be an oxidoreductase, preferably GDH, most preferably PQQ-GDH as described herein. As described herein, the adapter enzyme may be a β-lactamase. As described herein, the adapter enzyme may be a carbonic anhydrase, wherein the readout of the enzyme activity and therefore the readout of the biosensor may be a change in pH. The heterologous amino acid sequence is typically provided as an insert within the amino acid sequence of the adapter enzyme. The heterologous amino acid sequence may be calmodulin or a functional fragment thereof, as described herein. The peptide may be a calmodulin binding peptide (CaM-BP), as described herein. Thus, the composition or kit may further comprise a GDH enzyme comprising calmodulin or a functional fragment thereof, which is responsive to a calmodulin binding peptide (CaM-BP), wherein the binding of the CaM-BP to calmodulin or a functional fragment thereof reversibly activates the catalytic activity of the GDH enzyme, optionally wherein the catalytic product of the reporter protein as described herein is a substrate for the GDH enzyme. Calmodulin, or a functional fragment thereof, may be inserted into the sequence of the GDH enzyme, preferably in the loop connecting β-sheets 5 and 6, most preferably at positions 403-405 (amino acid residues Ser403 to Asn405) corresponding to PQQ-GDH of SEQ ID NO: 5. The adapter protein comprising a heterologous amino acid sequence may comprise or consist essentially of the sequence of SEQ ID NO: 63.
[0117] In some cases, the ligase comprising a heterologous amino acid sequence responsive to a peptide may further comprise a binding moiety (AB′), and the peptide may further comprise a respective binding moiety (AB″). The binding moieties (AB′ and / or AB″) may be as described herein. As described herein, the two binding moieties typically form a binding moiety pair. The binding moiety pair (AB′ and AB″) typically interacts, preferably via a target molecule (TM AB ) interaction. Therefore, the target molecule (TM AB The presence of ) leads to the interaction of the binding moieties (AB' and AB"), thereby colocalizing the peptide with the ligase, which then binds to the heterologous amino acid sequence and activates the catalytic activity of the ligase. Therefore, the activation of the catalytic activity of the ligase may depend on the target molecule (TM AB ) is present, which may be as described herein. Preferably, the ligase (TM AB) is different from the target molecules of the reporter proteins described herein (TM1 and TM2) contained in the biosensor of the present invention or the composition or kit of the present invention. Therefore, the pair of binding moieties (AB' and AB") attached to the ligase is generally different from the pair of binding moieties (B1' and B1", and B2' and B2") attached to the reporter enzyme described herein. Therefore, another input can be added to the biosensor system by including a ligase. For example, the signal from the ligase may only be (i) in the presence of one or more target molecules (TM1 and TM2) of the reporter protein / biosensor of the present invention as described herein, and (ii) in the presence of the target molecules (TM AB ) is detected in the presence of. When the reporter protein is an enzyme, the activity of the reporter protein needs to be activated to produce the product of the reporter protein, and the product of the reporter protein is usually the substrate of the connecting enzyme.
[0118] Also described herein is a detection device comprising a cell or chamber containing a reporter protein, a biosensor, or a composition, as described herein. Suitably, a sample can be introduced into a cell or chamber to facilitate detection of one or more target molecules (e.g., TM1 and TM2). The sample can be, for example, a biological or environmental sample as described herein. In some cases, the detection device is capable of providing an electrochemical, acoustic, and / or optical signal indicating the presence of one or more target molecules (e.g., TM1 and TM2). In some cases, the detection device may include an electrode. In some cases, the detection device may include a semiconductor device. In some cases, the detection device is a device suitable for current analysis. This device may include screen-printed electrodes, preferably layered with a dry mixture including a biosensor of the present invention and preferably an electron mediator.
[0119] The detection device can also provide disease diagnosis based on the diagnostic target results, by including: a processor and a memory coupled to the processor, the memory containing computer readable program code components, which, when executed by the processor, perform a set of functions including analyzing the diagnostic test results and providing a diagnosis of the disease or condition.
[0120] The detection device can also provide communication of diagnostic test results by including: a processor and a memory coupled to the processor, the memory containing computer readable program code components that, when executed by the processor, perform a set of functions including: sending the diagnostic results to a receiving device; and optionally receiving a diagnosis of the disease or condition from the or another receiving device.
[0121] Preferred biosensors
[0122] It is understood that any of the components of the above reporter protein / biosensor can be combined together to form the reporter protein / biosensor of the present invention. In this section, we describe some of the most preferred reporter protein / biosensor structures, which are non-limiting, but are provided to further illustrate the present invention and the functions of the reporter protein / biosensor described herein.
[0123] Thus, also described herein is a reporter protein that is an enzyme or a fluorescent protein, comprising a first calmodulin sequence that is responsive to binding to a first CaM-BP, and a second calmodulin sequence that is responsive to binding to a second CaM-BP, wherein binding of the first CaM-BP to the first calmodulin sequence and binding of the second CaM-BP to the second calmodulin sequence reversibly regulate the activity of the reporter protein, wherein the first calmodulin sequence and the second calmodulin sequence are provided as inserted fragments within the amino acid sequence of the reporter protein, preferably inserted at different positions within the amino acid sequence of the reporter protein. Preferably, wherein the reporter protein is an enzyme.
[0124] Also described herein is a reporter protein that is an enzyme or fluorescent protein, comprising a first calmodulin sequence that is responsive to binding to a first CaM-BP, and a second calmodulin sequence that is responsive to binding to a second CaM-BP, wherein binding of the first CaM-BP to the first calmodulin sequence and binding of the second CaM-BP to the second calmodulin sequence reversibly regulate the activity of the reporter protein, wherein the first and second calmodulin sequences are provided as inserted fragments within the amino acid sequence of the reporter protein, wherein the reporter protein further comprises two binding moieties (B1′ and B2′). Preferably, wherein both binding moieties B1′ and B2′ are proteins. The binding parts B1′ and B2″ can bind to the same type of target molecules (TM1=TM2). The amino acid sequences of the binding parts B1′ and B2′ can be the same. The first and second CaM-BPs can each also include corresponding binding parts (B1″ and B2″, wherein B1″=B2″), which form a binding pair with the binding part on the reporter protein, so that the binding parts (B1″ and B2″) on the CaM-BP can interact with the binding parts (B1′ and B2′) on the reporter protein through a single type of target molecules (TM1=TM2). Alternatively, the binding parts B1′ and B2″ can bind to different types of target molecules (TM1 and TM2, respectively). The amino acid sequences of the binding parts B1′ and B2′ can be different. The first CaM-BP may also include a binding portion (B1″) that forms a binding pair with the binding portion (B1′) on the reporter protein, and the second CaM-BP may also include a corresponding binding portion (B2″) that forms a binding pair with the binding portion (B2′) on the reporter protein, so that the two binding portion pairs interact with each other through two different types of target molecules: B1′ and B1″ interact through TM1, and B2′ and B2″ interact through TM2.
[0125] Also described herein is a reporter protein that is an enzyme or a fluorescent protein, comprising a first calmodulin sequence that is responsive to binding to a first CaM-BP, and a second calmodulin sequence that is responsive to binding to a second CaM-BP, wherein binding of the first CaM-BP to the first calmodulin sequence and binding of the second CaM-BP to the second calmodulin sequence reversibly regulate the activity of the reporter protein, wherein the first and second calmodulin sequences are provided as inserted fragments within the amino acid sequence of the reporter protein, wherein the reporter protein further comprises a binding portion (B1′). Preferably, the binding portion B1′ is a protein. The first and second CaM-BPs are linked (preferably, the first and second CaM-BPs are included in the same continuous amino acid sequence), and further comprises a corresponding binding portion (B1″) (preferably, also included in the same continuous amino acid sequence), which forms a binding pair with the binding portion (B1′) on the reporter protein, so that the binding portion (B1″) on the CaM-BP can interact with the binding portion (B1′) on the reporter protein through a single type of target molecule (TM1). Also described herein is a biosensor comprising a first component and a second component, wherein the first component comprises a reporter protein, which is an enzyme or a fluorescent protein, comprising a first calmodulin sequence responsive to binding to a first CaM-BP, and a second calmodulin sequence responsive to binding to a second CaM-BP, wherein binding of the first CaM-BP to the first calmodulin sequence and binding of the second CaM-BP to the second calmodulin sequence reversibly regulates the activity of the reporter protein, wherein the first and second calmodulin sequences are provided as inserts within the amino acid sequence of the reporter protein, and wherein the reporter protein The reporter protein further comprises a binding portion (B1′); and the second component comprises a binding portion (B1″) capable of interacting with the binding portion (B1′) on the reporter protein, which is connected to the first CaM-BP and the second CaM-BP. Optionally, the first and second CaM-BPs have a reduced affinity for calmodulin compared to wild-type CaM-BP. Alternatively, the CaM-BP is a caged CaM-BP, i.e., each is further connected to calmodulin, and the binding affinity of calmodulin to CaM-BP is reduced compared to the binding affinity of the calmodulin insert fragment on the reporter protein to CaM-BP.
[0126] Thus, in preferred cases, (i) the heterologous amino acid sequences (e.g., the first and second, and any additional heterologous amino acid sequences) are each calmodulin or a variant or functional fragment thereof, (ii) the regulatory moiety (e.g., the first and second regulatory moieties) are peptides, preferably CaM-BP, (iii) the reporter protein is an enzyme or a fluorescent protein, (iv) the reporter protein comprises two heterologous amino acid sequences, (v) the reporter protein comprises two binding domains (e.g., the first and second binding moieties B1′ and B2′), and (vi) the reporter protein / biosensor targets one or two different target molecules, depending on whether the two binding moiety pairs are the same or different.
[0127] In some cases, the reporter protein comprising a first heterologous amino acid sequence and a second heterologous amino acid sequence comprises, or consists of, a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity, optionally at least 80%, preferably at least 90%, most preferably at least 95% sequence identity to any one of SEQ ID NOs: 51, 52, 57, 62, 75, 81, 86, or 89. In some cases, the reporter protein comprising a first heterologous amino acid sequence and a second heterologous amino acid sequence comprises, or consists of, a sequence of any one of SEQ ID NOs: 51, 52, 57, 62, 75, 81, 86, or 89, or a variant thereof. In some cases, the reporter protein comprising a first heterologous amino acid sequence and a second heterologous amino acid sequence comprises or consists of SEQ ID NO: 51, 52, 57, 62, 75, 86, or 89, wherein one or both calmodulin inserts are replaced with different heterologous amino acid sequences as described herein, such as an affinity clamp or SBP. In some cases, the reporter protein comprising a first heterologous amino acid sequence and a second heterologous amino acid sequence comprises or consists of the sequence of SEQ ID NO: 81, wherein one or both affinity clamp inserts are replaced with different heterologous amino acid sequences as described herein, such as calmodulin or SBP.
[0128] The preferred biosensor generally includes a preferred reporter protein as described above. The biosensor can be configured to detect rapamycin, and the biosensor can include (i) a reporter protein (which can be an enzyme or a fluorescent protein, optionally a trehalase, a GDH enzyme or a β-lactamase), which includes two calmodulin inserts at different positions within the reporter protein amino acid sequence, and two FKBP binding portions, one at the N-terminus and one at the C-terminus of the reporter protein amino acid sequence; and (ii) a regulatory portion, which includes a calmodulin binding peptide and a FRB binding portion. When the reporter protein is an enzyme, the biosensor may also include a substrate for the enzyme. When the reporter protein is trehalase, the biosensor may also include an enzyme substrate, trehalose. When the reporter protein is a β-lactamase, the biosensor may also include an enzyme substrate, nitrocefin. Thus, a biosensor for detecting rapamycin may comprise a first component comprising, or consisting of, a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, preferably 80%, most preferably 90% sequence identity to SEQ ID NO:53 or 58; and a second component comprising, or consisting of, a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, preferably at least 80%, most preferably at least 90% sequence identity to SEQ ID NO:65.
[0129] The biosensor can be configured to detect tacrolimus, and the biosensor can include (i) a reporter protein (which can be an enzyme or a fluorescent protein, optionally a trehalase, a GDH enzyme, or a β-lactamase), which includes two calmodulin insertions at different positions within the reporter protein amino acid sequence, and two FKBP binding portions, one at the N-terminus and one at the C-terminus of the reporter protein amino acid sequence; and (ii) a regulatory portion, which includes a calmodulin binding peptide and a calcineurin A and B (CalA / B) binding portion.
[0130] When the reporter protein is an enzyme, the biosensor may further include a substrate for the enzyme. Thus, the biosensor for detecting tacrolimus may include a first component comprising or consisting of a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, preferably 80%, most preferably 90% sequence identity to SEQ ID NO: 53 or 58, and a second component comprising or consisting of a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, preferably at least 80%, most preferably at least 90% sequence identity to SEQ ID NO: 66.
[0131] The biosensor can be configured to detect methotrexate (MTX), and the biosensor can include (i) a reporter protein (which can be an enzyme or a fluorescent protein, optionally a trehalase, a GDH enzyme, or a β-lactamase), which includes two calmodulin inserts at different positions within the reporter protein amino acid sequence, and two MTX-specific VHH binding portions, one at the N-terminus and one at the C-terminus of the reporter protein amino acid sequence; and (ii) a regulatory portion, which includes a calmodulin binding peptide and an MTX-specific nanoCLAMP binding portion. When the reporter protein is an enzyme, the biosensor may also include a substrate for the enzyme. Thus, a biosensor for detecting MTX may comprise a first component comprising, or consisting of, a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, preferably 80%, most preferably 90% sequence identity to any one of SEQ ID NO:59, 84 or 87; and a second component comprising, or consisting of, a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, preferably at least 80%, most preferably at least 90% sequence identity to SEQ ID NO:67 or 88.
[0132] The biosensor can be configured to detect rapamycin and cyclosporin, and the biosensor can include (i) a reporter protein (which can be an enzyme or a fluorescent protein, optionally a trehalase, a GDH enzyme, or a β-lactamase), which includes two calmodulin insertions at different positions within the reporter protein amino acid sequence; a FKBP binding portion, optionally located at the N-terminus of the reporter protein amino acid sequence; and an affinity protein binding portion, optionally located at the C-terminus of the reporter protein amino acid sequence; (ii) a regulatory portion, which includes a calmodulin binding peptide and a FRB binding portion; and (iii) a regulatory portion, which includes a calmodulin binding peptide and a calcineurin A and B (CalA / B) binding portion. When the reporter protein is an enzyme, the biosensor can also include a substrate for the enzyme. When the reporter protein is trehalase, the biosensor can also include an enzyme substrate, trehalose. Thus, a biosensor for detecting rapamycin may include a first component comprising or consisting of a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, preferably 80%, most preferably 90% sequence identity to SEQ ID NO:54; a second component comprising or consisting of a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, preferably at least 80%, most preferably at least 90% sequence identity to SEQ ID NO:65; and a third component comprising or consisting of a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, preferably at least 80%, most preferably at least 90% sequence identity to SEQ ID NO:65. NO:66 has, or consists of, a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, preferably at least 80%, most preferably at least 90% sequence identity.
[0133] The biosensor can be configured to detect a protease, and the biosensor can include (i) a reporter protein (which can be an enzyme or a fluorescent protein, optionally a trehalase, a GDH enzyme, or a β-lactamase), which includes two calmodulin inserts at different positions within the reporter protein amino acid sequence; and (ii) a regulatory portion, which includes a CaM-BP connected to calmodulin via a peptide linker including a cleavage site for a target protease, wherein the calmodulin has a reduced binding affinity for the CaM-BP compared to the binding affinity of the calmodulin insert. When the reporter protein is an enzyme, the biosensor can also include a substrate for the enzyme.
[0134] The biosensor can be configured to detect a target molecule (TM1), and the biosensor can include (1) a reporter protein (which can be an enzyme or a fluorescent protein, optionally a trehalase, a GDH enzyme or a β-lactamase), comprising two calmodulin inserts at different positions within the reporter protein amino acid sequence, and a first binding moiety (B′) specific for TM1, optionally located at the N-terminus or the C-terminus of the reporter protein amino acid sequence; and either (2-i) a regulatory moiety, which includes a second binding moiety (B″), also specific for TM1 or specific for a complex of TM1 and B′ , linked to two CaM-BPs, wherein optionally, each CaM-BP has a reduced binding affinity for calmodulin compared to wild-type CaM-BP, or (2-ii) a regulatory portion, which includes a second binding portion (B″), also specific for TM1 or specific for a complex of TM1 and B′, linked to two caged CaM-BPs, wherein each caged CaM-BP includes a CaM-BP linked to calmodulin, and the binding affinity of calmodulin to the CaM-BP is reduced compared to the binding affinity of the calmodulin insert of the reporter protein. When the reporter protein is an enzyme, the biosensor may further include a substrate for the enzyme.
[0135] cascade
[0136] Two or more biosensors described herein can be used in series to create a cascade, such as an enzyme cascade, in which multiple steps can be regulated. Two or more biosensors can be used in a direct sequential step of a cascade, or two or more biosensors can be used in an indirect sequential step (e.g., where one or more intermediate steps are not monitored by a biosensor).
[0137] For example, a first biosensor described herein can be used to convert trehalose into glucose, and a second biosensor can be used to convert glucose into gluconate lactate. The first biosensor can be any biosensor that includes trehalase. Such a first biosensor can be configured to respond to rapamycin, for example, the first biosensor can include a reporter protein comprising, or consisting of, a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity, optionally at least 80%, preferably at least 90%, most preferably at least 95% sequence identity to SEQ ID NO:54, optionally further comprising a first heterologous amino acid sequence, wherein the first heterologous amino acid sequence comprises, or consists of, a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity, optionally at least 80%, preferably at least 90%, most preferably at least 95% sequence identity to SEQ ID NO:65, and a second heterologous amino acid sequence comprising, or consisting of, a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity, optionally at least 80%, preferably at least 90%, most preferably at least 95% sequence identity to SEQ ID NO:65. NO:66 has, or consists of, a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity, optionally at least 80%, preferably at least 90%, most preferably at least 95% sequence identity.
[0138] The second biosensor can be any biosensor comprising GDH. Such a second biosensor can be configured to respond to cyclosporin A, for example, the second biosensor can include a reporter protein comprising a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity to SEQ ID NO: 64, optionally at least 80%, preferably at least 90%, most preferably at least 95% sequence identity, or consisting thereof, and optionally a first heterologous amino acid sequence and a second heterologous amino acid sequence comprising a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity to SEQ ID NO: 66, optionally at least 80%, preferably at least 90%, most preferably at least 95% sequence identity, or consisting thereof. Alternatively, the second biosensor can be configured to respond to methotrexate (MTX), for example, the second biosensor can include a reporter protein comprising, or consisting of, a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity to SEQ ID NO: 84, optionally at least 80%, preferably at least 90%, most preferably at least 95% sequence identity, and optionally further comprising a first heterologous amino acid sequence and a second heterologous amino acid sequence, the sequence comprising, or consisting of, a sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or at least 100% sequence identity to SEQ ID NO: 67 or 88, optionally at least 80%, preferably at least 90%, most preferably at least 95% sequence identity.
[0139] Those skilled in the art will appreciate that any of the biosensors described herein may be configured to form a cascade.
[0140] method
[0141] Also described herein is a method for detecting one or more target molecules (preferably, one target molecule or two target molecules) (e.g., TM1 and TM2), the method comprising the step of contacting one or more biosensors described herein with a sample under conditions suitable for detecting the presence or absence of one or more target molecules in the sample. Also described herein is a method for detecting one or more target molecules (preferably, one target molecule or two target molecules) (e.g., TM1 and TM2), the method comprising the step of contacting one or more reporter proteins described herein with a sample under conditions suitable for detecting the presence or absence of one or more target molecules in the sample.
[0142] The sample may be any sample suspected of containing one or more target molecules. The sample may or may not include one or more target molecules (e.g., target molecule TM1 and / or target molecule TM2 described herein). The sample may be a biological sample or an environmental sample. The sample is preferably a biological sample. A biological sample may be understood to refer to a sample derived from an organic substance, preferably a sample obtained from a living organism. A biological sample may include an organ sample, a tissue sample, a cell sample, a body fluid sample, or any other sample that can be obtained, obtained, derivable, or derived from an organism or a component of an organism. For example, a biological sample may include a fermentation medium, a raw material, or a food, such as, but not limited to, a dairy product. Suitably, the enzyme activity of the biosensor is substantially not inhibited by sample components (e.g., serum proteins, metabolites, cells, cell fragments and components, naturally occurring protease inhibitors, etc.). The biological sample may be obtained from an animal (preferably a mammal, most preferably a human), a plant, or a fungus. The sample may be obtained from an agriculturally important animal or plant, such as livestock (e.g., cattle, sheep, pigs, chickens, etc.) or crops (e.g., vegetables, grains, or other foods). Preferably, the sample can be a biological sample, wherein the biological sample is selected from: tissue, blood, plasma, serum, saliva, interstitial fluid, milk, juice, sap, or homogenate. The biological sample can be obtained from a mammal (preferably a human). The biological sample can be a liquid sample such as blood, serum, plasma, urine, saliva, tears, sweat, cerebrospinal fluid or amniotic fluid. The sample can be a tissue sample, such as a tissue or organ biopsy sample, or a cell sample, such as a sample including red blood cells, lymphocytes, tumor cells or skin cells. A special type of biological sample is a pathological sample. The sample can be a blood, saliva, serum or urine sample of a human subject. The sample can be a blood or saliva sample collected from a human. The sample can be a serum or urine sample of a human subject. The human can be a patient. The human can be suffering from or suspected of having a disease, one or more of which target molecules are markers or biomarkers. Environmental samples can be understood as samples from inorganic substances, such as water samples, soil samples, rock samples or air samples.
[0143] In some cases, the biosensors and / or methods of using them may be applicable to drug testing, such as detecting the use of illegal addictive drugs (e.g., cannabinoids, amphetamines, cocaine, heroin, etc.) and / or detecting performance-enhancing substances in sports and / or masking agents that are typically used to avoid the detection of performance-enhancing substances. This may be applicable to the detection of banned performance-enhancing substances in humans and / or other mammals (e.g., racehorses and greyhounds) that may be illegally "doped" to enhance performance.
[0144] The biosensors of the present invention can also be used to screen proteins that bind to specific target molecules. For example, in some cases, the sample can include a known purified target molecule, such as a target protein, a target peptide, or a target small molecule. A plurality of biosensors can be provided, which include a set of different binding moiety pairs to screen for binding to one or more target molecules. As described herein, specific binding of the binding moiety to the target molecule will result in activation of the biosensor.
[0145] Also described herein is a method for diagnosing a disease or condition in an organism, the method comprising contacting one or more reporter proteins described herein, or one or more biosensors described herein, with a sample obtained from the organism under conditions suitable for detecting the presence or absence of one or more target molecules in the sample, wherein the presence or absence of the one or more target molecules in the sample indicates whether the organism suffers from the disease or condition, or is at risk of suffering from the disease or condition. Typically, the one or more target molecules are one target molecule or two target molecules. In some cases, determining the presence or absence of one or more target molecules helps diagnose a disease or condition. The organism can include plants and animals, including fish, birds, and mammals such as humans. Preferably, the organism is a mammal, most preferably a human.
[0146] The disease or condition can be any disease or condition for which detection of a target molecule is helpful in diagnosis. Suitable target molecules are described herein. The target molecule can include one or more coagulation factors (as previously described), kallikreins (including PSA), matrix metalloproteinases, viral and bacterial proteases, antibodies, glucose, triglycerides, lipoproteins, cholesterol, tumor antigens, lymphocyte antigens, autoantigens and autoantibodies, drugs, salts, creatinine, serum or plasma proteins, pesticides, uric acid, products and intermediates of human and animal metabolism, and metals. The target molecule preferably includes one or more of methotrexate, phenolic glucosides, rapamycin, tacrolimus, or cyclosporin A. These methods may be suitable for execution as a "point-of-care" method, whereby the presence or absence of a target molecule can be determined at the patient's location, and then analyzed at that location or transmitted to a remote location to diagnose the disease or condition.
[0147] Also described herein is a method for monitoring one or more target molecules in an organism, the method comprising contacting one or more reporter proteins described herein, or one or more biosensors described herein, with a sample obtained from an organism under conditions suitable for detecting the presence or absence of one or more target molecules in the sample. Multiple samples can be collected regularly over a specified time period (e.g., one day, one week, one month, or one year) to monitor the presence or absence of target molecules in the organism over the time period. The method may also include quantifying the level of the target molecule in the organism. The method may also include detecting and quantifying the target molecule therein. The method may also include monitoring the level of one or more target molecules in the organism, for example, over a period of time, wherein the period of time may be one day, one week, one month, one year, or many years. The method can be used to monitor different states of normal physiology of an organism. Therefore, the presence or absence of one or more target molecules in a sample can indicate a specific physiological state in an organism. The level (i.e., quantity or concentration) of one or more target molecules in a sample can indicate a specific physiological state in an organism.
[0148] In some aspects, the method can be used to monitor the reproductive cycle, and one or more target molecules are hormones, such as progesterone, estradiol, luteinizing hormone (LH) and follicle stimulating hormone (FSH). The method can be used to monitor psychological stress levels, and one or more target molecules are cortisol or alpha-amylase. The method can be used to monitor metabolic status, and one or more target molecules are insulin and glucose; the method can be used to monitor the level of therapeutic drugs, such as methotrexate, rapamycin, tacrolimus, or cyclosporin A. The method can be used to monitor the level of environmental pollutants, such as phenolic glucosides. The organism can be a plant (e.g., a plant with agricultural significance, such as a crop) or an animal, including, for example, fish, birds, mammals (e.g., animals with agricultural significance, such as livestock). The organism can be a mammal. Preferably, the organism is a human.
[0149] Also described herein is a kit or apparatus suitable for performing the methods described herein. A kit is described herein that includes one or more of the different biosensors described herein that are capable of detecting one or more different target molecules. In this regard, the kit may include a series of different biosensors described herein that are capable of detecting a plurality of different target molecules. The kit may also include one or more substrates for reporter proteins suitable for the biosensors, as described herein. The kit may also include other components, including reagents such as buffers and diluents, reaction vessels, and instructions for use.
[0150] In some cases, the reporter proteins or biosensors described herein can be used to measure protein-protein or protein-small molecule binding interactions. Thus, described herein is a method for measuring protein-protein or protein-small molecule interactions, comprising contacting a reporter protein or biosensor described herein with a sample under conditions suitable for detecting the presence or absence of an interaction between a pair of binding moieties or between a pair of binding moieties and their corresponding target molecules. The sample typically includes a substrate molecule suitable for the reporter protein or biosensor.
[0151] In the biosensors of the present invention, the activity of the reporter protein may depend on a specific protein-protein or protein-small molecule interaction between the binding moiety pair (i.e., no target molecule is required). Such biosensors can be used to measure the direct interaction between a first protein or small molecule of interest (i.e., one half of the binding moiety pair) and a second protein or small molecule of interest (i.e., the corresponding other half of the binding moiety pair). The direct interaction between the binding moiety on the reporter protein and the protein / small molecule of interest in the corresponding binding moiety on the regulatory moiety (forming the binding moiety pair) will cause the reporter protein to co-localize with the regulatory moiety, promote the binding of the regulatory moiety to the heterologous amino acid sequence of the reporter protein, and thereby activate the activity of the reporter protein, as described herein, and produce a detectable readout as described herein. Such a biosensor can be used to measure the direct interaction between the two halves of each binding moiety pair in the biosensor. Such a biosensor can also be used to measure activators and inhibitors of the interaction between the two halves of the binding moiety pair, and the binding moiety can be a protein or a small molecule. Therefore, the sample can also include putative activators and inhibitors, that is, molecules whose ability to activate or inhibit the interaction between the binding moiety pair is to be determined. Activators that enhance the interaction between the binding moiety pair will result in enhanced reporter protein activity. Inhibitors that inhibit, prevent or reduce the interaction between the pair of binding moieties will result in reduced reporter protein activity.
[0152] Also described herein are methods for converting an enzyme into a reversibly regulated enzyme whose catalytic activity depends on the presence of one or more target molecules. The method may include, in a first step (a), generating a library of single insertional enzyme mutants by inserting at a plurality of different positions in the enzyme sequence a heterologous amino acid sequence that is responsive to binding of a regulatory moiety.
[0153] Single insertion enzyme mutants can be produced by introducing a heterologous amino acid sequence at a specific position within the amino acid sequence of the enzyme. Typically, the heterologous amino acid sequence is inserted into a specific position within the amino acid sequence of the enzyme, typically between two consecutive residues in the amino acid sequence of the enzyme. Those skilled in the art can easily perform such insertions, for example using recombinant DNA manipulations (e.g., using restriction enzymes, ligation, and PCR techniques) and recombinant protein expression techniques well known in the art. Multiple single enzyme mutants can be generated, wherein each single enzyme mutant includes a heterologous amino acid sequence inserted at a specific position to form a single insertion enzyme mutant library. Typically, each single insertion enzyme mutant in the library includes a heterologous amino acid sequence inserted at different positions within the amino acid sequence of the enzyme. The enzyme and heterologous amino acid sequence are typically provided as a continuous amino acid sequence. For example, a single insertion enzyme mutant may include a first portion of the enzyme sequence from the N-terminus to the C-terminus, a heterologous amino acid sequence, and a second portion of the enzyme sequence. Typically, the first and second portions of the enzyme sequence substantially correspond to the amino acid sequence of the wild-type enzyme. The heterologous amino acid sequence that responds to the combination with the regulating portion may be any heterologous amino acid sequence as described herein. Preferably, the heterologous amino acid sequence is calmodulin or a functional fragment thereof, as described herein, and the regulatory moiety is a calmodulin binding peptide (CaM-BP), as described herein.
[0154] The method may also include determining the catalytic activity of the single insertion enzyme mutant library. Thus, the catalytic activity of each single insertion enzyme mutant in the library can be determined. Such an assay may include contacting a single insertion enzyme mutant with its substrate under conditions suitable for the catalytic activity of the enzyme. A signal or reading of the catalytic activity of the enzyme can be detected, measured and / or quantified. A person skilled in the art can easily select a suitable assay to detect, measure and / or quantify the catalytic activity of the enzyme. Typically, the activity assay is performed in the presence and absence of a regulating part. The method may also include selecting a single insertion enzyme mutant that exhibits a change in catalytic activity when the regulating part is bound, typically in the presence of a suitable enzyme substrate and under suitable reaction conditions. Preferably, the single insertion enzyme mutant exhibits a change in catalytic activity to the binding to the regulating part within a desired time window. For example, a single insertion enzyme mutant is required to exhibit a rapid response time to the addition of a regulating part. The selected single insertion enzyme mutant can exhibit a change in catalytic activity (i.e., a significant change, such as a catalytic activity that is at least twice the catalytic activity when there is no regulating part) within 30 seconds after the addition of the regulating part. The dynamic range of a single insertional enzyme mutant is preferably at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15 or at least 20 times, preferably between 2 and 20 times, and most preferably between 5 and 15 times. The desired time window may be less than 30 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, 2 minutes, or less than 1 minute, and most preferably less than 10 minutes. The change in catalytic activity that occurs within the desired time window is typically at least 2×, 3×, 4×, 5×, 6×, 7×, 8×, 9×, or at least 10× of the catalytic activity (i.e., signal change) in the absence of the modulating moiety, and preferably the change in catalytic activity that occurs within the desired time window is at least 5×, and most preferably at least 10×.
[0155] The method may also include step (b), generating a double insertion enzyme mutant library by inserting an additional heterologous amino acid sequence that is responsive to the binding of the regulatory part at the second site in the enzyme sequence. Double insertion enzyme mutants can be understood to include two heterologous amino acid sequences that are usually inserted into the amino acid sequence of the enzyme, usually at different positions in the amino acid sequence of the enzyme. The enzyme and the two heterologous amino acid sequences are usually provided as a continuous amino acid sequence. For example, the double insertion enzyme mutant can include a first part of the enzyme sequence, a first heterologous amino acid sequence, a second part of the enzyme sequence, a second heterologous amino acid sequence, and a third part of the enzyme sequence from the N-terminus to the C-terminus. Usually, the first, second and third parts of the enzyme sequence substantially correspond to the amino acid sequence of the wild-type enzyme. Each heterologous amino acid sequence can be a heterologous amino acid sequence as described herein. The two heterologous amino acid sequences can be the same or different sequences. Each of the two heterologous amino acid sequences can include calmodulin, or a functional fragment thereof, or consist of it. The double insertion enzyme mutant library usually includes a plurality of double insertion enzyme mutants, wherein each double insertion enzyme mutant in the library includes two heterologous amino acid sequences inserted at different positions. For each double insertion mutant, the insertion position of one heterologous amino acid sequence may be the same, while the other insertion position may be different. Or for each double insertion mutant, the insertion positions of both heterologous amino acid sequences may be different. In some cases, the insertion position of the double insertion mutant can be selected by combining the insertion positions that have the fastest response time of the single insertion mutant.
[0156] The method may also include the step of selecting those double insertion enzyme mutants, which show a change in catalytic activity in the presence of a regulating part and have an increased dynamic range within a desired time window compared to the corresponding single insertion enzyme mutant. Therefore, those double insertion enzyme mutants are selected whose catalytic activity changes after adding the regulating part, usually in the presence of an enzyme substrate and under appropriate reaction conditions. As described above, those skilled in the art can easily select an assay suitable for the catalytic activity of a particular enzyme. The change in catalytic activity after the addition of the regulating part of the double insertion mutant enzyme can be compared with the change in catalytic activity after the addition of the regulating part of the corresponding single insertion mutant enzyme, that is, the single insertion mutant enzyme has a heterologous amino acid sequence inserted at a position corresponding to one of the two positions where the heterologous amino acid sequence is inserted in the double insertion mutant enzyme. Preferably, those double insertion mutant enzymes that show an improved dynamic range within a desired time window compared to either single insertion mutant enzyme or preferably both single insertion mutant enzymes are selected. The dynamic range of the double insertion mutant enzyme can be at least 2×, 3×, 4×, 5×, 6×, 7×, 90×, 10×, 20×, 30×, 40×, 50×, 75×, or 100×, preferably at least 10×, and most preferably at least 25×, of the dynamic range of either and preferably both of the single insertion mutant enzymes. The desired time window can be less than 30 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, 2 minutes, or less than 1 minute, and most preferably less than 10 minutes. The change in catalytic activity that occurs within the desired time window is typically at least 2×, 3×, 4×, 5×, 6×, 7×, 8×, 9×, or at least 10× of the catalytic activity (i.e., signal change) in the absence of the modulating moiety, and preferably the change in catalytic activity that occurs within the desired time window is at least 5×, and most preferably at least 10×. Thus, preferably, for example for clinical applications, the reporter proteins or biosensors described herein can exhibit at least a 5× signal change (i.e., a change in catalytic activity when a modulating moiety is added compared to the catalytic activity in the absence of the modulating moiety) in 20 minutes or less, and most preferably, the reporter proteins or biosensors described herein can exhibit at least a 10× signal change in 10 minutes or less. Most preferably, the reporter proteins or biosensors described herein can exhibit at least a 10-fold signal change in 10 minutes or less.
[0157] Thus, described herein is a method for converting a constitutively active enzyme into a reversibly regulated enzyme, the catalytic activity of which is dependent on the presence of one or more target molecules, comprising:
[0158] (a) generating a library of single insertional enzyme mutants by inserting heterologous amino acid sequences responsive to binding of a regulatory moiety at multiple different positions in the enzyme sequence and selecting those single insertional enzyme mutants that exhibit a change in catalytic activity within a desired time window after binding of the regulatory moiety;
[0159] (b) generating a library of double insertion enzyme mutants by inserting an additional heterologous amino acid sequence responsive to binding of a modulatory moiety at a second site within the enzyme sequence, and selecting those double insertion enzyme mutants that exhibit a change in catalytic activity in the presence of the modulatory moiety and have an increased dynamic range compared to the corresponding single insertion enzyme mutant, preferably wherein the double mutant insertion enzyme also exhibits a change in catalytic activity within a desired time window.
[0160] Nucleic Acids
[0161] The invention also provides one or more isolated nucleic acids encoding a reporter protein of the invention, a biosensor of the invention, or a component of a biosensor of the invention. The nucleic acid may encode any one of SEQ ID NOs: 1 to 67, 69, 70, or 73 to 82, or a variant thereof. The nucleic acid may encode an amino acid sequence comprising the sequence of one or more, or any one, of SEQ ID NOs: 1 to 67, 69, 70, or 73 to 82. The nucleic acid may include SEQ ID NOs: 68 or 71, or a variant thereof.
[0162] One or more genetic constructs comprising one or more isolated nucleic acids of the invention are described herein. One or more vectors comprising one or more isolated nucleic acids of the invention are described herein. One or more vectors suitable or applicable for expressing a reporter protein described herein, a biosensor described herein, or a component of a biosensor described herein, such as in a suitable host cell (see, e.g., SEQ ID NO: 68 or 71) are also described herein. Host cells comprising one or more isolated nucleic acids, one or more genetic constructs, or one or more vectors described herein are also described herein (see, e.g., Fig.15 –18).
[0163] The term "nucleic acid" as used herein refers to single-stranded or double-stranded mRNA, RNA, cRNA, RNAi, siRNA and DNA, including cDNA, mitochondrial DNA (mtDNA) and genomic DNA. Preferably, the nucleic acid of the present invention is DNA. The present invention also provides variants and / or fragments of isolated nucleic acids. Variants may include nucleotide sequences having at least 70%, at least 75%, preferably at least 80%, at least 85%, more preferably at least 90%, 91%, 93%, 94%, 95%, 96%, 97%, 98% or 99% nucleotide sequence identity with any nucleotide sequence disclosed herein. In other cases, nucleic acid variants may hybridize with any nucleotide sequence described herein under high stringency conditions. Fragments may include or consist of up to 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95-99% of the contiguous nucleotides present in any nucleotide sequence described herein. Fragments may include or consist of up to 20, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900 950, 1000, 1050, 1100, 1150, 1200, 1350, or 1300 contiguous nucleotides present in any nucleotide sequence described herein.
[0164] The nucleic acid of separation can be operably connected to one or more other nucleotide sequences, such as one or more promoters and / or one or more enhancers. The one or more other nucleotide sequences are usually regulatory nucleotide sequences. Operably connected or operably connected refers to that the regulatory nucleotide sequence is positioned relative to the nucleic acid to be expressed, to start, regulate or otherwise control the expression of nucleic acid. As generally used herein, "genetic construct" is an artificially produced nucleic acid that incorporates and / or promotes the use of the nucleic acid of separation disclosed herein. In particular cases, such constructs can be used for recombinant manipulations, propagation, amplification, homologous recombination and / or expression of the nucleic acid of separation.
[0165] The regulatory nucleotide sequence will usually be suitable for the host cell for expression. Suitable expression vectors of many types known in the art and suitable regulatory sequences are used for a variety of host cells. One or more regulatory nucleotide sequences can include but are not limited to promoter sequence, leader or signal sequence, ribosome binding site, transcription initiation and termination sequence, translation initiation and termination sequence, splicing donor / acceptor sequence and enhancer or activator sequence. Constitutive or inducible promoters known in the art can be used, and include for example nisin inducible, tetracycline repressible, IPTG inducible, alcohol inducible, acid inducible and / or metal inducible promoters. In an example, the expression vector includes a selective marker gene. Selectable markers can be used for selecting transformed bacterium (for example bla, kanR, ermB and tetR) or transformed mammalian cells (for example hygromycin, G418 and puromycin resistance) .
[0166] Also described herein is a method for producing (i) a reporter protein of the present invention, or (ii) a biosensor of the present invention or a component thereof, the method comprising the step of expressing the reporter protein, biosensor or a component thereof in a suitable host cell. Also described herein is a method for producing (i) a reporter protein of the present invention, or (ii) a biosensor of the present invention or a component thereof, the method comprising the step of introducing one or more nucleic acids of the present invention into a suitable host cell and incubating the host cell under conditions suitable for expressing the reporter protein, biosensor or a component thereof. The method may be a recombinant expression method. As used herein, a genetic construct for recombinant protein expression is referred to as an expression construct, wherein the isolated nucleic acid to be expressed is operably linked or operably linked to one or more additional nucleotide sequences in an expression vector. The expression vector may be a self-replicating extrachromosomal vector, such as a plasmid, or a vector that is integrated into the host genome.
[0167] Suitable host cells for expression can be prokaryotic or eukaryotic cells, such as bacterial cells including Escherichia coli (e.g., DH5α), yeast cells such as Saccharomyces cerevisiae or Pichia pastoris, insect cells such as SF9 cells used with baculovirus expression systems, or various mammalian or other animal host cells such as CHO, BHK or 293 cells. The introduction of the expression construct into a suitable host cell can be performed by techniques well known in the art, including, for example, electroporation, heat shock, calcium phosphate precipitation, DEAE dextran-mediated transfection, liposome-based transfection (e.g., lipofection, lipofectamine), protoplast fusion, microinjection, or microprojectile bombardment.
[0168] Purification of the reporter protein, biosensor or component of the biosensor produced by recombinant can be carried out by any method known in the art. In preferred cases, the recombinant protein molecule includes a fusion partner (preferably a C-terminal His tag) that allows purification by means of an appropriate affinity matrix, which in the case of a His tag will be a nickel matrix or resin. The resulting engineered mutant is preferably expressed as an epitope-tagged protein in bacteria such as Escherichia coli and purified by affinity chromatography.
[0169] The reporter proteins or biosensors of the invention can be expressed in host cells, for example, for metabolic engineering applications. Fig.15 As described in -17, suitable host cells in which the reporter proteins and / or biosensors of the present invention for metabolic engineering applications can be expressed may be prokaryotic or eukaryotic. The host cell may be selected from microbial cells, bacterial cells (including Escherichia coli, such as DH5α), yeast cells (such as Saccharomyces cerevisiae or Pichia pastoris), insect cells (such as SF9 cells used with a baculovirus expression system), plant cells (such as cells of wheat, corn or other crops), or mammalian cells (such as CHO, BHK or 293 cells). Preferably, the host cell is a microbial cell, a bacterial cell (e.g., preferably an Escherichia coli cell) or a yeast cell, most preferably a bacterial cell. The introduction of the construct for expressing the reporter protein / biosensor described herein can be introduced into a suitable host cell by any suitable technique known in the art and depending on the host cell, such as electroporation, heat shock, calcium phosphate precipitation, DEAE dextran-mediated transfection, liposome-based transfection (e.g., lipofection, lipofectamine), protoplast fusion, microinjection or microprojectile bombardment.
[0170] For example, reporter proteins / biosensors can be used to trigger or control a host cell to respond to certain properties of one or more target molecules. For example, certain reporter proteins / biosensors based on antibiotic resistance markers (e.g., where the reporter protein is a β-lactamase or an aminoglycoside phosphotransferase) can be used to construct a biosensor that induces antibiotic resistance in a host cell, which is typically a microbial cell (e.g., a bacterial cell, a yeast cell, an E. coli cell, etc.), in response to one or more target molecules of the biosensor. For example, in order to select cells that produce high levels of a particular compound or protein of interest, a biosensor based on an antibiotic resistance marker is prepared, with the compound or protein of interest as the target molecule. The cells being tested are mutagenized to express the biosensor, challenged with the relevant antibiotic, and surviving cell colonies are selected, which will include cells that produce enough target molecules to activate the biosensor and turn on enough antibiotic resistance to survive. For example, see Fig.15–17. In such applications, the large dynamic range of the biosensor of the present invention is very important, so the host cell bacteria cannot survive simply by producing more low-activity resistance proteins. Similarly, the reporter protein / biosensor can be based on fluorescence (such as a FRET (fluorescence resonance energy transfer) system) or a luminescent protein (such as a BRET (bioluminescence resonance energy transfer) system), and can be used to construct a biosensor that induces fluorescence or luminescence in the host cell in response to one or more target molecules of the biosensor. For example, in order to select cells that produce high levels of a specific compound or protein of interest, a biosensor based on a fluorescent or luminescent protein is prepared, with the compound or protein of interest as the target molecule. The cells to be tested are mutagenized to express the biosensor, and positive CLOSE can be detected by high levels of fluorescence / luminescence and can be separated, for example, using fluorescence activated cell sorting (FACS). The selected cells are cells that produce enough target molecules to activate the biosensor and turn on high levels of fluorescence / luminescence.
[0171] Another application of the biosensor of the present invention is metabolic switching. For example, in certain applications, it is not desirable to produce a certain product until the host cells have grown to an optimal or maximum density. A biosensor according to the present invention is prepared that has a cellular metabolite as a target molecule, whose production or high concentration indicates an optimal or maximum cell density. The biosensor is expressed in the host cell, and when the target metabolite reaches the desired level, the biosensor is activated with a reading or signal from the biosensor, which indicates that the cells are ready for production of the desired product.
[0172] Further metabolic engineering applications will be apparent to those skilled in the art, and based on the teachings of the present invention, suitable reporter proteins and biosensors suitable for specific applications can be readily prepared.
[0173] The present invention may be better understood by reference to the following examples.
[0174] Aspects of the Invention
[0175] 1. A reporter protein comprising a first heterologous amino acid sequence responsive to binding to a first regulatory moiety and a second heterologous amino acid sequence responsive to binding to a second regulatory moiety, wherein binding of the first regulatory moiety to the first heterologous amino acid sequence and binding of the second regulatory moiety to the second heterologous amino acid sequence reversibly regulates the activity of the reporter protein.
[0176] 2. The reporter protein of aspect 1, wherein the reporter protein is an enzyme, and wherein the activity of the reporter protein is the catalytic activity of the enzyme; or wherein the reporter protein is a fluorescent protein, and wherein the activity of the reporter protein is the fluorescence of the fluorescent protein.
[0177] 3. The reporter protein of aspect 1 or 2, wherein the binding of the first regulatory moiety to the first heterologous amino acid sequence and the binding of the second regulatory moiety to the second heterologous amino acid sequence reversibly activates the activity of the reporter protein.
[0178] 4. The reporter protein according to any one of aspects 1-3, wherein the dynamic range of the reporter protein is at least 10-fold, optionally at least 20-fold.
[0179] 5. The reporter protein of any one of aspects 1-4, wherein the first heterologous amino acid sequence is provided as an insertion fragment within the amino acid sequence of the reporter protein and the second heterologous amino acid sequence is provided as an insertion fragment within the amino acid sequence of the reporter protein.
[0180] 6. The reporter protein according to any one of aspects 1 to 5, wherein the first heterologous amino acid sequence and the second heterologous amino acid sequence are inserted at different positions within the amino acid sequence of the reporter protein.
[0181] 7. The reporter protein according to any one of aspects 1 to 6, wherein the first heterologous amino acid sequence and / or the second heterologous amino acid sequence is a protein.
[0182] 8. The reporter protein of any one of aspects 1 to 7, wherein the first heterologous amino acid sequence and the second heterologous amino acid sequence are proteins capable of undergoing a conformational change in response to binding to a regulatory moiety.
[0183] 9. The reporter protein according to any one of aspects 1 to 8, wherein the first heterologous amino acid sequence and the second heterologous amino acid sequence are the same protein or a functional fragment thereof.
[0184] 10. The reporter protein according to any one of aspects 1 to 9, wherein the first heterologous amino acid sequence and / or the second heterologous amino acid sequence is calmodulin or an affinity clamp, or a functional fragment thereof.
[0185] 11. The reporter protein according to any one of aspects 1 to 10, wherein the reporter protein further comprises one or more additional heterologous amino acid sequences.
[0186] 12. The reporter protein according to any one of aspects 1 to 11, wherein one or more additional heterologous amino acid sequences are provided as inserted fragments within the amino acid sequence of the reporter protein.
[0187] 13. The reporter protein according to any one of aspects 1 to 12, wherein each heterologous amino acid sequence is inserted into the amino acid sequence of the reporter protein at a different insertion position.
[0188] 14. A reporter protein as described in any of aspects 1-13, wherein the binding of the regulatory part to the first heterologous amino acid sequence causes a conformational change in the structure of the first heterologous amino acid sequence, and wherein the binding of the regulatory part to the second heterologous amino acid sequence causes a conformational change in the structure of the second heterologous amino acid sequence.
[0189] 15. The reporter protein of any one of aspects 1-14, wherein the first regulatory moiety and / or the second regulatory moiety is a peptide.
[0190] 16. A reporter protein according to any one of aspects 1 to 15, wherein the first and second regulatory moieties are the same peptide.
[0191] 17. The reporter protein of any one of aspects 1-16, wherein the first regulatory moiety and / or the second regulatory moiety is a calmodulin binding peptide or an affinity clamp RGS peptide ligand.
[0192] 18. The reporter protein of any one of aspects 1-17, wherein the first regulatory moiety and / or the second regulatory moiety is a calmodulin binding peptide having a reduced binding affinity for calmodulin compared to a wild-type calmodulin binding peptide.
[0193] 19. The reporter protein of aspect 18, wherein the first and second regulatory moieties are linked together, optionally via a linker, optionally as a fusion protein.
[0194] 20. A reporter protein as described in aspect 19, wherein the first and second regulatory moieties are each further linked to a protein that is a variant of the first or second heterologous amino acid sequence, respectively, and whose binding affinity for the regulatory moiety is reduced compared to the binding affinity of the corresponding heterologous amino acid sequence on the reporter protein.
[0195] 21. A reporter protein as described in aspect 20, wherein (i) the first and second heterologous amino acid sequences are calmodulin, and (ii) the first and second regulatory parts are calmodulin binding peptides, each of which is further linked to calmodulin, and the binding affinity of calmodulin to the calmodulin binding peptide is reduced compared to the binding affinity of calmodulin on the reporter protein.
[0196] 22. The reporter protein according to any one of aspects 1 to 21, wherein the binding of the calmodulin binding peptide to the first heterologous amino acid sequence and the second heterologous amino acid sequence, both of which are calmodulin, activates the activity of the reporter protein.
[0197] 23. A reporter protein as described in any of aspects 1-22, (i) wherein the reporter protein is an enzyme selected from the group consisting of trehalase, oxidoreductase, glucose dehydrogenase, β-lactamase, aminoglycoside phosphotransferase, α-amylase, and carbonic anhydrase; or (ii) wherein the reporter protein is a fluorescent protein selected from the group consisting of GFP, Cherry, mNeon, a fluorescent protein based on bacterial phytochrome (BphP), or a fluorescent protein derived from cyanobacterial phytochrome (CBCR).
[0198] 24. The reporter protein according to any one of aspects 1 to 23, wherein the reporter protein further comprises a first binding portion B1′.
[0199] 25. The reporter protein according to any one of aspects 1 to 24, wherein the first and second regulatory moieties are linked together and further linked to a binding moiety B1″ which is capable of interacting with the first binding moiety B1′ on the reporter protein.
[0200] 26. The reporter protein of aspect 25, wherein the first and second regulatory moieties and the binding moiety B1″ are linked as a fusion protein, optionally via one or more linkers.
[0201] 27. A reporter protein as described in aspect 25, wherein the interaction between the binding parts B1′ and B1″ co-localizes the first regulatory part, the second regulatory part, and the reporter protein, thereby enhancing the binding of the first and second regulatory parts to the first heterologous amino acid sequence and the second heterologous amino acid sequence, respectively, and thereby activating the activity of the reporter protein.
[0202] 28. The reporter protein according to any one of aspects 1 to 24, wherein the reporter protein further comprises a second binding portion B2′.
[0203] 29. The reporter protein according to any one of aspects 1 to 28, wherein the first regulatory part comprises a binding part B1″ which is capable of interacting with the first binding part B1′ on the reporter protein.
[0204] 30. The reporter protein of aspect 28 or 29, wherein the second regulatory moiety comprises a binding moiety B2″ which is capable of interacting with a second binding moiety B2′ on the reporter protein.
[0205] 31. A reporter protein according to any of aspects 28 to 30, wherein the interaction of the binding parts B1' and B1" and the interaction of the binding parts B2' and B2" modulates the activity of the reporter protein, optionally activates the activity of the reporter protein.
[0206] 32. The reporter protein according to any one of aspects 28 to 31, wherein the activity of the reporter protein is activated only upon interaction of the binding parts B1′ and B1″ and upon interaction of the binding parts B2′ and B2″.
[0207] 33. The reporter protein of any one of aspects 24-32, wherein the interaction between the binding moieties B1′ and B1″ co-localizes the first regulatory moiety and the reporter protein, thereby enhancing the binding of the first regulatory moiety to the first heterologous amino acid sequence.
[0208] 34. The reporter protein of any one of aspects 28-33, wherein the interaction between the binding moieties B2′ and B2″ co-localizes the second regulatory moiety and the reporter protein, thereby enhancing the binding of the second regulatory moiety to the second heterologous amino acid sequence.
[0209] 35. A reporter protein as described in any of aspects 28-34, wherein the interaction between the binding parts B1′ and B1″ and the interaction between the binding parts B2′ and B2″ co-localize the first regulatory part, the second regulatory part and the reporter protein, thereby enhancing the binding of the first and second regulatory parts to the first heterologous amino acid sequence and the second heterologous amino acid sequence, respectively, and thereby activating the activity of the reporter protein.
[0210] 36. The reporter protein according to any of aspects 24-35, wherein the binding moieties B1′ and B1″ are capable of directly binding to each other and / or the binding moieties B2′ and B2″ are capable of directly binding to each other.
[0211] 37. A reporter protein according to any of aspects 24 to 36, wherein the interaction of the binding moieties B1' and B1" is dependent on the presence of the first target molecule TM1.
[0212] 38. A reporter protein according to any one of aspects 28 to 37, wherein the interaction of the binding moieties B2' and B2" is dependent on the presence of a second target molecule TM2.
[0213] 39. A reporter protein as described in any of aspects 28-38, wherein the interaction between the binding parts B1′ and B1″ and the interaction between the binding parts B2′ and B2″ depend on the presence of both the first target molecule TM1 and the second target molecule TM2, so that the activity of the reporter protein is only activated in the presence of both target molecules TM1 and TM2.
[0214] 40. The reporter protein according to any one of aspects 24 to 39, wherein in the presence of the first target molecule TM1, the first binding portion B1' on the reporter protein interacts with the binding portion B1" on the first regulatory portion.
[0215] 41. The reporter protein according to any one of aspects 28 to 40, wherein in the presence of a second target molecule TM2, the second binding portion B2' on the reporter protein interacts with the binding portion B2" on the second regulatory portion.
[0216] 42. The reporter protein according to any one of aspects 24 to 41, wherein the binding moieties B1' and B1" form a pair of binding moieties that bind simultaneously to the target molecule TM1.
[0217] 43. A reporter protein according to any of aspects 28 to 42, wherein the binding moieties B2' and B2" form a pair of binding moieties that simultaneously bind to the target molecule TM2.
[0218] 44. A reporter protein according to any one of aspects 28 to 43, wherein the binding moieties B1' and B1" and the binding moieties B2' and B2" are the same pair of binding moieties or different pairs of binding moieties.
[0219] 45. A reporter protein according to any one of aspects 37-44, wherein the target molecules TM1 and TM2 are the same or different.
[0220] 46. A reporter protein as described in any of Aspects 37-45, wherein in the presence of a first target molecule TM1 and a second target molecule TM2, the first binding part B1′ on the reporter protein interacts with the binding part B1″ on the first regulatory part and the second binding part B2′ on the reporter protein interacts with the binding part B2″ on the second regulatory part, wherein such co-localization of the reporter protein with the first and second regulatory parts results in the first regulatory part binding to the first heterologous amino acid sequence on the reporter protein and the second regulatory part binding to the second heterologous amino acid sequence on the reporter protein, thereby reversibly regulating the activity of the reporter protein, and optionally activating the activity of the reporter protein.
[0221] 47. The reporter protein according to any one of aspects 1 to 46, wherein the presence of the first target molecule TM1 and the second target molecule TM2 reversibly regulates the activity of the reporter protein, and optionally activates the activity of the reporter protein.
[0222] 48. A biosensor comprising:
[0223] (a) a reporter protein as described in aspects 1-47;
[0224] (b) a first modulating moiety as defined in any of aspects 1-47; and
[0225] (c) A second modulating moiety as defined in any of aspects 1-47.
[0226] 49. A composition or kit comprising:
[0227] (a) a reporter protein as described in aspects 1-47; or
[0228] (b) The biosensor according to aspect 48.
[0229] 50. The biosensor of aspect 48 or the composition or kit of aspect 49, wherein the reporter protein is an enzyme, further comprising a substrate for the enzyme.
[0230] 51. The biosensor, composition or kit according to any one of aspects 48-50, further comprising a target molecule TM1.
[0231] 52. The biosensor, composition or kit according to any one of aspects 48 to 51, further comprising a target molecule TM2.
[0232] 53. The biosensor, composition or kit of any one of aspects 48-52, wherein the target molecule TM1 is the same as the target molecule TM2; or wherein the target molecule TM1 is different from the target molecule TM2.
[0233] 54. The biosensor, composition or kit according to any one of aspects 48 to 53, further comprising a biological sample, wherein the biological sample may or may not include the target molecule TM1 and / or the target molecule TM2.
[0234] 55. A biosensor, composition or kit as described in any of Aspects 48-54, wherein the reporter protein is an enzyme, and further comprising a second enzyme, which comprises a heterologous amino acid sequence responsive to peptide P, wherein binding of peptide P to the heterologous amino acid sequence reversibly regulates the catalytic activity of the second enzyme, wherein the substrate of the second enzyme is the catalytic product of the enzyme as described in Aspects 1-47.
[0235] 56. A biosensor, composition or kit as described in aspect 55, wherein (a) the second enzyme is an oxidoreductase, optionally a glucose dehydrogenase, (b) the heterologous amino acid sequence is calmodulin or a functional fragment thereof, and (c) the peptide P is a calmodulin binding peptide.
[0236] 57. A method for detecting one or more target molecules, comprising contacting a reporter protein as described in any one of aspects 1-47; a biosensor or composition or kit as described in any one of aspects 48-56; with a sample under conditions suitable for detecting the presence or absence of one or more target molecules in the sample.
[0237] 58. The method of aspect 57, wherein the one or more target molecules comprise or consist essentially of target molecule TM1 and target molecule TM2.
[0238] 59. The method of aspect 57 or 58, wherein target molecule TM1 and target molecule TM2 are the same or different.
[0239] 60. The method of any one of aspects 57-59, wherein the one or more target molecules are selected from the group consisting of methotrexate, phenol glucoside, rapamycin, tacrolimus and cyclosporin A.
[0240] 61. A method for diagnosing a disease or condition in an organism, comprising contacting a reporter protein as described in any of Aspects 1-47, a biosensor or a composition or kit as described in any of Aspects 48-56, with a sample obtained from the organism under conditions suitable for detecting the presence or absence of one or more target molecules in the sample, wherein the presence or absence of the one or more target molecules in the sample indicates whether the organism has the disease or condition, or is at risk of having the disease or condition.
[0241] 62. A method for monitoring one or more target molecules in an organism, the method comprising contacting a reporter protein as described in any of Aspects 1-47; a biosensor or composition or kit as described in any of Aspects 48-56 with a sample obtained from the organism under conditions suitable for detecting and / or quantifying the presence or absence of one or more target molecules in the sample.
[0242] 63. The method of aspect 62, wherein the presence or absence of one or more target molecules in the sample is indicative of a particular physiological state in the organism; optionally wherein:
[0243] (i) the method is used to monitor the reproductive cycle, and the one or more target molecules are hormones, such as progesterone, estradiol, luteinizing hormone (LH) and follicle stimulating hormone (FSH);
[0244] (ii) the method is used to monitor psychological stress levels, and the one or more target molecules are cortisol or α-amylase;
[0245] (iii) the method is used to monitor metabolic status and the one or more target molecules are insulin and glucose;
[0246] (iv) the method is used to monitor the level of a therapeutic drug, such as methotrexate, rapamycin, tacrolimus, or cyclosporine A;
[0247] (v) the method is used to monitor the level of environmental pollutants, such as phenolic glucosides; or
[0248] (vi) The method is used to monitor metabolites of interest.
[0249] 64. A method for monitoring a metabolite of interest in an organism, the method comprising expressing in the organism a reporter protein as described in any one of aspects 1-47 or a biosensor as described in any one of aspects 48-56 under conditions suitable for detecting and / or quantifying the metabolite of interest in the organism, optionally wherein the organism is a bacterial cell.
[0250] 65. A method for determining protein-protein or protein-small molecule interactions, comprising contacting a reporter protein as described in any of Aspects 1-47; a biosensor or composition or kit as described in any of Aspects 48-56; with a sample under conditions suitable for detecting the presence or absence of an interaction between binding parts B1′ and B1″ and / or an interaction between binding parts B2′ and B2″; or an interaction between binding parts B1′ and B1″ and target molecule TM1 and / or an interaction between binding parts B2′ and B2″ and target molecule TM2.
[0251] 66. The method of aspect 65, wherein the binding moieties B1' and B1" and the binding moieties B2' and B2" are proteins.
[0252] 67. The method of aspect 65 or 66, wherein the target molecule TM1 and the target molecule TM2 are proteins or small molecules.
[0253] 68. The method of any of aspects 65-67, wherein the binding moieties B1' and B1" and the binding moieties B2' and B2" are the same pair of binding moieties, and the target molecule TM1 and the target molecule TM2 are the same.
[0254] 69. A detection device comprising a cell or chamber, wherein the cell or chamber comprises a reporter protein according to any one of aspects 1 to 47 or a biosensor according to any one of aspects 48 to 56.
[0255] 70. One or more nucleic acids encoding a reporter protein according to any one of aspects 1 to 47 or a biosensor according to any one of aspects 48 to 56.
[0256] 71. One or more expression vectors comprising one or more nucleic acids of aspect 70 operably linked to one or more promoters.
[0257] 72. A host cell comprising a reporter protein according to any one of aspects 1-47, a biosensor according to any one of aspects 48-56, one or more nucleic acids according to aspect 70, or one or more expression vectors according to aspect 71.
[0258] 73. A method for converting a constitutively active enzyme into a reversibly regulated enzyme, the catalytic activity of which is dependent on the presence of one or more target molecules, the method comprising:
[0259] (a) generating a library of single insertional enzyme mutants by inserting heterologous amino acid sequences responsive to binding to a regulatory moiety at multiple different positions in the enzyme sequence and selecting those single insertional enzyme mutants that exhibit a change in catalytic activity in response to binding to the regulatory moiety;
[0260] (b) generating a library of double insertion enzyme mutants by inserting an additional heterologous amino acid sequence responsive to binding of a regulatory moiety at a second site within the enzyme sequence, and selecting those double insertion enzyme mutants that exhibit a change in catalytic activity in the presence of the regulatory moiety and have an increased dynamic range compared to the corresponding single insertion enzyme mutants.
[0261] 74. The method of aspect 66, wherein the change in catalytic activity occurs in less than 10 minutes, optionally less than 5 minutes.
[0262] 75. A reporter protein as described in any of aspects 1-17, wherein the first and second regulatory parts are the same calmodulin binding peptide (CaM-BP), and wherein the first and second heterologous amino acid sequences of the reporter protein are the same calmodulin; optionally, wherein the CaM-BP is also optionally connected to the calmodulin via a linker, and the calmodulin has a reduced binding affinity for the CaM-BP compared to the calmodulin of the reporter protein.
[0263] 76. The reporter protein of aspect 18, wherein the linker connecting CaM-BP to calmodulin with reduced binding affinity comprises a protease cleavage site.
[0264] 77. A biosensor comprising a reporter protein as described in aspect 75 or 76, and a first regulating moiety and a second regulating moiety as defined in aspect 75 or 76, configured for detecting a protease as a target molecule.
[0265] 78. A method for detecting the activity of a reporter protein as described in any of Aspects 1-47 using an electrochemical method, wherein the reporter protein is an enzyme, wherein the electrochemical method is capable of distinguishing a substrate from a product of the enzyme; optionally wherein the hydrolysis of the substrate is electrochemically monitored; optionally wherein the method is performed in a biological fluid such as serum; optionally wherein the reporter protein is β-lactamase and the substrate is nitrocefin.
[0266] Example
[0267] As hinted in the introduction, the overall nature of allosteric systems poses major problems for producing a state in which one conformation dominates the overall state. The design of the following exemplary biosensors of the present invention is based on the assumption that in a chimeric switch system, the regulatory domain allows a specific array of conformations in each of its conformational states. Although the active "on" state may be similar to that of the parent molecule, the "off" state is expected to be achieved by a wide range of mechanisms. Therefore, many engineering challenges focus on producing an effective and reversible "off" state in the reporter protein. As shown for the first time herein, the conformationally induced inactivation change in the reporter protein is produced by two or more insertions of heterologous amino acid sequences at different sites, which interact in the free state, resulting in the compound effect demonstrated herein.
[0268] Example 1 - Trehalase-based AND-gate biosensor
[0269] A series of insertion mutants of trehalase and calmodulin were constructed. Trehalase degrades trehalose to glucose and its activity can be easily monitored by a coupled glucose oxidation reaction. The trehalase structure (PDB:2jg0) was analyzed and eight trehalase-calmodulin (Tre-CaM) chimeras were designed. The regulatory calmodulin domain was placed in the enzyme sequence at a position assuming that such an insertion was unlikely to perturb the overall folding or active site of the enzyme. The resulting chimeric proteins were expressed in Escherichia coli and purified to homogeneity. The activity of the chimeric proteins was determined using a coupled assay in which glucose produced by trehalase was oxidized to gluconolactone by PQQ-glucose dehydrogenase (GDH). The assay was optimized in such a way that the activity of trehalase was rate limiting and therefore behaved as a first order reaction. Using this assay, the activity of wild-type trehalase as well as Tre-CaM chimeras was monitored in the presence or absence of calmodulin binding peptide (CaM-BP). As Figure 2 As shown in D, some mutants showed little or no activity, some were active but did not exhibit CaM-BP dependence, and some were activated by the peptide to varying degrees. The switchable variants showed a modest dynamic range between 2- and 11-fold, which was mainly due to incomplete inactivation of the reporter in the absence of the ligand peptide. Analysis of selected variants confirmed that they bound CaM-BP with nanomolar affinity, as expected.
[0270] Chimeric enzymes combining multiple insertions identified in the initial screen were constructed to test for additive effects. To this end, the insertion at position 104 was combined with an insertion at position 321 or 440 ( Figure 3 A). These chimeras showed a dynamic range of more than 50-fold and bound CaM-BP saturably and dose-dependently ( Figure 3 B, 3E), and the apparent K d The value is 68 nM. This is probably an overestimate because the FIT program does not take into account the dual binding sites ( Figure 3 F).
[0271] The ability of this 2CaM-Tre switch to operate in a larger biosensor system was tested. Thus, the N- and C-termini of 2CaM-Tre were each fused to a FKBP domain, which is able to form a ternary complex with the target molecule rapamycin and the FRB domain ( Figure 4 A). When the FKBP-2CaM-Tre-FKBP fusion protein was mixed with FRB and a fusion of a low-affinity CaM-BP developed in a previous study [4], the resulting system showed rapamycin-dependent activity and a large dynamic range ( Figure 4 B, C). The experiments demonstrated that the developed AND-gated reporter construct can be incorporated into a more advanced biosensor signaling system.
[0272] Other biosensors were constructed to test whether the individual CaM proteins included in the 2CaM-Tre switch could each be operated by a different input. To this end, a variant biosensor was constructed in which a cyclophilin (CPY) domain was attached to the C-terminus of the FKBP-2CaM-Tre fusion protein to generate the FKBP-2CaM-Tre-CPY fusion protein. This construct was able to bind to FRB-CaM-BP in a rapamycin-dependent manner and to a fusion polypeptide containing calcineurin A and B (CalA / B) and CaM-BP (CalA / B-CaM-BP) in a cyclosporine A-dependent manner ( Figure 4 D) Figure 4 As shown in Figure E, the addition of ligands rapamycin or cyclosporin A to the mixture of FKBP-2CaM-Tre-CPY, FRB-CaM-BP, and Cal A / B-CaM-BP resulted in a mild activation of trehalase activity. However, the simultaneous addition of both ligands resulted in full activation of the system ( Figure 4 D, E).
[0273] Example 2 - GDH-based AND gate biosensor
[0274] A series of insertion mutants of glucose dehydrogenase (GDH) and calmodulin were constructed. GDH catalyzes the conversion of glucose into gluconolactone and generates electrons simultaneously. The activity of GDH was monitored using methyl methacrylate (PMS) as an electron mediator and 2,6-dichloroindophenol (DCPIP) as a reporter dye that changes from blue to colorless when reduced. The GDH structure (PDB: 1c9u) was analyzed and a library of CaM domain insertions was generated. The regulatory calmodulin domain was placed in the enzyme sequence at a position where it was assumed that such an insertion would be unlikely to perturb the overall folding of the enzyme. The resulting chimeric protein was expressed in Escherichia coli and purified to homogeneity. The activity of the chimeric protein was determined using the DCPIP assay. The activity of wild-type GDH and GDH-CaM chimeras were monitored in the presence or absence of CaM-BP (M13). The single insertion mutants GDH-CaM_48N and GDH-CaM_212N exhibited CaM-BP-dependent activity with a rapid activation time and a moderate dynamic range of approximately 4 or 5 times ( Fig.11 A, B) A chimeric enzyme was constructed that combines the first CaM insertion at position 48 and the second CaM insertion at position 212. Fig.11 As shown in C, the chimera exhibited a more than 20-fold enhanced dynamic range, bound CaM-BP saturably and dose-dependently, and displayed a clinically useful activation time.
[0275] Example 3 - β-lactamase-based AND gate biosensor
[0276] BLA-CaM
[0277] A series of insertion mutants of the enzyme β-lactamase (BLA) and calmodulin were constructed. β-lactamase degrades the β-lactam ring in nitrocefin and can be detected by a color change from yellow to red ( Figure 5 A). The β-lactamase structure (PDB: 3gmw) was analyzed and a series of calmodulin (BLA-CaM) chimeras were designed. The regulatory calmodulin domain was repositioned in the enzyme sequence at a position where it was assumed that such an insertion would be unlikely to perturb the overall folding of the enzyme ( Figure 5 B). The resulting chimeric protein was expressed in E. coli and purified to homogeneity. The activity of the chimeric protein was determined using the nitrocefin assay. The activity of wild-type β-lactamase as well as the BLA-CaM chimera was monitored in the presence or absence of CaM-BP (M13). Twenty (20) different insertion sites were analyzed, such as Figure 5 C. To construct double-crossover variants, single insertion mutants BLA-CaM 41G and BLA-CaM 197E were selected, which showed CaM-BP-dependent activity with rapid activation time and moderate dynamic range of approximately 7- or 8-fold, respectively ( Figure 6 A–D). A chimeric enzyme was constructed that combines the first CaM insertion at position 41 and the second CaM insertion at position 197 ( Figure 6 E). Figure 5 As shown in F and 5G, the chimera displayed a remarkable dynamic range of over 7000-fold, bound CaM-BP saturably and dose-dependently, and displayed a clinically useful activation time.
[0278] Analysis of the catalytic activity of the developed switch module showed that the activity of the double insertion chimera was only modestly reduced compared to the parent single switch enzyme. The double insertion variant retained approximately 25% of the activity observed for the wild-type enzyme ( Figure 6 H). Importantly, the double insertion mutant exhibited significantly higher maximal activity compared to the best performing single mutant (CaM-BLA 253G chimera), retaining less than 5% of maximal activity compared to the wild-type enzyme ( Figure 6 I).
[0279] FKBP-2CaM-BLA-FKBP& FRB-CaM-BP
[0280] To test the utility of the developed 2CaM-BLA switch module, the FKBP domains were provided at the N- and C-termini (FKBP-2CaM-BLA-FKBP) and the activity of FKBP was tested in the presence or absence of rapamycin as well as a fusion between the FRB domain and a truncated calmodulin binding peptide (FRB-CaM-BP) ( Figure 7 A). Addition of rapamycin to FKBP-2CaM-BLA-FKBP and FRB-CaM-BP solutions resulted in a dose-dependent increase in β-lactamase activity ( Figure 7 B) Data fitting to obtain apparent K d The value is 11nM, and the dynamic range is 171 times ( Figure 7 C). The biosensor was fully activated within 10 minutes ( Figure 7 D).
[0281] FKBP-2CaM-BLA-FKBP and calcineurin A / B-CaM-BP
[0282] The FRB domain was then replaced with a fusion between calcineurin A and B to form a calcineurin A / B-CaM-BP fusion ( Figure 8 A), and tested the response of a mixture of FKBP-2CaM-BLA-FKBP and calcineurin A / B-CaM-BP to tacrolimus. Addition of tacrolimus to the mixture resulted in a dose-dependent increase in β-lactamase activity ( Figure 8 B) Data fitting to obtain apparent K d The value is 14nM, and the dynamic range is 60 times ( Figure 8 C). The biosensor was fully activated within 10 minutes ( Figure 8 D).
[0283] MTX Biosensor (VHH-2CaM-BLA-VHH & NanoCLAMP-CaM-BP)
[0284] To test the developed biosensor platform on small molecule analytes with different structures, we constructed a methotrexate (MTX) biosensor by fusing 2CaM-BLA to a VHH binder of methotrexate (PDB: 3qxv). The nanoCLAMP domain, which is capable of recognizing the VHH∶MTX complex, was then fused to a low-affinity calmodulin binding peptide. Addition of MTX to the mixture of VHH-2CaM-BLA-VHH and nanoCLAMP-CaM-BP resulted in a rapid increase in β-lactamase activity ( Fig. 9 B), comparable maximal activity was achieved when VHH-2CaM-BLA-VHH was activated by the addition of M13 binding peptide. The response was dose-dependent ( Fig. 9 C) and apparent K d The value is 7.3 nM, which is close to the affinity of the VHH∶MTX interaction ( Fig. 9 D). The biosensor reached half-maximal activation within 5 minutes and full activation within 15 minutes ( Fig. 9 E–F).
[0285] By porting the assay to a Beckman AU-480 clinical chemistry analyzer ( Fig.10 A) , the utility of the developed test was validated, where the VHH-2CaM-BLA-VHH based assay demonstrated the ability to quantify MTX in human serum ( Fig.10 B, C).
[0286] Thermally stable MTX biosensor
[0287] To test whether the MTX biosensor platform is feasible between various β-lactamase-calmodulin variant sequences, a thermostabilized β-lactamase-calmodulin chimeric MTX biosensor was constructed. The biosensor was constructed by constructing a 2CaM-BLA insertion mutant (SEQ ID NO: 86) from a thermostable BLA including K55Q, S82A, G92D, T140K, H153R, V184A mutations (TEM-1BLA, SEQ ID NO: 85). The use of the mutant TEM-1BLA resulted in increased thermostability ( Fig. 22B). The 2CaM-BLA was then fused to a VHH binder to methotrexate (PDB: 3qxv) to generate a thermostable VHH-2CaM-BLA-VHH biosensor (SEQ ID NO: 87, also referred to as 2VHH 2CaM-BLA-41G 197E). The nanoCLAMP domain, which is capable of recognizing VHH:MTX complexes, was then fused to a low affinity calmodulin binding peptide. MTX was added to the VHH-2CaM-BLA-VHH and nanoCLAMP-CaM-BP mixture, resulting in a rapid increase in β-lactamase activity ( Fig. 22 F).
[0288] Example 4 - Signal Cascade Including AND Gate Biosensor
[0289] The proposed method can be applied to more than a single enzyme, thus enabling the modulation of both enzymatic and signaling cascades.
[0290] Through the infusion of rapamycin, trehalose is converted to glucose; through the infusion of cyclosporine A, glucose is converted to gluconic acid. ester
[0291] To illustrate the application of biosensors in this system, Figure 4 The dual-input switch module shown in F is combined with the previously described CaM-GDH biosensor responsive to cyclosporin A [4] ( Figure 4 G) combination. In this system, the production of glucose from trehalose by 2FKBP-tre-2CaM and FRB-CaM-BP biosensors is regulated by rapamycin input. Glucose is subsequently converted to gluconolactone by CaM-GDH-CpY and Cal A / B-CaM-BP biosensors, with simultaneous electron production, which is controlled by cyclosporin A, which regulates GDH activity. Activity analysis of this system revealed that while rapamycin and cyclosporin A alone produced responses close to background, their combination resulted in a substantial increase in activity, consistent with the idea of pathway regulation at multiple nodes.
[0292] Trehalose to glucose via rapamycin infusion; glucose to gluconolactone via MTX infusion
[0293] To illustrate the application of multiple dual-input switches connected in series, Figure 4 The dual-input switch shown in F is combined with a CaM-GDH biosensor responsive to MTX ( Fig.21A). In this system, glucose production from trehalose by FKBP-2CaM-Tre-CpY and FRB-CaM-BP biosensors is regulated by rapamycin input. Glucose is subsequently converted to gluconolactone by 2CaM-GDH-2VHH (also referred to as VHH-2CaM-GDH-VHH) and nanoCLAMP-CaM-BP biosensors, with simultaneous electron production, which is controlled by MTX, which regulates GDH activity. Activity analysis of this system revealed that while rapamycin and MTX alone produced responses close to background, their combination resulted in a substantial increase in activity ( Fig.21 B), which is consistent with the idea of pathway regulation at multiple nodes.
[0294] References
[0295] (1)Wodak, SJ; et al., Allostery in Its Many Disguises: From Theory to Applications. Structure 2019, 27(4), 566–578.
[0296] (2)Clark,JJ;et al.,Inherent versus Induced Protein Flexibility:Comparisons within and between Apo and Holo Structures.PLoS Comput.Biol.2019,15(1),1–21.
[0297] (3)Stein, V.; Alexandrov, K.Protease-Based Synthetic Sensing and SignalAmplification.Proc.Natl.Acad.Sci.USA2014,111(45),15934–15939.
[0298] (4)Guo,Z.;et al.,Generalizable Protein Biosensors Based on SyntheticSwitch Modules.J.Am.Chem.Soc.2019,141(20),8128–8135.
[0299] (5)Nadler,D.C.;et al.,Rapid Construction of Metabolite BiosensorsUsing Domain-Insertion Profiling.Nat.Commun.2016,7,12266.
[0300] (6)Merithew,E.;et al.,Structural Plasticity of an InvariantHydrophobic Triad in the Switch Regions of Rab GTPases is aDeterminant ofEffector Recognition.J.Biol.Chem.2001,276(17),13982–13988.
[0301] (7)Guntas,G.;et al.,Directed Evolution of Protein Switches and TheirApplication to the Creation of Ligand-Binding Proteins.Proc.Natl.Acad.Sci.U.S.A.2005,102(32),11224–11229.
[0302]
[0303]
[0304]
[0305]
[0306]
[0307]
[0308]
[0309]
Claims
1. A reporter protein comprising a first heterologous amino acid sequence responsive to binding to a first regulatory moiety and a second heterologous amino acid sequence responsive to binding to a second regulatory moiety, wherein binding of the first regulatory moiety to the first heterologous amino acid sequence and binding of the second regulatory moiety to the second heterologous amino acid sequence reversibly regulates the activity of the reporter protein.
2. The reporter protein of claim 1, wherein the reporter protein is an enzyme, and wherein the activity of the reporter protein is the catalytic activity of the enzyme; or wherein the reporter protein is a fluorescent protein, and wherein the activity of the reporter protein is the fluorescence of the fluorescent protein.
3. The reporter protein of claim 1 or 2, wherein the binding of the first regulatory moiety to the first heterologous amino acid sequence and the binding of the second regulatory moiety to the second heterologous amino acid sequence reversibly activates the activity of the reporter protein.
4. The reporter protein according to any one of claims 1 to 3, wherein the dynamic range of the reporter protein is at least 10-fold, optionally at least 20-fold.
5. The reporter protein of any one of claims 1-4, wherein the first heterologous amino acid sequence is provided as an insertion fragment within the amino acid sequence of the reporter protein and the second heterologous amino acid sequence is provided as an insertion fragment within the amino acid sequence of the reporter protein.
6. The reporter protein according to any one of claims 1 to 5, wherein: (a) the first heterologous amino acid sequence and / or the second heterologous amino acid sequence is a protein; (b) the first heterologous amino acid sequence and the second heterologous amino acid sequence are proteins capable of undergoing a conformational change in response to binding to a regulatory moiety; (c) the first heterologous amino acid sequence and the second heterologous amino acid sequence are the same protein or a functional fragment thereof; (d) The first heterologous amino acid sequence and / or the second heterologous amino acid sequence is calmodulin, or a functional fragment thereof.
7. The reporter protein according to any one of claims 1 to 6, wherein: (a) the first regulatory moiety and / or the second regulatory moiety is a peptide; (b) the first and second regulatory moieties are the same peptide; and / or (c) the first modulating moiety and / or the second modulating moiety is a calmodulin binding peptide.
8. The reporter protein of any one of claims 1 to 7, wherein binding of the regulatory moiety to the first heterologous amino acid sequence causes a conformational change in the structure of the first heterologous amino acid sequence, and wherein binding of the regulatory moiety to the second heterologous amino acid sequence causes a conformational change in the structure of the second heterologous amino acid sequence; Optionally, binding of the calmodulin binding peptide to the first and second heterologous amino acid sequences, both of which are calmodulin, activates the activity of the reporter protein.
9. A reporter protein as described in any one of claims 1-8, (i) wherein the reporter protein is an enzyme selected from the group consisting of trehalase, oxidoreductase, glucose dehydrogenase, β-lactamase, aminoglycoside phosphotransferase, α-amylase, and carbonic anhydrase; or (ii) wherein the reporter protein is a fluorescent protein selected from the group consisting of GFP, Cherry, a fluorescent protein based on bacterial phytochrome (BphP), or a fluorescent protein derived from cyanobacterial phytochrome (CBCR).
10. The reporter protein according to any one of claims 1 to 9, wherein the reporter protein further comprises a first binding portion B1'; optionally wherein the reporter protein further comprises a second binding portion B2'.
11. The reporter protein according to any one of claims 1 to 10, wherein: (a) the first and second regulatory moieties comprise a binding moiety B1″ capable of interacting with a first binding moiety B1′ on the reporter protein; or (b) the first regulatory moiety comprises a binding moiety B1″ capable of interacting with a first binding moiety B1′ on the reporter protein; or (c) the second regulatory moiety comprises a binding moiety B2″ capable of interacting with a second binding moiety B2′ on the reporter protein; or (d) The first regulatory part includes a binding part B1" capable of interacting with a first binding part B1' on the reporter protein and the second regulatory part includes a binding part B2" capable of interacting with a second binding part B2' on the reporter protein.
12. The reporter protein according to claim 10 or 11, wherein: (a) the interaction between the binding moieties B1′ and B1″ modulates the activity of the reporter protein, optionally activating the activity of the reporter protein; or (b) the interaction between the binding parts B1′ and B1″ and the interaction between the binding parts B2′ and B2″ modulates the activity of the reporter protein, optionally activating the activity of the reporter protein; or (c) The activity of the reporter protein is activated only upon interaction of the binding parts B1′ and B1″ and upon interaction of the binding parts B2′ and B2″.
13. The reporter protein according to any one of claims 10 to 12, wherein: (a) the binding parts B1′ and B1″ are capable of directly binding to each other and / or the binding parts B2′ and B2″ are capable of directly binding to each other; or (b) the interaction of binding moieties B1' and B1" depends on the presence of a first target molecule TM1; and / or the interaction of binding moieties B2' and B2" depends on the presence of a second target molecule TM2.
14. A reporter protein as described in any one of claims 10-13, wherein the interaction between the binding parts B1′ and B1″ and the interaction between the binding parts B2′ and B2″ depend on the presence of both the first target molecule TM1 and the second target molecule TM2, so that the activity of the reporter protein is only activated in the presence of both the target molecules TM1 and TM2.
15. The reporter protein according to any one of claims 10 to 14, wherein: (a) binding moieties B1′ and B1″ and binding moieties B2′ and B2″ are the same pair of binding moieties or different pairs of binding moieties; and / or (b) The target molecules TM1 and TM2 are the same or different.
16. The reporter protein according to any one of claims 1 to 15, wherein the presence of the first target molecule TM1 and the second target molecule TM2 reversibly regulates the activity of the reporter protein, and optionally activates the activity of the reporter protein.
17. A biosensor comprising: (a) a reporter protein as claimed in claims 1 to 16; (b) a first regulating portion as defined in any one of claims 1 to 16; as well as (c) A second regulating portion as defined in any one of claims 1 to 16.
18. A composition or kit comprising: (a) a reporter protein as described in claims 1 to 16; or (b) The biosensor according to claim 17.
19. The biosensor according to claim 17 or the composition or kit according to claim 18: (a) wherein the reporter protein is an enzyme, further comprising a substrate of the enzyme; and / or (b) further comprising a target molecule TM1; and / or further comprising a target molecule TM2; optionally wherein the target molecule TM1 is the same as the target molecule TM2; or wherein the target molecule TM1 is different from the target molecule TM2; and / or (c) further comprising a biological sample, wherein the biological sample may or may not include the target molecule TM1 and / or the target molecule TM2; and / or (d) wherein the reporter protein is an enzyme, further comprising a second enzyme comprising a heterologous amino acid sequence responsive to peptide P, wherein binding of peptide P to the heterologous amino acid sequence reversibly regulates the catalytic activity of the second enzyme, wherein the substrate of the second enzyme is the catalytic product of the enzyme as described in claims 1-16; optionally, wherein (a) the second enzyme is an oxidoreductase, optionally glucose dehydrogenase, (b) the heterologous amino acid sequence is calmodulin or a functional fragment thereof, and (c) the peptide P is a calmodulin binding peptide.
20. A method for detecting one or more target molecules, comprising contacting a reporter protein according to any one of claims 1 to 16; a biosensor or a composition or a kit according to any one of claims 17 to 19; with a sample under conditions suitable for detecting the presence or absence of one or more target molecules in the sample; Optionally where: (a) the one or more target molecules include or essentially consist of target molecule TM1 and target molecule TM2; and / or (b) target molecule TM1 and target molecule TM2 are the same or different; and / or (c) The one or more target molecules are selected from the group consisting of methotrexate, phenol glucoside, rapamycin, tacrolimus and cyclosporin A.
21. A method comprising: (a) diagnosing a disease or condition in an organism, comprising contacting a reporter protein as claimed in any one of claims 1 to 16; a biosensor or a composition or a kit as claimed in any one of claims 17 to 19 with a sample obtained from an organism under conditions suitable for detecting the presence or absence of one or more target molecules in the sample, wherein the presence or absence of the one or more target molecules in the sample indicates whether the organism has the disease or condition, or is at risk of having the disease or condition; or (b) monitoring one or more target molecules in an organism, the method comprising contacting a reporter protein according to any one of claims 1 to 16; a biosensor or a composition or a kit according to any one of claims 17 to 19 with a sample obtained from an organism under conditions suitable for detecting and / or quantifying the presence or absence of the one or more target molecules in the sample; or (c) monitoring a metabolite of interest in an organism, the method comprising expressing in the organism a reporter protein as claimed in any one of claims 1 to 16 or a biosensor as claimed in any one of claims 17 to 19 under conditions suitable for detecting and / or quantifying the metabolite of interest in the organism, optionally wherein the organism is a bacterial cell; or (d) Determining protein-protein or protein-small molecule interactions, comprising contacting a reporter protein as described in any one of claims 1 to 16; a biosensor or a composition or a kit as described in any one of claims 17 to 19; with a sample under conditions suitable for detecting the presence or absence of an interaction between binding moieties B1′ and B1″ and / or an interaction between binding moieties B2′ and B2″; or an interaction between binding moieties B1′ and B1″ and target molecule TM1 and / or an interaction between binding moieties B2′ and B2″ and target molecule TM2.
22. A detection device comprising a cell or a chamber, wherein the cell or the chamber comprises the reporter protein according to any one of claims 1 to 16 or the biosensor according to any one of claims 17 to 19.
23. One or more nucleic acids encoding a reporter protein according to any one of claims 1 to 16 or a biosensor according to any one of claims 17 to 19; or one or more expression vectors comprising the one or more nucleic acids operably linked to one or more promoters.
24. A host cell comprising the reporter protein of any one of claims 1-16, the biosensor of any one of claims 17-19, or one or more nucleic acids or one or more expression vectors of claim 23.
25. A method for converting a constitutively active enzyme into a reversibly regulated enzyme, the catalytic activity of which is dependent on the presence of one or more target molecules, the method comprising: (a) generating a library of single insertional enzyme mutants by inserting heterologous amino acid sequences responsive to binding to a regulatory moiety at multiple different positions in the enzyme sequence and selecting those single insertional enzyme mutants that exhibit a change in catalytic activity in response to binding to the regulatory moiety; (b) generating a library of double insertion enzyme mutants by inserting an additional heterologous amino acid sequence responsive to binding of a modulatory moiety at a second site within the enzyme sequence, and selecting those double insertion enzyme mutants that exhibit a change in catalytic activity in the presence of the modulatory moiety and have an increased dynamic range compared to the corresponding single insertion enzyme mutants; Optionally, wherein the change in catalytic activity occurs in less than 10 minutes, optionally less than 5 minutes.
Citation Information
Cited By
Lilium regale cyclo-philin antibacterial protein gene LrCYP1 and application thereof
CN118685428A
A gene LrCYP1, an antimicrobial protein of cyclophilin from Lilium minjiangense, and its application.
CN118685428B
